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ABSTRACT 
Biological markers (“biomarkers”) may have applications in inflammatory bowel disease 
(IBD), a chronic disease of the gastrointestinal tract. Clinicians are presented with several 
challenges when treating IBD. Instead of performing expensive and invasive endoscopic 
procedures - if even possible, as resources for these procedures can be limited - biomarkers could 
be used to diagnose, assess disease activity and prognosis, and guide medical therapy, 
particularly in situations where novel biologics are involved. At this time, the use of biomarkers 
is limited, since few have been useful in predicting disease severity, prognosis and therapeutic 
response in IBD. Previous research cohorts studying biomarkers are limited due to varying 
heterogeneity between subjects that confounds the results since patients have variable disease 
courses.  
The main aim of this work was to evaluate the utility of biomarkers in IBD. To do this, 
biomarkers were included into a composite score with other patient reported outcomes (PRO) to 
predict endoscopic disease activity. Next, we examined the role of biomarkers in newly 
diagnosed IBD. Lastly, fecal calprotectin (FC) was evaluated in healthy pregnant and IBD 
patients, establishing reference values and practicality in this clinical group. We also studied the 
relationship between biomarkers and environmental factors, such as fecal microbiota. We 
hypothesized biomarker concentration would be elevated with increased clinical and endoscopic 
measures, and predictive of response to medical therapy in newly diagnosed patients. 
Additionally, we theorized the inclusion of biomarkers into composite scores would outperform 
existing scoring models in predicting endoscopic severity. Furthermore, FC levels would be 
below the limit of detection in healthy pregnancy and elevated in IBD pregnancy.  
The inclusion of biomarkers into composite scoring models outperformed existing 
clinical scores. In newly diagnosed patients, modest relationships were found between 
biomarkers and clinical and endoscopic markers of disease. Lastly, the presence of FC was 
elevated in pregnant IBD and not significant in healthy pregnancy; thus, FC is useful in IBD and 
pregnancy. Our work confirmed the significance of biomarkers in several clinical areas of IBD, 
along with the issues presented in recruiting newly diagnosed patients in small research centres. 
Future work will incorporate biomarkers into medical triage and as an endpoint in nutritional 
interventions.  
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CHAPTER 1 
INTRODUCTION 
1.1  Rationale 
 Inflammatory Bowel Disease (IBD) is a major health concern in developed countries, 
including Canada. IBD encompasses a multisystem group of disorders, with underlying chronic 
inflammation and specific clinical and pathological features, that primarily affects the 
gastrointestinal tract (Burri & Beglinger, 2012). Classical IBD consists of two main forms: 
Crohn’s disease (CD) and ulcerative colitis (UC). Although grouped together, CD and UC differ 
with respect to some important clinical, immunophenotypic and pathologic characteristics, 
including disease location, complications and histology (Bamias et al., 2005; Podolsky, 2002).  
 
 An aberrant immune response, a product of environmental and genetic factors, is central 
to pathogenesis and etiology of IBD (de Souza and Fiocchi, 2015). This inappropriate and 
ongoing response is driven by the presence of normal luminal bacteria, and is propagated by 
abnormalities in both the mucosal barrier function and immune system (Podolsky, 2002).  
Environmental influences occur at the local microenvironment (enteric microflora) and 
nutritional environment (Shanahan, 2001).  
 
 Chronic inflammation in the gastrointestinal tract is associated with diarrhea, abdominal 
pain and variable amounts of bleeding, in addition to generic systemic inflammatory 
manifestations (i.e. fever, weight loss), as well as extraintestinal manifestations (i.e. arthritis, 
uveitis) (Roy, 1997; de Mattos et al., 2015). Therefore, clinical assessment of inflammation is 
key to the diagnosis and monitoring of IBD (Konikoff & Denson, 2006). Since inflammation of 
the gastrointestinal tract may be subclinical, and thus difficult to observe and assess by patients 
or physicians, various techniques and systems have been developed to quantify the severity and 
extent of this inflammation (Konikoff & Denson, 2006). Medical therapy in IBD focuses on 
halting the acute inflammatory response by interfering with the immune response that creates 
this inflammation. Clinicians apply a combination of symptom scoring, clinical examination, 
laboratory indices, radiology, in addition to endoscopy with biopsy to make a diagnosis, assess 
severity and predict the outcome of disease (Vermeire, Van Assche, & Rutgeerts, 2006).  
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Although expensive and invasive, endoscopy is the gold standard for measuring inflammatory 
disease activity in IBD. However, due to cost, access to resources and patient burden, clinicians 
rely on the assessment of clinical symptoms. A patient-reported outcome (PRO) is any report or 
score supplied solely by the patient about a health condition or treatment (Feagan, Hanauer, 
Coteur, & Schreiber, 2011; Guyatt et al., 1989). Although assessment of clinical symptoms is 
important for the management of IBD, patient-derived and clinical scores of disease activity are 
subjective. Additionally, they are ineffective at discriminating between other medical conditions, 
like Irritable Bowel Syndrome (IBS) and active inflammatory disease (Lahiff et al., 2013).  
 
The clinical symptoms of IBD, particularly CD, are not specific and unfortunately no 
hallmark sign or symptom exists (Burri & Beglinger, 2012). There is considerable overlap in the 
symptoms found in functional disorders, such as IBS, and organic diseases like IBD. Thus, 
differentiating between organic and functional disease is difficult and often requires a 
colonoscopy with histology. Laboratory markers that are specific to IBD and could accurately 
detect inflammation and monitor disease would be useful clinically (Abraham & Kane, 2012).  A 
marker, or set or markers, to fulfill this role would provide an objective measure of disease 
activity while avoiding invasive and expensive procedures (Vermeire et al., 2006). Currently, 
few biomarkers are clinically useful in terms of their predictive power for disease severity, 
prognosis and therapeutic response in IBD (Jones & Loftus, 2007; Sands et al., 2003). 
Additionally, previous biomarker studies in IBD have excluded pregnant patients.  
 
Previous cohort studies in IBD exploring predictors of disease course have had 
limitations due to the heterogeneity and confounding effect of numerous subject and disease-
related characteristic of the subjects within the sample population. When studying a population 
of patients with long-established disease, they are all subject to different medications and dietary 
intakes, complications and surgeries, all of which distort the usefulness and calculation of 
biomarker concentrations and measures of disease activity. Thus, it is important to study newly 
diagnosed patients – a more homogenous sample population limits some of the confounding 
found in prevalent cohorts.  
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1.2  Hypotheses 
This thesis is divided into four main sections, which tested the following hypotheses 
(hypothesis is numbered for organizational purposes):  
BIOMARKER BASED MODELS (Ch. 4) 
 Biomarkers have a strong, positive correlation with endoscopic disease activity (4-1) 
 Biomarker-based models are more accurate than the Crohn’s disease Activity Index (CDAI) 
for predicting endoscopic disease activity (4-2) 
INCEPTION COHORT (Ch. 5) 
 Fecal and serological biomarker concentrations are elevated with active clinical and 
endoscopic disease activity (5-1) 
 Fecal and serological biomarker concentrations are predictive of disease activity at repeated 
measurements (5-2) 
 Food groups and nutrient intake are lower in newly diagnosed population IBD patients 
compared with reference standards (5-3) 
 Glycemic index and glycemic load have a strong, positive correlation with fecal biomarkers 
in newly diagnosed IBD patients (5-4) 
CALPROTECTIN IN PREGNANCY (Ch. 6) 
 Fecal calprotectin is not detectable in healthy pregnant women (6-1) 
 Fecal calprotectin is a feasible and useful marker of intestinal inflammation in pregnant IBD 
patients (6-2) 
FECAL MICROBIOTA AND SHORT CHAIN FATTY ACIDS (SCFA) IN IBD (Ch. 7) 
 Fecal SCFA are reduced with increased clinical and endoscopic disease activity (7-1) 
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1.3  Objectives 
This thesis is divided into four main sections, with the following objectives:  
BIOMARKER BASED MODELS (Ch. 4) 
 Analyze individual components of the CDAI (both PRO- and lab-based), biomarkers and 
other variables of interest in predicting endoscopic disease activity 
 Create a new composite scoring formula for the SES-CD including biomarkers 
INCEPTION COHORT (Ch. 5) 
 Assess feasibility of recruiting newly diagnosed cohorts in small research centres 
 Provide a nutritional assessment, observing food group and nutrient intake, and carbohydrate 
quality, in newly diagnosed, Canadian IBD patients 
CALPROTECTIN IN PREGNANCY (Ch. 6) 
 To determine the median concentrations, per trimester, of FC in normal healthy pregnancies. 
 To assess the utility of FC for following disease activity in pregnant patients with IBD 
 Assess if FC concentration correlates with clinical outcomes   
FECAL MICROBIOTA AND SCFA IN IBD (Ch. 7)  
 Analyze the impact disease activity has on fecal organic acids and fecal microbiota in newly 
diagnosed IBD patients 
 Examine the relationship between Faecalibacterium prausnitzii and fecal butyric acid is in 
newly diagnosed patients  
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CHAPTER 2 
LITERATURE REVIEW 
2.1  Introduction 
IBD is a major health concern in developed countries, including Canada. The objective of 
this literature review is to introduce the clinical research area of IBD, with a specific emphasis 
on newly emerging research surrounding inflammatory biomarkers, and how existing research 
strategies may be tailored to investigate long-standing questions associated with IBD.   
2.1.1 Inflammatory Bowel Disease: IBD encompasses a multisystem group of disorders, 
with underlying chronic inflammation and specific clinical and pathological features, that 
primarily affects the gastrointestinal tract (Burri & Beglinger, 2012). An aberrant immune 
response, a product of environmental and genetic factors, is central to pathogenesis and etiology 
of IBD (de Souza and Fiocchi, 2015) .  This inappropriate and ongoing response is driven by 
bacteria and is propagated by abnormalities in both the mucosal barrier function and immune 
system (Podolsky, 2002).  
 Chronic inflammation leads to IBD related symptoms. Therefore, clinical assessment of 
inflammation is key to the diagnosis and monitoring of IBD (Konikoff & Denson, 2006). 
Periodic bouts of diarrhea, abdominal pain and variable amounts of bleeding are associated with 
chronic inflammatory conditions of the gastrointestinal tract, in addition to generic systemic 
inflammatory manifestations (i.e. fever, fatigue and weight loss) as well as extraintestinal 
manifestations (i.e. arthritis, uveitis) (Roy, 1997; de Mattos et al., 2015). Since inflammation 
may be subclinical, and thus difficult to observe and assess by patients or physicians, various 
techniques and systems have been developed to quantify the severity and extent of this 
inflammation (Konikoff & Denson, 2006). Clinicians apply a combination of symptom scoring, 
 6 
 
clinical examination, laboratory indices, radiology, in addition to the current gold- standard of 
endoscopy with biopsy to make a diagnosis, assess severity and predict the outcome of disease 
(Vermeire et al., 2006).  
Left untreated, IBD can cause many debilitating symptoms and complications leading to 
significant disease-related morbidity and impaired quality of life (Munkhom & Binder, 2004). 
The prevalence of IBD in Canada has been estimated to be amongst the highest in the world, 
with increased mortality in patients with CD (Bernstein et al., 2006). Bernstein and colleagues 
(2006) estimated that 13 and 12 cases of CD and UC, respectively, are diagnosed per 100,000 
Canadians every year. Due to the early age of diagnosis for this lifelong disease, IBD is a large 
financial burden due to its effect on health-related quality of life (HRQL), work productivity and 
direct medical costs (Gregor et al., 1997).  
Classical IBD consists of two main forms: CD and UC. Although generally grouped 
together, CD and UC differ with respect to some important clinical, immunophenotypic and 
pathologic characteristics, including disease location, complications and select histopathological 
features (Bamias et al., 2005; Podolsky, 2002) (Table 2.1). 
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Table 2.1 Key and distinguishing factors of Crohn’s disease and ulcerative colitis 
Feature Ulcerative colitis Crohn’s disease 
Clinical Features   
     Fever Fairly common Common 
     Abdominal pain Varies Common 
     Diarrhea  Very common Fairly common 
     Rectal bleeding Very common Fairly common 
     Weight loss Fairly common Common  
     Malnutrition Fairly common Common  
     Perianal disease Absent Fairly common 
     Abdominal mass  Absent Common 
     Growth failure Occasional Common 
Site   
    Colon Exclusively 2/3 of patients 
    Ileum Infrequent (backwash 
ileitis) 
2/3 of patients 
    Jejunum Never Infrequent 
    Stomach or 
duodenum 
Never Infrequent 
    Esophagus Never Infrequent 
Intestinal 
complications 
  
   Stricture Unknown Common 
   Fistula  Absent Fairly common 
   Toxic mega colon Infrequent Uncommon 
   Perforation Unknown Uncommon 
   Cancer Common Fairly common 
Endoscopic findings   
   Friability Very common Fairly common 
   Aphthous and linear 
ulcers  
Absent Common 
   Cobblestone 
appearance 
Absent  Common 
   Pseudopolyps Common Fairly common 
   Rectal involvement Very common Fairly common 
Radiologic findings   
   Distribution Continuous Discontinuous, 
segmented 
   Ulceration  Fine, superficial Deep, submucosal 
extension    Fissures Absent Comm  
   Strictures or fistulas Rare  Common 
   Ileal involvement Dilated Narrow, nodular  
Adapted from Podolsky (2002) 
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2.1.2 Crohn’s disease: CD is a chronic inflammatory condition characterized by a 
transmural, segmental or patchy inflammatory process that can affect any part of the 
gastrointestinal tract (Van Assche et al., 2010). CD may be defined by location (terminal ileal, 
colonic, ileocolonic, upper gastrointestinal) or by pattern of disease (inflammatory, stricturing, or 
fistulising) (Van Assche et al., 2010). Additionally, CD is distinguished by macrophages that 
typically form non-caseating granulomas. Inflammation can occur anywhere in gastrointestinal 
tract; however, the terminal ileum is most commonly involved in CD, with the earliest mucosal 
lesions appearing over Peyer's patches (Xavier & Podolsky, 2007).  
2.1.3 Ulcerative colitis: UC is a chronic inflammatory condition causing continuous 
mucosal inflammation of the colon without granulomas on biopsy, affecting the rectum and 
extending proximally to a variable extent of the colon (Silverberg et al., 2005; Stange et al., 
2008). Three major phenotypes of UC have been described: proctitis (limited to the rectum), left-
sided disease (distal to the splenic flexure), and pancolitis (extending past the splenic flexure) 
(Podolsky, 2002). Regardless of the extent of disease, the appearance of blood in stool is a 
notable characteristic of UC (Roy, 1997). In addition to the absence of granulomas, histology 
reveals the presence of a significant number of neutrophils within the lamina propria and the 
crypts of the gastrointestinal mucosa, where they form micro-abscesses. UC is characterized by 
considerable superficial mucosal ulceration, as opposed to the transmural nature of CD (Xavier 
& Podolsky, 2007).  
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2.1.4 Current Medical Model and Treatment of Disease: In response to an acute 
inflammatory stimulus, the body will mount an acute phase reaction by the up or down 
regulation of various acute phase proteins.  Upon resolution of this event, the acute phase 
proteins will return to baseline levels, albeit not all at the same speed (Gabay & Kushner, 1999). 
More specifically, the presence of active gut inflammation in IBD is associated with an acute 
phase reaction and migration of leucocytes to the gut. This event translates into production of 
several proteins, some that are directly involved in the immune response and others that are by-
products, detected in serum or stools of IBD patients (Mazlam & Hodgson, 1992; Niederau, 
Backmerhoff, Schumacher, & Niederau, 1997; Pepys, Druget, & Klass, 1977; J. Tibble et al., 
2000).  Medical therapy in IBD aims to stop the acute inflammatory response, usually through 
drug therapy, by interfering with the immune response that creates this inflammation. However, 
this approach is limited and includes the use of nonspecific anti-inflammatory medications, such 
as 5-ASAs (e.g. mesalazine), and immunosuppressive medications (e.g. azathioprine) (Bamias et 
al., 2005; Roberfroid et al., 2010). Novel biologic therapeutics, such as infliximab, an antibody 
that blocks tumour necrosis factor (anti-TNF agent), have been used effectively in the treatment 
of patients greatly improving HRQL (Bamias et al., 2005; Feagan, Yan, Bala, Bao, & 
Lichtenstein, 2003; Hanauer et al., 2002; Sandborn et al., 2004; Sands et al., 2004). Recently, 
new therapy has been introduced due to the discovery of new targets, such as anti-IL12-23 agents 
(e.g. Ustekinumab) and anti-integrins (e.g. Vedolizumab) (Feagan et al., 2013; Sandborn et al., 
2012). However, the effectiveness of these agents is accompanied by high cost and the 
possibility of serious adverse events. Additionally, natural history studies have shown that 
approximately half of IBD patients will follow a mild disease course (Farmer, Whelan, & Fazio, 
1985; Munkholm, 1997). Despite this knowledge, some experts are still opting for a more wide 
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spread application of early and aggressive use of biologics (“top-down therapy”) (D’Haens et al., 
2008). Some experts advocate for this approach since treating some patients earlier will give a 
better response to medication, thus better disease control, attenuated progression and fewer 
complications (D’Haens, Sartor, Silverberg, Petersson, & Rutgeerts, 2014). However, this 
approach may unnecessarily expose half the IBD population to a biologic or immunosuppressive 
medication. The ability to identify patients with active inflammation, and furthermore, stratify 
patients that are likely to have a severe disease course, would help a physician select appropriate 
medical therapies. This type of clinical research may help minimize health care cost and adverse 
outcomes to these therapeutic agents.   
2.1.5 Populations with IBD: Population based studies have shown IBD to be a disease of the 
young (Bernstein et al., 2006). Bernstein et al. (2006) observed peak incidence of CD between 
20-29 years, and although there was no peak age for prevalence or incidence for UC, rates rise 
around 30 years of age. Consequently, management of IBD during pregnancy is very common. 
Endoscopy can be safely performed during pregnancy; however, most patients and clinicians 
prefer to avoid invasive measures during this time (Fowler, Jones, Martel, & Mytopher, 2013). 
Poorly controlled IBD during pregnancy is associated with poor pregnancy outcomes including 
preterm delivery and small for gestational aged babies, but pregnancy outcomes when IBD is 
well controlled are good. Therefore, non-invasive surrogate markers for intestinal inflammation 
would be vital to the care of pregnant IBD patients.  
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2.2 Clinical Research in IBD 
2.2.1 Measures of Disease Activity and Study Outcomes: Currently, several aspects of the 
management of IBD present challenges to gastroenterologists and health care teams. A 
combination of colonoscopy with biopsies (for histology), symptom-based scoring, clinical 
examination and laboratory indices or markers, are used to make a diagnosis and subsequently 
assess the severity, predict the outcome and select appropriate medications in the treatment of the 
disease (Vermeire et al., 2006).  
 
2.2.1.1 Colonoscopy 
 The current “gold” standard for assessing and detecting intestinal inflammation is 
performing an endoscopy. This technique allows a gastroenterologist to visually examine the 
gastrointestinal tract. During this procedure, biopsy samples from the mucosa can be obtained for 
histology. In addition to giving a visual assessment of the affected areas, colonoscopy provides 
information on the location, extent and severity of the disease. However, colonoscopy is an 
invasive procedure, one that increases the risk of perforation and bleeding, and requires a health-
care team to perform, in addition to a high patient burden and substantial health-care cost. These 
limitations prevent frequent assessment of disease activity by colonoscopy (Konikoff & Denson, 
2006).  
 IBD is characterized by the presence of extensive ulceration in the gut. Until recently, the 
focus of medical treatment in IBD was on improving the signs and symptoms of the disease, 
instead of treating the ulceration of the bowel (Rutgeerts, Vermeire, & Van Assche, 2007). Many 
of the complications encountered in IBD (i.e. perforation, bleeding, and fistulas) are a result of 
this ulceration. Therefore, a logical objective of medical treatment would aim for mucosal 
healing in parallel with clinical remission (Rutgeerts et al., 2007). A mounting body of evidence 
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suggests that mucosal healing, evaluated through colonoscopy, is a surrogate marker of sustained 
controlled CD (D’Haens et al., 2008; Rutgeerts et al., 2004; Van Assche et al., 2010). Therefore, 
the use of frequent endoscopic monitoring in the effort to assess mucosal healing is advocated 
(Van Assche et al., 2010).  
Endoscopy, although considered the gold-standard and the most objective test available, 
is still a subjective measure that has been historically limited by interobserver variation (de 
Dombal & Softley, 1987). Some of the earliest versions of endoscopic activity scoring were not 
validated for use in clinical trials (Gomes, du Boulay, Smith, & Holdstock, 1986; Olaison, 
Sjödahl, & Tagesson, 1990). The Crohn’s disease Endoscopic Index of Severity (CDEIS) is a 
validated scoring tool used for assessment in CD (Mary & Modigliani, 1989). Recently, a more 
simplified score, called the Simple Endoscopic Score for Crohn’s disease (SES-CD), has been 
developed and also validated (Daperno et al., 2004). Sandborn et al. (2002) have performed a 
review of endoscopic indices in CD, in addition to other indices of disease activity. This review 
found that the CDEIS score to be the standard for assessing endoscopic healing of CD. However, 
the authors noted that more prospective research is needed to validate the prognostic relevance of 
the CDEIS, and, more importantly, will be required before endoscopic disease activity is utilized 
as a primary endpoint. D’Haens et al. (2007) have performed an extensive review of endoscopic 
indices in UC, such as the Simple Clinical Colitis Activity Index and Mayo Score. This review 
recommended that an endoscopic endpoint, used as a composite score in a larger assessment or 
scored separately, should be incorporated into the primary study endpoint. Furthermore, the 
authors added that an "optimal" scoring tool in UC has yet to be developed. The substantial 
complexity, with scores that include partial endoscopic and partial clinical scoring, and sheer 
abundance of scoring methods are beyond the scope of this literature review. However, even 
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though there is no perfect marker or test of disease activity, endoscopic assessment remains the 
standard in assessment of disease activity. 
 
2.2.1.2 Patient Reported Outcomes and Clinical Indices  
Assessments of patient symptoms are important for the clinical management of 
inflammation. However, patient-derived reports and clinical scores of disease activity are 
subjective. Furthermore, they may be influenced by other non-inflammatory features of the 
disease, (i.e. intestinal strictures, bile salt malabsorption) or even non-disease related 
occurrences, such as emotional state (Konikoff & Denson, 2006).  
Clinical Indices in Crohn’s disease 
In the 1970’s, experts involved with the National Cooperative Crohn’s disease study, 
void of an index to score the severity of disease in CD, gathered to create a method to assess the 
response or lack of response to a treatment regimen (Best, Becktel, Singleton, & Kern, 1976). 
The CDAI, derived through a multiple regression model of 8-variables, has since been widely 
used in clinical trials in CD and is still used today (Sandborn et al., 2002). Scores of less than 
150 indicate remission, whereas greater than 450 indicate severe disease. When compared with 
more objective endpoints of disease activity, such as laboratory indices and endoscopy, the 
CDAI has been shown to correlate poorly (Gomes et al., 1986; Jones, Loftus, Panaccione, Chen, 
Peterson, McConnell, et al., 2008; Kiss et al., 2011; Thia et al., 2008). Also, the CDAI score has 
been shown to be poorly reproducible, with a weak response to change over time (de Dombal & 
Softley, 1987). Additionally, more recent work has shown the CDAI to be ineffective at 
discriminating between IBS and active CD (Lahiff et al., 2013). The Harvey-Bradshaw Index 
(HBI) is a strongly correlated (r = 0.90) simplification of the CDAI, designed to make data 
collection and computation easier (Harvey & Bradshaw, 1980).  
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Clinical Indices in UC 
In 1955, Truelove and Witts reported the results of a trial for treating active UC; in that 
they described an instrument they used to measure disease activity. The Truelove and Witts 
Severity Index is composed of six variables: number of stools per day; blood in stools; 
temperature; pulse; hemoglobin; and erythrocyte sedimentation rate (ESR) (Truelove & Witts, 
1955). At present, it is useful only to broadly classify patients, as it does not sufficiently measure 
changes in disease activity.  
In 1978, the Powell-Tuck index (PT), also known as the St. Mark’s Index, was described 
(Powell-Tuck, Bown, & Lennard-Jones, 1978). The PT includes 10 clinical variables: general 
health, abdominal pain, bowel frequency, stool consistency, bleeding, anorexia, nausea or 
vomiting, abdominal tenderness, extra intestinal complications (eye, mouth, joint, skin), and 
temperature. The score ranges from 0 to 20, with remission being defined as 0, and a 2-point 
decrease recognized as a clinical improvement. This scoring method has not been validated.  
In 1993, Hanauer and colleagues reported the results of a placebo-controlled trial in 
active UC that utilized the Physician Global Assessment (PGA) (Hanauer et al., 1993). The PGA 
is a multicomponent measure of disease activity, which utilizes the physician’s assessment of the 
patient. Scores range from 1 to 6, with a treatment success defined as 1 or 2 and treatment benefit 
as 1. This score and accompanying definitions have not been validated.  
In 1987, Schroeder and colleagues (Schroeder, Tremaine, & Ilstrup, 1987) reported the 
results of a placebo-controlled trial utilizing a measurement called the Mayo Score or Disease 
Activity Index (DAI). The score consists of 4 items: stool frequency, rectal bleeding, findings of 
flexible proctosigmoidoscopy and PGA. Scores range from 0 to 12 points. Complete remission is 
defined as a score of zero, meaning normal stool frequency, no rectal bleeding, the patient is 
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generally well, and a PGA score of 0. A partial response has also been defined. The Mayo Score 
and accompanying definitions have not been validated. 
An extensive overview of the clinical indices and efficacy endpoints in UC has been 
reviewed by D’Haens and colleagues (D’Haens et al., 2007).  There are a variety of clinical 
disease activity scores, some of that contain endoscopic sub-score components that are likely to 
increase accuracy of the score. However, none of these scores are validated.  
 
2.2.2 Biological Markers: The clinical symptoms of IBD, particularly CD, are not 
specific and unfortunately no hallmark sign or symptom exists (Burri & Beglinger, 2012). There 
is considerable overlap in the symptoms found in functional disorders, such as IBS and organic 
diseases like IBD. Thus, differentiating between the organic and functional disease is difficult 
and often requires a colonoscopy with histology. Laboratory markers that are specific to IBD and 
could accurately detect inflammation and monitor disease would be useful clinically (Abraham 
& Kane, 2012).  A marker, or set or markers, to fulfill this role would provide an objective 
measure of disease activity while avoiding invasive and expensive procedures (Vermeire et al., 
2006).  
A biological marker ("biomarker") is a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention (Biomarkers Definitions Working Group., 2001). 
Currently, few biomarkers are clinically useful in terms of their predictive power for disease 
severity, prognosis and therapeutic response in IBD (Jones & Loftus, 2007; Sands et al., 2003). 
The majority of current biomarkers lack the specificity for gastrointestinal inflammation or do 
not have the extensive research required to be clinically useful. In the context of IBD, 
biomarkers may be used to assess disease activity, severity, and predict the course of the disease 
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with low expense, high reliability and comparative ease to other assessments (Desai, Faubion, & 
Sandborn, 2007). Further information on the qualities of an ideal biological marker can be found 
in Table 2.2.  
Table 2.2 Performance and qualities of an ideal marker 
Performance Qualities 
Simple  Disease specific: identify at risk individuals 
and distinguish IBD from non-IBD 
Easy to perform Objectively measure disease activity 
Not/minimally invasive  Predict disease course 
Cheap  Monitor effect of treatment 
Rapid Prognostic value: asses morbidity/mortality 
Reproducible between labs and 
individuals  
 
Adapted from Vermeire (2006)V. 
 
 Recently, an influx of research has been exploring the role of biomarkers for their 
diagnostic ability, as non-invasive measures of disease activity and their accuracy in predicting 
disease progression and response to medication. In diagnostics, one of the simplest tests utilizes 
the results of investigation to classify patients into two groups, due to the presence or absence of 
a sign (Altman & Bland, 1994).  Within this test, the measures of sensitivity and specificity can 
be measured. These two measures are closely related to the concepts of Type I and II errors 
(“Sensitivity and specificity,” 2013). The positive predictive value (PPV) assesses the 
performance of the test, measures of the proportion of true positive test to combined true and 
false positive results. The negative predictive value (NPV) is the proportion of subjects with a 
negative test result who are correctly diagnosed. Figure 2.1 displays the diagnostic role of 
biomarkers (“Sensitivity and specificity,” 2013).  
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Figure 2.1 Diagnostics of biomarkers. Adapted from “Sensitivity and specificity” (“Sensitivity 
and specificity,” 2013).  
 
 Serological markers have been shown to be problematic in terms of sensitivity and 
specificity. The transcriptional control of many serological markers, such as C-reactive protein, 
make them complex markers to assess and utilize. The various serological, fecal and novel 
biomarkers studied in clinical IBD research will now be discussed.   
2.2.2.1 Serum Markers 
As previously mentioned, the acute inflammatory response is marked by the upregulation 
of several plasma proteins (≈40 proteins) (Henriksen et al., 2008). A set of markers that could 
accurately assess inflammation and monitor disease activity would prove useful in IBD. In 
response to an acute phase stimulus, white blood cell count, platelet count, or erythrocyte 
sedimentation rate (ESR) are typically altered (Vermeire et al., 2006). Unfortunately, the 
drawbacks to these measurements are the lack of sensitivity and specificity for intestinal 
inflammation. Due to various physiological parameters, such as short half-life and high 
sensitivity, C-reactive protein (CRP) has been widely utilized and studied in IBD.  
  
Table 3. Diagnostics of Biomarkers
Condition (-)
Adapted from "Sensitivity and Specificity"
Condition (as determined by 
gold standard)
Positive Predictive Value (PPV) 
= True + / Test Outcome (+)
Negative Predicitve Value (NPV) 
= True - / Test Outcome (-)
Sensitivity = 
∑ True + / ∑ 
Condition (+)
Specificity = 
∑ True -  / ∑ 
Condition (-)
Condition (+)
True +
False - (Type 
II Error)
False + (Type 
I Error)
True -
Test 
Outcome
Test 
Outcome (+)
Test 
Outcome (-)
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C-reactive protein 
CRP, a pentameric protein consisting of five monomers, is one of the most vital acute 
phase proteins in humans (Vermeire, Van Assche, & Rutgeerts, 2004). CRP is produced almost 
exclusively by hepatocytes in the liver, although extra-hepatic production has been demonstrated 
(Henriksen et al., 2008). The main stimulus for CRP production is the pro-inflammatory cytokine 
interleukin-6 (IL-6), originating at the site of inflammation. This response is enhanced in 
combination with interleukin 1-beta (IL1-ß) and TNF-alpha (Henriksen et al., 2008; Vermeire et 
al., 2004). After binding to its ligand, the CRP–ligand complex activates the complement 
cascade and induces phagocytosis, fulfilling an important role in the innate human immune 
system. The full function of how CRP functions in disease is not well understood.  
CRP is useful marker in the detection and follow-up of acute response events due to its 
short half-life (≈19 hours) (Vermeire et al., 2006). Thus, CRP is suitable to trace the onset and 
resolution of inflammation compared with other acute proteins with longer half-lives (Vermeire 
et al., 2006). Additionally, medical therapy does not seem to influence CRP production in the 
hepatocytes; therefore, changes observed during treatment should be caused be the observed 
treatment on the existing disease (Henriksen et al., 2008). Under typical conditions, CRP is 
produced by hepatocytes in low quantities (≈ 1.0 mg/L) and is partially genetically regulated 
(Ford et al., 2003; Tall, 2004). Following an acute phase reaction, such as gut inflammation, 
CRP is rapidly produced, with potential for peak levels reaching between 350-400 mg/L.  In 
cases of mild inflammation or viral infections, the concentration of CRP is typically observed 
between 10-40 mg/L.  
 As previously mentioned, CRP is upregulated in most inflammatory diseases, including 
IBD.  However, since it may be affected by other non-IBD related phenomenon, the utility of 
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CRP in IBD is limited. Historically, a notable difference exists between the strong CRP 
responses in CD compared with the moderate, weak or absent CRP responses in UC, despite 
active inflammation (Vermeire et al., 2006).  
 
Unfortunately, the correlation between CRP and disease activity in IBD has been 
inconsistent (Andre, Descos, Landais, & Fermanian, 1981; Boirivant et al., 1988; Brignola et al., 
1986; Buckell et al., 1979; Fagan et al., 1982; Niederau et al., 1997).  However, the more recent 
assessment of high-sensitivity C-reactive protein (hsCRP) in CD patients suggests a stronger 
association with disease activity. The assay for hsCRP measures the same serological CRP 
molecule, however, hsCRP can detect very small amounts in the blood that were previously 
below the detection limit (0.5-10 mg/L) (“CRP: Common Questions”; Sidoroff, Karikoski, 
Raivio, Savilahti, & Kolho, 2010). The assessment hsCRP was observed to be more effective 
(100% sensitivity/67% specificity) in differentiating between functional and new IBD diagnoses 
(Poullis et al., 2002). Additionally, serum levels of CRP (when an individual mounts a CRP 
response) are useful for assessing a patient’s risk of relapse and response to medication (Van 
Assche et al., 2010; Vermeire et al., 2004). However, it’s utility is limited in IBD as some 
patients do not mount a CRP response (Jones, Loftus, Panaccione, Chen, Peterson, Mcconnell, et 
al., 2008) 
 
2.2.2 Fecal Markers 
Although serum markers are useful in assessing active inflammation, they are non-
specific and elevated in conditions unrelated to IBD. Ideally, a specific marker or set of markers 
of gastrointestinal inflammation would make endoscopy avoidable in various IBD related 
instances (i.e. diagnosis, monitoring therapy). The inflamed intestinal mucosa is populated with a 
larger number of neutrophils that are in direct contact with the fecal stream. Neutrophil derived 
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proteins, calprotectin and lactoferrin being the most widely studied, present the most ideal type 
of biomarkers in the study of gut inflammation (Abraham & Kane, 2012). Furthermore, although 
assumed, analyzing a fecal derived marker improves sample accessibility in this patient 
population. 
Fecal Inflammatory Markers 
Calprotectin, a calcium-binding protein discovered in 1980, is found in neutrophils, and 
to a lesser degree in monocytes and macrophages, and comprises a large portion of cytosolic 
(60%) and total (≈5%) protein of these neutrophils (Dale, Brandtzaeg, Fagerhol, & Scott, 1985; 
Fagerhol, Andersson, Naess-Andresen, Brandtzaeg, & Schjønsby, 1990; Røseth, Fagerhol, 
Aadland, & Schjønsby, 1992). Calprotectin plays a regulatory role in the inflammatory process, 
has bacteriostatic and fungistatic properties and can be measured in various biological fluids, 
including plasma, urine, and stool.  Plasma calprotectin has been observed to increase between 5- 
and 40-fold in infectious and inflammatory conditions (Bunn, Bisset, Main, & Golden, 2001).  
Measurement in feces has proven advantageous to the study of gut inflammation, mainly due to 
the characteristics of neutrophils. Neutrophils migrate through the intestinal mucosa and into the 
lumen as the last step in their turnover (Røseth et al., 1992). Therefore, the presence of FC in 
human feces is directly proportional to neutrophil migration in the gastrointestinal tract 
(Vermeire et al., 2006). The concentration of FC is ~6 times that of normal plasma levels 
(Fagerberg, Lööf, Merzoug, Hansson, & Finkel, 2003). FC is an attractive clinical marker; it is 
resistant to colonic bacterial degradation and is evenly distributed and stable in stool for up to 
one-week at room temperature (Røseth et al., 1992). The release of FC is more than likely a 
result of cell disruption and death, a by-product of the inflammatory process, although it can also 
be actively secreted (Rammes et al., 1997; Voganatsi, Panyutich, Miyasaki, & Murthy, 2001).   
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FC has been consistently observed at increased concentrations in IBD, colorectal 
carcinoma, and nonsteroidal enteropathy patients (Kristinsson et al., 1998; Meling, Aabakken, 
Røseth, & Osnes, 1996; Røseth, Aadland, Jahnsen, & Raknerud, 1997; Røseth et al., 1992; 
Teahon, Roseth, Foster, & Bjarnason, 1997; Tibble et al., 2001; Tibble et al., 1999). A meta-
analysis conducted by von Roon and colleagues (2007) found FC to be superior to serological 
markers (i.e. CRP, ESR) in its ability to diagnose IBD (von Roon et al., 2007). An exceptional 
meta-analysis by Van Rheenen and colleagues (2010) investigated the use of FC in a similar 
vein; however, the analysis only incorporated the diagnostic accuracy of FC studies with 
suspected cases of IBD (not IBS or healthy controls) and analyses that occurred prior to 
endoscopy. The pooled sensitivity and specificity rates of FC in this meta-analysis were 93% and 
96%, respectively (van Rheenen et al., 2010). Burri and Beglinger (2012) provide an extensive 
review of the relationship between FC and endoscopic measures of disease activity. Table 2.2 
presents the studies investigating the correlation between FC and endoscopic activity in both UC 
and CD (Burri & Beglinger, 2012). FC displays modest to good correlation with endoscopic 
activity. In UC, the correlation is stronger with more objective measures of endoscopic scoring 
(i.e. Sutherland, Mayo). Differences in study design and type of endoscopic assessment are 
hypothesized to play a role in the range of observed correlations. 
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Table 2.3 Relationship between fecal calprotectin and endoscopic disease activity 
Author 
Patients/ 
No. of 
Endo. 
Disease  Scoring 
r 
Bunn, SK (2003) 22/22 UC/CD Saverymutt
u 
0.75 
D’Inca, R (2007)  46/46 UC Mayo Score 0.51 
D’Inca, R (2007)  31/31 CD SES-CD 0.48 
Langhorst, J (2008) 42/42 UC RI 0.49 
Langhorst, J (2008) 43/43 CD SES-CD 0.35 
Roseth, AG (1997) 62/64 UC Mayo Score 0.57 
Jones, J (2008) 164/164 CD SES-CD 0.72 
Schoepfer, AM (2010) 140/140 CD CDEIS 0.75 
Denis, MA (2007) 28/28 CD CDEIS ns 
Xiang, JY (2008) 66/66 UC Sutherland 0.87 
Hanai, H (2004) 31/31 UC Matts’ 
Index 
0.81 
Aomatsu, T (2011) 17/17 UC Matts’ 
Index 
0.84 
Aomatsu, T (2011) 18/18 CD SES-CD 0.76 
Langhorst, J (2005) 31/31 UC RI 0.51 
Sipponen, T (2008a) 61/87 CD SES-CD 0.64 
Fagerburg, UL (2003) 39/39 UC/CD Custom 
Score 
0.52 
Sipponen, T (2008b) 77/106 CD CDEIS 0.73 
Schoepfer, AM (2009) 134/134 UC RI 0.83 
Sipponen, T (2008c)  15/15 CD CDEIS 0.83 
Adapted from Burri and Beglinger (2012). r, correlation value, UC, Ulcerative colitis, 
CD, Crohn’s disease, SES-CD, Simple Endoscopic Score for Crohn’s disease, RI, Rachmilewitz 
index, ns, not significant.  
 
The majority of IBD patients with clinically inactive disease seem to have some degree of 
residual mucosal inflammation (Saverymuttu, Hodgson, Chadwick, & Pepys, 1986). 
Interestingly, elevated FC levels have been detected in patients in clinical remission (Taina 
Sipponen & Kolho, 2010). In a seminal study investigating disease relapse, Tibble and 
colleagues (2000) found that within clinical remission, higher levels of FC were found among 
patients that experienced a relapse as opposed to patients staying in remission (Tibble et al., 
2000). Since then, several studies have observed that FC levels predict relapse in IBD patients 
(Costa et al., 2005; D’Incà et al., 2007, 2008; Diamanti et al., 2008; Gisbert et al., 2009; Kallel et 
al., 2010; Sipponen & Kolho, 2010; Walkiewicz et al., 2008). Limited work has be conducted in 
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regards to FC and the response to therapy (Aadland & Fagerhol, 2002; Røseth, Aadland, & 
Grzyb, 2004). Although the studies are small with various designs, the general trend suggests FC 
may have a role in predicting response to therapy (Ho et al., 2009; Sipponen et al., 2008, 2010; 
Turner, Leach, et al., 2010; Turner, Mack, et al., 2010; Wagner, Peterson, Ridefelt, Sangfelt, & 
Carlson, 2008).  
Lactoferrin (Lf), an iron-binding glycoprotein secreted by the majority of mucosal 
membranes, is a major component of the secondary granules in polymorphonuclear neutrophils 
(PMN) (Baveye, Elass, Mazurier, Spik, & Legrand, 1999; Guerrant et al., 1992; Levay & 
Viljoen, 1995). PMN cells play a crucial role in the acute primary inflammatory response 
(Kayazawa et al., 2002). Lf is released upon activation and degranulation of these cells (Guerrant 
et al., 1992; Hayakawa, Jin, Ko, Kitagawa, & Ishiguro, 2009). Lf possesses anti-microbial 
properties and is resistant to proteolysis in feces (Angriman et al., 2007).  
Similar to FC, Lf has been observed to be very accurate in diagnosing IBD. In 
discriminating from IBS, Schoepfer and colleagues (2008) found that Lf was 91% specific. 
Overall accuracy for discrimination of IBS from patients with CD in remission (CDAI<150) was 
90% for both Lf and FC (Schoepfer et al., 2008).  
Additionally, elevated levels of fecal Lf are increased in active ulcerative UC and CD. Lf 
is also elevated in inactive IBD, above levels from IBS patients and healthy controls. 
Furthermore, fecal Lf concentration has a 93% correlation with measures of disease activity 
(Sugi, Saitoh, Hirata, & Katsu, 1996; van der Sluys Veer, Biemond, Verspaget, & Lamers, 1999; 
Walker et al., 2004). In additional studies, sensitivity of fecal Lf for IBD was 78% (95% 
confidence interval [CI], 69%–83%), and the specificity was 90% (95% CI, 83%– 96%), 
correlating well with endoscopic and histologic grading of disease activity (Kane et al., 2003; 
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Uchida et al., 1994). Furthermore, elevated fecal Lf was 100% specific in ruling out IBS (Kane 
et al., 2003). Finally, in 177 patients with active IBD, fecal Lf was significantly higher in those 
with active IBD compared with those with inactive disease, IBS patients, those with enteric 
infection, and healthy volunteers. The sensitivity and specificity of fecal Lf were 92% and 88%, 
respectively, for UC, and 92% and 80%, respectively, for CD (Dai, Liu, Zhao, Hu, & Ge, 2007).  
In a study of 164 patients with CD, no significant associations between the CDAI scores 
and the fecal concentrations of Lf were found. However, Jones and colleagues (2008) found 
significant association between Lf concentration and endoscopic activity (Jones, Loftus, 
Panaccione, Chen, Peterson, McConnell, et al., 2008). As previously mentioned, Kane and 
colleagues (2003) found fecal Lf correlated well with endoscopic and histologic grading of 
disease activity in CD (Kane et al., 2003). Furthermore, Sipponen (2008) and colleagues 
evaluated endoscopic scores, through CDEIS, in 77 CD patients undergoing ileocolonoscopy. Lf 
correlated significantly with CDEIS (Spearman’s r =0.773, p<0.001). Setting a fecal Lf cut-off 
value at 10 µg/g gave a sensitivity, specificity, PPV, and NPV of 66%, 92%, 94%, and 59%, 
respectively, in contrast to a CDAI value (>150) producing a sensitivity of 27%, specificity of 
94%, of PPV 91%, and of NPV 40% to detect endoscopically active disease (Sipponen et al., 
2008). Vieira and colleagues (2009) evaluated 78 patients presenting with IBD: 52 patient 
samples demonstrated inflammation based on histology. From these, 49 were Lf positive, with 
fecal Lf concentration correlating with disease activity, measured through the Mayo Disease 
Activity Index Values (Vieira et al., 2009). Masoodi and colleagues (2009) demonstrated the 
utility of Lf in diagnosing IBD, finding elevated Lf levels having 94% sensitivity and 100% 
specificity in diagnosing UC. Importantly, after treatment, fecal Lf significantly decreased along 
with disease activity, measured through Mayo scores (Masoodi et al., 2009). Gisbert, McNicholl, 
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and Gollomon (2009) provide an extensive review of many common questions pertaining to 
fecal Lf and IBD.  Overall, Lf may be a helpful non-invasive tool to distinguish between IBD 
and functional disease, although it may not be as accurate as FC (Jones et al., 2008). 
Furthermore, the use of fecal Lf to assess disease activity and as a marker of therapeutic response 
in IBD holds promise. 
 
 
Previous cohort studies in IBD exploring predictors of disease course have had 
limitations due to the heterogeneity and confounding effect of numerous subject and disease-
related characteristics of the subjects within the sample population. When studying a population 
of patients with long-established disease, patients are subject to different medications, 
complications and surgeries, distorting the usefulness and calculation of biomarker 
concentrations and measures of disease activity. Thus, studying newly diagnosed patients 
provides a more homogenous sample population and limits confounders. Table 2.4 summarizes 
the utility of fecal biomarkers in IBD.  
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Table 2.4 Summary of fecal biomarker utility 
Type Calprotectin Lactoferrin 
Distinguish IBD vs. IBS yes yes 
Distinguish CD vs UC  no no 
Active disease vs. remission  yes yes 
Sensitivity 78 – 100% 66 – 80% 
Specificity  44 – 100% 67 – 100% 
Assess mucosal healing yes Yes 
Correlation coefficient (r) 0.48 - 0.83 0.19 – 0.87 
Predict relapse yes yes 
Predict response to treatment yes yes 
Adapted from Lewis (2011). UC, ulcerative colitis, CD, Crohn’s disease, IBD, 
Inflammatory Bowel Disease, IBS, irritable bowel syndrome.  
 
 
Short Chain Fatty Acids 
Short-chain fatty acids (SCFA) are by-products of anaerobic fermentation of dietary fibre 
and sugars in the colon (Flint, Duncan, Scott, & Louis, 2015). Acetate, propionate, and butyrate 
are the major SCFA. Colonic epithelial cells (colonocytes) rapidly absorb and oxidize these 
SCFA, using butyrate as their primary source of energy (Hamer et al., 2008). Butyrate also plays 
a major role in the physiology of the colonic mucosa. Butyrate metabolism was first shown to be 
impaired in IBD by Roediger (Roediger, 1980). In this disease state butyrate is underutilized due 
to a decrease in its β-oxidation. Cummings (1981) reported that the major SCFA are found in 
human feces in a ratio as 60:24:16 of acetic : propionic : butyric acid, respectively. Although its 
role in the etiology of IBD is in question, butyric acid has a well-recognized anti-inflammatory 
potential in addition to influencing the colonic defence barrier and intestinal wall permeability 
(Hamer et al., 2008; Segain et al., 2000; Van Immerseel et al., 2010). Fecal concentrations of 
SCFA and lactate, collectively termed organic acids, have been observed to be positively 
correlated with clinical measures of disease activity using the Truelove-Witts criteria and CDAI 
(Mortensen & Clausen, 1996; Roediger et al., 1982; Treem, Ahsan, Shoup, & Hyams, 1994). 
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Conversely, the concentration of organic acids in relation to disease activity, in both active and 
inactive states of IBD have been inconsistent (Hove & Mortensen, 1995; Hove, Nordgaard-
Andersen, & Mortensen, 1994).  
Recently, Huda-Faujan et al. (2010) investigated the concentration of fecal SCFA in IBD 
patients. In the IBD patients the level of acetic acid, 162.0 µmol/g wet feces, butyric acid, 86.9 
µmol/g wet feces, and propionic acid, 65.6 µmol/g wet feces, was significantly lower when 
compared with that of healthy individuals, 209.7, 176.0, and 93.3 µmol/g wet feces, respectively. 
It should be noted that the study was conducted in Malaysia where the diet consists mainly of 
starch. The study was also limited by a very small sample size (n=8). Overall, there is 
contradictory data in the observation of organic acids in IBD. Furthermore, limited studies have 
assessed organic acids with endoscopic disease activity data; in addition to clinical disease 
activity has never been performed.  
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2.3 Causation and Environmental Determinants in IBD 
2.3.1 Environmental Determinants of IBD: The pathogenesis and aetiology of IBD, although 
not completely understood, is hypothesized to develop as a result of the interaction between three 
factors: genetic susceptibility, environmental exposures and host immune response (Cashman & 
Shanahan, 2003). Different genes have been implicated in the pathogenesis of IBD. The 
influence of environmental factors on disease onset and progression has been suggested by low 
concordance rates in identical (monozygotic) twins with IBD (CD [B50%] and UC [B10%]) 
(Halfvarson, Bodin, Tysk, Lindberg, & Järnerot, 2003). Additionally, population-based data 
points to an increasing incidence of IBD in migrant populations highlighting the importance of 
environmental factors in the pathogenesis of IBD (Cashman & Shanahan, 2003). Furthermore, 
the discovery that genetically engineered animal models of IBD do not develop colitis under 
germ-free conditions displays the importance of the intestinal microflora as an environmental 
factor that influence IBD pathogenesis (Taurog et al., 1994).  
 These environmental influences may occur at both the local microenvironment (enteric 
microflora) and the nutritional environment (Shanahan, 2001). The influence of hygiene and 
nutritional factors, in combination with unfavourable alterations of the gut microbiota, on the 
regulation of inflammation has designated them as “prime environmental triggers for the 
development and modification of lifestyle-related chronic diseases”, not solely IBD (Haller, 
2010).   
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2.3.1.1 Smoking 
The extensive study of the relationship between environmental factors and IBD has 
resulted in widespread connections, none of that are more puzzling than the effect of smoking on 
the disease. Generally, it has been observed that the smoking of cigarettes is a risk factor for 
patients with CD, whereas non-smoking is a risk factor of UC (Harries, Baird, & Rhodes, 1982; 
Reif, Klein, Arber, & Gilat, 1995; Somerville, Logan, Edmond, & Langman, 1984). Smoking has 
been shown to be an independent risk factor for clinical, surgical and endoscopic recurrence in 
CD, with further influence on disease activity after surgery. Interestingly, although the exact 
component of tobacco that produces this effect is unknown, the addition of nicotine to 
conventional medical therapy was observed to improve symptoms in mild to moderate UC 
(Pullan et al., 1994). Mechanistically, this association is plausible; nicotine has been shown to 
have a modulatory effect on immune responses in vitro (Madretsma et al., 1996). This important 
observation may highlight specific differences between the pathogenesis of CD and UC.  
 
2.3.1.2 Microbiota and Bacterial Composition 
 The increased incidence of IBD may be due to local phenomena within the intestinal 
microenvironment coupled with genetic polymorphisms and harmful environmental exposures 
prevalent in westernized lifestyles and industrialized environments. In particular, diet has been 
implicated as an important modifiable risk factor in the development of chronic digestive 
diseases (“Chronic Disease,” n.d.). Human health is highly dependent on the relationship 
between the gut and the resident microbial flora it contains. Changes to this microbial 
community can stimulate the immune system, create dysfunction in gut epithelial cells, and 
increase the permeability in the gastrointestinal tract, leading to chronic inflammation of the 
gastrointestinal tract (Sartor, 2008). Healthy individuals have a microbial ecology that is 
 30 
 
characterized by a stable dominant microbiota, referred to as "normobiosis", that exhibit high 
biodiversity and resilience (Marteau, 2009; Roberfroid et al., 2010). In contrast, the microbiota in 
IBD patients display decreased diversity, a state known as "dysbiosis", where one or a select few 
potentially harmful micro-organisisms are dominnant (Kelly & Mulder, 2012; Roberfroid et al., 
2010). Reduced diversity may create innappropriate mucosal cellular responses, that may be 
responsible for the prolonged inflammatory response observed in intestinal disease (Murphy, 
Kwon, & Boone, 2012). Microbiota and fungi increase in concentration and complexity 
throughout the gastrointestinal tract, from 102-103 aerobic organisms/g of luminal contents in the 
stomach and duodenum to 1011-1012 bacteria/g of contents in the colon and cecum (Figure 2.2). 
It has been shown that greater than 99% of gut microbiota is composed of species within four of 
the following bacterial phyla: Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria 
(Eckburg & Relman, 2007; Frank et al., 2007).  
 31 
 
 
Figure 2.2 Composition and luminal concentrations of dominant microbial species (listed in 
alphabetical order) in the gastrointestinal track (adapted from Sartor, 2008).  
 
The following observations implicate the resident microbiota in the pathogenesis of IBD. 
First, from animal models of IBD, interleukin-10 (IL-10) deficient mice do not develop intestinal 
inflammation under germ-free conditions (Sellon et al., 1998). However, these animals will 
develeop intestinal inflammation when they are introduced to non-sterile conditions or artifically 
colonized with microbiota. In humans, a similar concept demonstrates the significance of the 
mictobiota in inflammation. The use of an ileostomy, that diverts the fecal stream from the active 
inflammation, results in remission in 65% of patients, while reversal of this procedure results in 
disease relapse in 60% of patients. Therefore, this luminal content may play a role in active 
inflammation (Fasoli, Kettlewell, Mortensen, & Jewell, 1990). However, not all gut microbiota 
have a negative impact on intestinal inflammation. Some bacteria, in both animal models and 
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IBD patients, have been shown to decrease abnormal intestinal permeability (Garcia Vilela et al., 
2008; Miyauchi, Morita, & Tanabe, 2009). The decrease in intestinal permeability is thought to 
reduce the exposure of the mucosal immune system to the gut microbiota (Roberfroid et al., 
2010). Additionally, some strains of bacteria, particularly bifidobacteria, up-regulate the 
production of IL-10 by dendritic cells, a response shown to be therapeutic in animal models of 
IBD (Hart et al., 2008; Lindsay & Hodgson, 2001). Therefore, the use of anti- and probiotics in 
the management of IBD is logical, and extensive reviews have been completed elsewhere 
(Hedin, Whelan, & Lindsay, 2007; Sartor, 2008). Alternatively, fecal microbiota transplants 
(FMT), which transfer gut microbiota from healthy donors by way of stool infusion, have been 
used occasionally in IBD (Borody & Khoruts, 2012). A recent systematic review found 17 
studies (n=41) using FMT therapy in IBD (Anderson, Edney, & Whelan, 2012). The majority of 
patients undergoing FMT saw improvements in IBD symptoms, with remission from disease and 
cessation of IBD therapy (Anderson et al., 2012).  
 
 Recently, the use of 16S rRNA sequencing has been employed to investigate different 
microbial populations in CD and UC patients and healthy individuals. In a study by Frank and 
colleagues (2007), a specific subset of CD and UC patients were observed to have a significantly 
different microbial profile than controls and other IBD patients of a different subset. This subset 
was observed to have a depletion of commensal bacteria, with a tenfold lower bacterial load, that 
affected both major classes of commensal phyla, Firmicutes and Bacteroidetes. Changes to the 
gut microflora in human IBD are displayed in Table 2.5. 
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Table 2.5 Microbial flora change in IBD 
Decreased abundance Increased abundance Total Bacterial 
Amount 
Sample 
Origin 
Bacteroidetes including 
Bacteriodes thetaiomatciron1 
Proteobacteria 
including 
Enterobacteriae 
(relative, not absolute) 
1,4,6,8 
Decreased in recent 
16S rRNA studies 1,4 
Intestinal 
Clostridia class of Firmicutes 
including Faecalibaceterium 
praunsnitzii 1-2, 4-6 and 
butyrate-producing spp 1.   
Reduced diversity 5-7. 
Bacilli class of 
Firmicutes1 
Increase in mucosal 
adherent bacteria 
(particularly in 
adjacent uninflamed 
mucosa)3 
Increase in DGGE and 
FISH studies 3,9 
 
Adapted from Kaser (2010). rRNA, ribosomal ribonucleic acid, DGGE, degraded gradient gel 
electrophoresis, FISH, fluorescence in situ hybridization. 1(Frank et al., 2007); 2(Sokol et al., 
2008); 3(Swidsinski et al., 2002); 4(Baumgart et al., 2007); 5(Manichanh et al., 2006); 6(Gophna, 
Sommerfeld, Gophna, Doolittle, & Veldhuyzen van Zanten, 2006); 7(Ott et al., 2004); 
8(Martinez-Medina, Aldeguer, Gonzalez-Huix, Acero, & Garcia-Gil, 2006); 9(Bibiloni, Mangold, 
Madsen, Fedorak, & Tannock, 2006).  
 
 Additionally, specific dietary components, such as prebiotics, have the potential to alter 
this microbial community. A prebiotic is defined as "a selectively fermented ingredient that 
allows specific changes, both in the composition and/or activity in the gastrointestinal microflora 
that confers benefits upon host well-being and health" (Gibson, Probert, Loo, Rastall, & 
Roberfroid, 2004). The further study of resident microbiota, and the components that may 
influence it, could identify alternative methods to managing intestinal inflammation (Roberfroid 
et al., 2010)  
 
2.3.1.3 Diet 
The relationship between nutrition and IBD can be divided into three main subcategories: 
1) specific dietary components in the pathogenesis of the disease, 2) malnutrition or nutritional 
deficiencies in the course of disease, and 3) nutritional therapy in response to the disease 
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(Geerling, Stockbrügger, & Brummer, 1999). Maconi et al. (2010) explains the difficulty in 
elucidating a clear relationship between diet and IBD because of the “the possibility that early 
symptoms of the disease may lead to a modification in dietary habits and the inability of the 
patients to accurately remember their diet before the onset of symptoms”. The prevalence of 
nutrition deficiencies and malnutrition in IBD and the effect on disease progression are well 
documented (Han, Burke, Baldassano, Rombeau, & Lichtenstein, 1999; Vagianos, Bector, 
McConnell, & Bernstein, 2007). However, the role of an optimal diet or dietary 
recommendations during this period is less clear.  
 No standard diet is given to newly diagnosed patients with IBD (Steinhart, 2012). When 
the disease is under control, a patient is advised to follow the healthy eating habits such as found 
in Health Canada’s “Eating Well with Canada's Food Guide” (“Eating Well with Canada’s Food 
Guide,” 2007). However, when the disease is active, dietary modifications can be made to 
normalize bowel function, reduce gastrointestinal symptoms, maintain or improve hydration and 
electrolyte status, and to avoid malnutrition. Important to remember is that these experiences are 
patient specific. When discussing the role dietary management plays in CD, Russell (1991), 
states the merit of “lactose restriction, low-fat diets and low-residue diets,... in specifically 
indicated clinical situations”. In the past, low-residue or low-fibre diets (sometimes used 
interchangeably) were often recommended to minimize food residue, in turn limiting 
gastrointestinal distress (Hosoi, 1928). However, the benefits of fibre (i.e. production of SCFA) 
warranted further study of this relationship. Dietary fibre lessens the features of colitis in mouse 
models, but the results in human studies have been conflicting (Cabré & Domènech, 2012; 
Fernandez-Banares et al., 1999; Nanau & Neuman, 2012; Ritchie, Wadsworth, Lennard-Jones, & 
Rogers, 1987). Furthermore, IBD patients modify their diets as they experience gastrointestinal 
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symptoms even before diagnosis of the disease. In a case-control study of 83 new cases (within 
12 months of diagnosis) of IBD (41 UC, 42 CD), Maconi and colleagues observed that 38.6 % of 
patients made intentional changes to their diet, due to the presence of symptoms (Maconi et al., 
2010). Changes included the reduction of fat and calorie intake (12 patients), or the reduction or 
complete elimination of dietary fibre (18 patients) and milk or cheese (9 patients). Thus, it is 
prudent that a patient suffering from IBD discusses dietary modifications with a physician or 
registered dietitian in order to avoid unnecessary and potentially harmful dietary restrictions.  
2.3.2 Specific Nutritional Components of Diet:  
2.3.2.1 Nutritional Deficiency 
 The potential for nutritional deficiency in IBD is well documented, largely due to the use 
of objective markers of nutritional status and a relatively homogeneous patient population (active 
disease, inpatients) (Geerling, Badart-Smook, Stockbrügger, & Brummer, 2000; Han et al., 1999; 
Vagianos et al., 2007). Particularly, the lack of zinc in CD patients has been observed, leading to 
immune dysfunction (Ainley, Cason, Slavin, Wolstencroft, & Thompson, 1991). Generally, it is 
easier to observe how the disease affects the diet, but the reverse, how diet may affect the disease 
process is difficult to elucidate. Additionally, active intestinal disease can induce decreased food 
intake, coupled with an alteration in the normal physiology of digestion and absorption, leading 
to depletion of macro- and micronutrients. Protein loss is a longstanding observation in IBD 
(Kirsner & Koch, 2006).  
2.3.2.2 Dietary Protein and Meat Consumption  
The observed increase in the incidence of IBD, in both developed and developing 
countries, has urged researchers to evaluate population models in the search for a specific dietary 
cause. Shoda and colleagues (1996) observed the association of increase dietary protein intake 
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and incidence of CD in Japan (Shoda, Matsueda, Yamato, & Umeda, 1996). This dietary trend 
was also observed in Belgium, with a reported 50% increase of per capita meat consumption per 
year, between the 1950s and 1978 (Larsen, 2003). Additionally, a few, but not all, retrospective 
case control studies have shown a higher consumption of meat and fish in CD patients compared 
with controls (Abubakar et al., 2007; Sakamoto et al., 2005). Conversely, a large prospective 
study in multiple European centres failed to find any association between UC incidence and the 
consumption of a particular macronutrient (Hart et al., 2008). A recent cohort of French women 
observed the development of IBD was associated with total protein (hazard ratio for third vs first 
tertile, 3.31; 95% CI, 1.41-7.77) and animal protein intake (hazard ratio, 3.03; 95% CI, 1.45-
6.34) (Jantchou, Morois, Clavel-Chapelon, Boutron-Ruault, & Carbonnel, 2010). The 
relationship between dietary protein and meat consumption is unclear. However, the metabolic 
by-products of animal protein, metabolized in the colonic lumen by gut flora, have been 
hypothesized to play a role in IBD pathophysiology.  
 
2.3.2.3 Dietary Carbohydrates  
Carbohydrates and Chronic Disease 
 Carbohydrates are the principal dietary constituents that influence postprandial glycemia 
(the rise in blood sugar after a meal) and insulin secretion (Brand-Miller, 2004). Many have 
hypothesized that increased postprandial glycemia has a principal role in the etiology of many 
chronic diseases, a theory that continues to be investigated. Proponents of this hypothesis claim 
that “higher postprandial glycemia is a universal mechanism for disease progression” as stated 
by Barclay et al. (2008) in conclusion to their meta-analysis of observational studies 
investigating the relationship between postprandial glycemia and chronic disease risk. This meta-
analysis included 37 prospective cohorts (a total of 40,129 incident cases) investigating the 
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relationship between glycemic index (GI), glycemic load (GL) and chronic disease risk. In this 
meta-analysis, Barclay et al. (2008) found that diets with a high GI or GL independently 
increased the risk of type 2 diabetes (GI RR 1.40; GL RR 1.27), heart disease (GI RR1.25), 
gallbladder disease (GI RR1.26; GL RR 1.41), breast cancer (GI RR 1.08), and all diseases 
studied combined (GI RR 1.14; GL RR 1.09). This study was strengthened by the number of 
incident cases available in the analysis, but limited in the fact the patient population was 90 
percent female and that no study validated the assessment of GI and GL against another dietary 
collection method. Nonetheless, the role postprandial glycemia may play in chronic disease 
remains a contentious subject in clinical nutrition (Barclay et al., 2008).  
 Traditionally, carbohydrates in the diet have been classified by chemical structure (mono, 
di, oligo-, and polysaccharides, starch and fibre) (Chen, Shaw, & Moyer-Mileur, 2010; Riccardi, 
Rivellese, & Giacco, 2008). However, classifying carbohydrates by chemical structure dismisses 
their impact on a physiological level - carbohydrates have variable impact on glucose and insulin 
levels, in addition to an effect on satiety and gastric emptying (Chen et al., 2010). 
Role of Dietary Carbohydrates in IBD 
 The most consistent observation in the study of nutrition and IBD (mostly CD and limited 
UC) has been an increase in sugar consumption in the diet (Cashman & Shanahan, 2003; 
Geerling, Stockbrügger, et al., 1999). This association first appeared in observational studies in 
the mid-1970s, showing significantly increased consumption of refined carbohydrates (large 
quantities of sweets, prior to diagnosis) in CD patients compared with controls (Martini & 
Brandes, 1976; Miller, Fervers, Rohbeck, & Strohmeyer, 1976).  
 This association prompted several clinical trials testing the therapeutic effect of a low-
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refined carbohydrate, high-fibre diet in IBD. These studies produced conflicting results (Jones et 
al., 1985; Lorenz-Meyer et al., 1996; Ritchie, Wadsworth, Lennard-Jones, & Rogers, 1987). 
However, these studies contain various methodological limitations and flaws. The study 
conducted by Ritchie and colleagues (1987) was a large-scale multi-centre trial investigating the 
effect of a low-refined carbohydrate and high-fibre diet in CD. In the study, 162 patients were 
counselled to either continue on with consuming their traditional diet (i.e. high in refined 
carbohydrate and low in fibre) or counselled to adhere to the interventional diet (low in refined 
carbohydrate and high in fibre). Results showed good dietary compliance in both groups; 
however, the diet had no effect on disease activity. The major criticism of this study (Cashman & 
Shanahan, 2003) is that the study actually tested the use of dietary counselling for patients rather 
than the effect of the specific diet (Husain & Korzenik, 1998). Also interesting, Ritchie and 
colleagues found their results “disappointing”, but nonetheless emphasized that “a therapeutic 
response would have been more likely among patients with active disease” (Ritchie et al., 1987).  
However, a study in patients with active disease would not be conducted because the primary 
medical therapy would confound the results (Ritchie et al., 1987). The study by Lorenz-Meyer et 
al. (1996) studied the effect of a reduced carbohydrate diet, not reduced refined-carbohydrate 
diet.  The rationale for this strategy was that some refined carbohydrate sources are contained in 
the elemental diets shown to be “very effective in treating an acute flare-up in Crohn’s disease”. 
However, remission rates between patients on the two diets were identical after 1-year. Overall, 
the major issues with these dietary interventions were associated with data captured too far from 
diagnosis and the heterogeneity of the study population (Geerling, Houwelingen, Badart-Smook, 
Stockbrügger, & Brummer, 1999). However, several studies that have assessed dietary intake in 
newly diagnosed patients with CD, have demonstrated an increased consumption of sugar by CD 
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patients than that of controls (Geerling et al., 2000; Geerling & Houwelingen, et al., 1999; 
Mayberry et al., 1981).  Geerling et al. (2000) further investigated the relationship between 
carbohydrate intake and disease activity in CD.  Patients with high disease activity (CDAI >150) 
showed a significantly (P<0.025) higher total carbohydrate intake (56.4% ± 5.4) (% of daily 
energy intake) than CD patients in remission (48.7% ± 5.8). These results have implicated 
another limitation to this type of observatory study: a greater consumption of carbohydrates may 
be a result of the disease rather than the cause. In their review of consumption of sugar and CD, 
Riordan, Ruxton and Hunter (1998) suggest that the increase in sugar consumption may be a 
consequence of disease. Riordan et al. (1998) suggested this can be explained by the dietary 
advice to adhere to a low-fibre diet (less likely to produce symptoms) and that sugar containing 
foods are more palatable.  
Glycemic Index and Glycemic Load 
In an effort to quantify the glycemic response to carbohydrate-containing foods, the GI 
was introduced in 1981 (Jenkins et al., 1981). The GI value of a food is determined by measuring 
the glycemic response of a fixed amount of available carbohydrate in test food against the same 
amount of a standard food (glucose, white bread) in the same subject. This GI value is then 
quantified as the area under the blood glucose curve as a percentage of the standard (Jenkins et 
al, 2002). Therefore, as Dickinson and Brand-Miller (2005) describe, a lower GI suggests a 
slower digestion and absorption of glucose from foods and, therefore, is reflective of the quality 
of carbohydrate found in the diet (Hu, Block, Sternfeld, & Sowers, 2009). Foods can be 
classified by GI as low, moderate and high according to their glycemic response (as shown in 
Table 2.6).  To quantify the quality and quantity of carbohydrates in the diet researchers have 
turned to a measure called the glycemic load (GL). The glycemic load of a food is the product of 
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the glycemic index and the amount of carbohydrate contained in the food. This value has direct 
physiologic meaning, as stated by Liu and colleagues (2001), because each unit can be 
interpreted as the equivalent of 1 g of carbohydrate from white bread. Liu et al. (2001) continues 
on to explain the utility of the GL as a tool to avoid categorizing a food as “good” or “bad” based 
solely on GI. For example, the GI of a carrot has been reported as 131 compared to bread, 
however, the GL for carrots is small because the amount of carbohydrates in one serving is small 
(7 g). In order to produce an incremental glycemic response 1.31 times that of 100 g of test 
standard, one would need to consume 700 grams of carrots (Liu et al., 2001) . Foster-Powell, 
Holt and Brand-Miller (2002) have compiled an international table of GI and GL values. 
  
 41 
 
Table 2.6 Sample list of glycemic index values 
High GI (>70) Moderate GI (56-69) Low GI (<55) 
White bread Brown rice Barley 
High sugar cereal Banana, grape Milk, yogurt 
Bagel Ice cream Beans, chickpeas 
Pretzels Corn tortilla Tree fruit 
Hard candy Spaghetti Tomato 
Russet potatoes Corn, peas Apple 
Carrots Whole wheat bread Chocolate 
Pancakes/waffles Red potatoes Peanuts 
Glucose/sucrose Lactose Orange 
Sports drinks Soups Fructose 
Rice Pizza Non-starchy vegetable 
Adapted from Chen (2010). GI, glycemic index. 
 
In recent years, the values of GI and GL in the human diet have increased, mainly due to 
increases in carbohydrate consumption and advances in food processing (Ludwig, 2002). The GI 
and GL are important tools in nutrition research because they directly measure the postprandial 
glucose responses. The presence of excess postprandial blood glucose has been implicated as a 
developmental risk factor for cardiovascular disease and diabetes in prospective observational 
studies (Beulens et al., 2007; Schulze et al., 2004).  
Glycemic Index, Glycemic Load, and Inflammation in IBD 
As previously described, selected non-specific serological markers of inflammation, such 
as CRP, have been shown to be elevated and positively correlated with endoscopic disease 
activity scores in patients with CD. Interestingly, there is a potential association between dietary 
carbohydrates and acute phase proteins, such as CRP. In an investigation of 244 healthy women, 
Liu and colleagues (Liu et al., 2002) observed a strong and statistically significant positive 
association between dietary GL and plasma hsCRP. Furthermore, the observation of diets low in 
GL or GI have been shown to significantly lower the concentration of hsCRP in healthy 
overweight adults and type II diabetics (Nilsson, Ostman, Granfeldt, & Björck, 2008; Pittas, 
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Joseph, & Greenberg, 2004). These observations have led to the understanding that a diet with a 
“high intake of rapidly digested and absorbed carbohydrates may worsen the inflammatory 
process”, as shown by the increases in markers of systemic inflammation (Hu et al., 2006; Qi & 
Hu, 2007). Oxidative stress may be the underlying physiological process responsible for these 
differences (Ludwig, 2002). Mechanistically, hyperglycemia causes an overproduction of 
superoxide anions by the mitochondrial electron transport chain that creates reactive oxygen 
species (ROS) and, therefore, contributes to oxidative stress (Brownlee, 2005). This theory has 
displayed merit; subjects who followed a low GI diet had a significant increase in total 
antioxidant capacity (Botero et al., 2009). The impact of GI and GL on inflammatory markers 
suggests that dietary carbohydrate is a principal contributor in any disease where inflammation 
or oxidative stress is a factor, such as IBD (Buyken et al., 2010; Mirrahimi et al., 2014).  
Rationale for investigation of GI and GL in IBD 
The quality and quantity of carbohydrates in the diet may play a role in the disease course 
of IBD. Furthermore, research investigating the role of nutrition in IBD when analyzing the 
endoscopic scores of disease is lacking.  Lastly, the measures of GI and GL have never been 
assessed in IBD. There is a need for more research that investigates sugar consumption and its 
impact of IBD course and disease activity (Cashman & Shanahan, 2003).  
The major weakness in many observational studies investigating influence of diet in IBD 
is they capture dietary information too far from diagnosis and, therefore, introduce a large 
amount of recall bias into the study. Studying diet in a newly diagnosed cohort of IBD patients 
would limit the confounding experienced during the study of heterogeneous (disease duration, 
disease behaviour, medical therapy, surgical history and altered gastrointestinal anatomy) IBD 
patient populations.   
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FODMAPs 
 Gibson and Shepherd (2005) have proposed a potential etiological dietary factor that may 
impact intestinal permeability. Due to their influence on osmotic activity and fermentation, the 
consumption of poorly absorbed, short-chain carbohydrates (Fermentable Oligo-, Di- and 
Monosaccharides and Polyols. “FODMAPs”) have been targeted in dietary strategies to 
minimize functional symptoms (Barrett & Gibson, 2010). Elimination of FODMAPs containing 
foods may minimize functional symptoms in IBD patients, however, as Lomer (Lomer M C E, 
2011) highlights, “it can be difficult to distinguish between whether symptoms are functional in 
nature or due to the ongoing inflammatory process”. The elimination of functional symptoms 
may increase patient quality of life (QOL), which has been shown in mild to moderate chronic 
constipation and IBS, although the impact on the organic, inflammatory aspect of IBD is largely 
unknown (Rao, Yu, & Fedewa, 2015). 
2.3.3 Methodological Design: 
2.3.3.1 Disease Onset, Functional vs. Organic Disease 
 A clear relationship between diet and IBD is made even more difficult to ascertain due to 
a diagnostic bias. The time-line between environmental exposures, the onset of symptoms, the 
diagnosis of the disease and the introduction to an observational study all complicates the capture 
of dietary exposure (Molodecky, Panaccione, Ghosh, Barkema, Kaplan, et al., 2011). 
Furthermore, evidence showing that a patient will change their diet upon the appearance of 
symptoms complicates the study further (Maconi et al., 2010). Additionally, changes in dietary 
intake that may alleviate functional symptoms of disease may not be reflective of the ongoing 
inflammatory process (Issa & Saeian, 2011). As previously discussed, functional symptoms, 
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such as abdominal pain and diarrhea, can be present in both organic and functional intestinal 
conditions. Indices that evaluate these subjective symptoms must be used with caution. 
2.3.3.2 Study Design and Outcomes 
Historically, the study of diet in IBD study has relied on case-control studies gathering 
nutritional parameters between patients and controls. Rarely, does the study design measure the 
impact of intervention on disease activity. Disease activity can be assessed in IBD using clinical 
disease activity indices, endoscopic indices, serum serological markers, fecal markers and 
miscellaneous tests (Desai et al., 2007). The use of clinical scoring is partially subjective, as 
patients assess some parameters, and only give an indirect measure of disease activity (Desai et 
al., 2007). Endoscopic scoring is accurate; however, it is expensive and invasive. Recently, there 
has been a push to identify surrogate serological and fecal biomarkers. In the context of IBD, 
biomarkers may be used to assess disease activity, severity, and predict the course of the disease 
with low expense, high reliability and comparative ease to other assessments (Desai et al., 2007). 
In regards to nutrition interventions, the use of biomarkers may provide a more accurate way to 
measure impact on intestinal inflammation (Kuhnle, 2012). The disease process found in IBD is 
driven by active gut inflammation that is associated with an acute phase reaction and the 
migration of leukocytes to the gut (Langhorst et al., 2008). Therefore, the use of specific 
biomarkers, reflective of active gut inflammation, as a study outcome may give a better 
indication of the impact of a nutritional intervention of IBD.  
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CHAPTER 3 
OVERVIEW OF EXPERIMENTAL DESIGN 
The hypotheses outlined in Chapter Two were tested using the following experimental 
designs (Figure 3.1): 
In Chapter 4, a previous dataset was examined from a study conducted at two tertiary 
care centres between 2004 and 2006. Overall, one hundred and sixty-four (n=164) patients were 
observed, with biomarker, endoscopic and clinical measures of disease activity being collected. 
This data was used to evaluate the relationship between biomarkers and endoscopic disease 
(Hypothesis 4-1). We postulated that a model including biomarkers would outperform the CDAI, 
a conventional scoring system for disease activity (Hypothesis 4-2).    
In Chapter 5, the role of biomarkers in a longitudinal, inception cohort of newly 
diagnosed IBD patients was studied. The initial target for recruitment was 75 patients based on 
statistical power calculations, but was reduced to a target goal of 50 after 21 subjects were 
recruited in the first two years. Therefore, the scope of this study changed from an inception 
cohort to a pilot study, focusing on a descriptive analysis of our patient population. In total, 42 
patients were recruited to the study between 2010 and 2015. We collected data on biomarkers 
(hsCRP, FC, Lf) and disease activity (endoscopic and clinical scores) to assess the relationship 
between markers and disease status (Hypothesis 5-1).  These data were also used to evaluate if 
biomarkers could predict response through repeated measurements (160 total observations) 
(Hypothesis 5-2).  Dietary intake was assessed through a validated Food Frequency 
Questionnaire (FFQ). Food groups were compared with reference standards to assess adequacy 
(Hypothesis 5-3). Furthermore, measures of carbohydrate quality, GI and GL were calculated 
and correlated with fecal biomarkers (Hypothesis 5-4).    
In Chapter 6, FC was evaluated in healthy pregnant patients and pregnant patients with 
IBD. The aim was to recruit fifty (50) patients in this healthy cohort and test FC throughout 
pregnancy to establish healthy reference values (Hypothesis 6-1).  Furthermore, ten (10) 
pregnant patients suffering from IBD were recruited to assess the relationship between FC and 
disease activity during this time (Hypothesis 6-2).   
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Lastly, in Chapter 7, a smaller subset of patients from our pilot cohort was used to 
observe fecal microbiota and SCFA in newly diagnosed IBD patients. The sample size was 
smaller (n=15) than the full cohort, as this project started after initial recruitment and aspects of 
sample collection were altered. As previously discussed, since measures of endoscopic and 
clinical disease activity were collected we hypothesized fecal SCFA would decrease with disease 
severity (Hypothesis 7-1).  Specifically, it was postulated that the concentration of fecal butyric 
acid would increase with the presence of the Faecalibacterium prausnitzii strain (Hypothesis 7-
2).   
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Figure 3.1 Biomarkers in IBD experimental design. CDAI, Crohn’s disease Activity Index, SES-CD, Simple endoscopic score in 
Crohn’s disease, FC, Calprotectin, hsCRP, high sensitivity C-reactive protein, Lf, lactoferrin, FFQ, food frequency questionnaire, 
SCFA, short chain fatty acids. HP, healthy pregnancy, IBDP, inflammatory bowel disease pregnancy
4
7
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CHAPTER 4 
BIOMARKER-BASED MODELS OUTPERFORM TRADITIONAL PATIENT 
REPORTED OUTCOME-BASED SCORES IN PREDICTING ENDOSCOPIC 
INFLAMMATORY DISEASE ACTIVITY  
 Marc W. Morris1, Samuel A. Stewart1, William J. Sandborn2, Edward V. 
 Loftus3, Gordon A. Zello1, Sharyle A. Fowler1, Jennifer L. Jones1 
 Not yet published  
 The CDAI, a composite disease activity score comprised of patient and laboratory scores, 
has known limitations for accurately measuring inflammatory disease burden, but is still a widely 
used clinical tool. A PRO is any report or score supplied solely by the patient about a health 
condition or treatment. Although expensive and invasive, endoscopy is the gold standard for 
measuring inflammatory disease activity in IBD. In the future, there will likely be a move toward 
the use of a pure-PRO as a co-primary endpoint with endoscopy as the outcome measure of 
interest in clinical trials of novel therapeutics for the treatment of IBD. However, non-invasive 
markers of inflammation, such as the biomarkers discussed at length in this thesis, could prove 
more useful in the assessment and monitoring of disease activity. The objective of this study was 
to analyze the accuracy of individual components of the CDAI (both PRO- and lab-based), 
biomarkers and other variables of interest in predicting endoscopic disease activity, and to use 
the findings to create a new composite score.  
Author role: I completed the data-mining, data entry and manuscript preparation and 
writing for this chapter.  
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CHAPTER 4 
BIOMARKER BASED MODELS 
4.1  Introduction 
CD is a complex disorder that is thought to arise from an interplay between a patient’s 
genetics and their environment. A diagnosis of CD is made based on several factors including 
clinical history and physical exam, and endoscopic and histologic findings (Lennard-Jones, 
1989; Vermeire, Van Assche, & Rutgeerts, 2006).  Given the phenotypic heterogeneity of CD, 
clinical symptoms vary broadly. Multiple diagnostic tools, including the use of objective 
measures of intestinal inflammation, must be employed to confirm a diagnosis of IBD and to 
assess and follow inflammatory disease burden. However, the use of diagnostic tools and scoring 
systems as endpoints in CD are often inconsistent (Sandborn et al., 2002). Frequently, clinical 
symptoms do not correlate well with the actual burden of intestinal inflammation in terms of 
location, extent or severity (D’Haens, Geboes, Ponette, Penninckx, & Rutgeerts, 1997; Jones et 
al., 2008; Mary & Modigliani, 1989). For that reason, the use of these symptoms to estimate 
inflammatory activity and to adjust therapy may be inaccurate. The incorporation of more 
objective measures of disease activity into scoring systems may be important in this population 
and needs to be explored.  
 
Although assessment of clinical symptoms is important for the management of IBD, 
patient-derived and clinical assessments of disease activity are subjective. Additionally, they 
may be influenced by other non-inflammatory features of the disease (i.e. intestinal strictures). 
To measure the impact of clinical symptoms, clinicians often rely on PRO.  A PRO is any report 
or score supplied by the patient about a health condition or treatment. A PRO offers a unique 
perspective about the impact of chronic disease since it comes directly from the patient without 
being analyzed or interpreted (Feagan et al., 2011; Guyatt et al., 1989).  In the 1970s, the 
National Cooperative Crohn’s disease Study created a validated index of disease severity to 
assess clinical response to a treatment regimen (Best et al., 1976). The CDAI, derived through a 
multivariate regression model of 8-variables, has since been widely used in clinical trials in CD 
(Sandborn et al., 2002). The scoring components of the CDAI are comprised of symptoms 
reported by the patient (number of liquid stools, abdominal pain and general well-being), along 
  
51 
 
 
with laboratory and physical examination parameters (presence of an abdominal mass).  In a 
fourth category patients report current disease-related complications (arthritis, athralgia, iritis, 
uveitis, anal fissure/fistula, other fistula, fever>37.8° C, erythema nodosum or pyoderma 
gangrenosum) and opiate use. Lastly, the score requires the measurement of hematocrit and 
percent deviation from standard weight. Each component does not contribute equally to overall 
score. Since the CDAI is a composite score including laboratory parameters, it is not considered 
a pure PRO. However, a significant, negative correlation has been observed between other PROs 
and the CDAI (Feagan et al., 2011; Ren, Lai, Chen, Irvine, & Zhou, 2007). The CDAI has been 
shown to correlate poorly with endoscopic disease activity (Gomes et al., 1986; Jones, Loftus, 
Panaccione, Chen, Peterson, McConnell, et al., 2008; Kiss et al., 2011; Thia et al., 2008). This is 
perhaps because several components of the CDAI are not CD specific (Williet, Sandborn, & 
Peyrin-Biroulet, 2014). Recent work has shown the CDAI to be ineffective at discriminating 
between irritable bowel syndrome (IBS) and active CD (Lahiff et al., 2013). Also, the CDAI 
score has been shown to have poor reproducibility, with poor sensitivity to changes over time (de 
Dombal & Softley, 1987). The increasing prevalence of obesity in CD patients and the inclusion 
of ideal bodyweight in the CDAI score raises concerns about the score’s accuracy in measuring 
the inflammatory disease burden, among other issues. The Food and Drug Administration (FDA) 
in the United States and Health Canada are moving away from the use of the CDAI to measures 
that are exclusively derived from patient self-report (Levesque et al., 2015).  The addition of 
PROs to composite scores may provide a unique and patient specific view of the impact of IBD. 
This qualitative assessment explores issues that may be important to patients, generating 
knowledge about individual patient experiences in IBD, that may be overlooked by health care 
professionals (Dür et al., 2014; Finlay & Ballinger, 2006; Mayberry, Lobo, Ford, & Thomas, 
2013). However, during the development and validation of PRO, investigators need to consider 
the varied disease characteristics of IBD patients (i.e., IBD phenotype, location, extent of bowel 
involvement). Also, outside of the subjectivity of PRO, this type of assessment may burden the 
patient (U.S. Department of Health and Human Services FDA Center for Drug Evaluation and 
Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation 
and Research, & U.S. Department of Health and Human Services FDA Center for Devices and 
Radiological Health, 2006). In the future, it is likely that a pure PRO will be used as a co-
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primary endpoint, along with endoscopy, in clinical trials of investigational agents in IBD 
(Williet et al., 2014; Yellen, Cella, Webster, Blendowski, & Kaplan, 1997).  
 
 At the present time, colonoscopy is considered by many to be the gold standard for 
detecting and quantifying the degree of intestinal inflammation in IBD.  However, colonoscopy 
itself is a surrogate marker for disease activity as it does not capture the transmural nature of the 
chronic intestinal inflammation of CD. Nevertheless, it does provide information about the 
location, extent and severity of inflammation and the development of luminal structural 
complications. Disease extent and severity of mucosal ulceration are important to know as these 
have been shown to be independent predictors of long-term disease course.  As well, mucosal 
healing (MH) has been associated with significantly fewer hospitalizations, surgeries and 
intensive care unit stays in patients receiving anti-tumour necrosis factor alpha (anti-TNF) 
therapy (Baert et al., 2010; Isaacs, 2010; Rutgeerts et al., 2004). Although most of the evidence 
related to MH is indirect, endoscopic healing of ulcerations has been proposed as a fundamental 
goal of therapeutic treatment in CD. However, the frequent use of endoscopy to monitor IBD 
disease activity is burdensome to the health care system and to the patient and may lead to 
overutilization of scarce endoscopic resources and increased health-care costs. Access to 
endoscopic resources is also limited in Canada. These limitations prevent frequent endoscopic 
assessment of disease activity (Konikoff & Denson, 2006). There are several scoring instruments 
used by endoscopists. The Crohn’s disease Endoscopic Index of Severity (CDEIS) is a 
prospectively developed and validated tool used for the assessment of severity of mucosal 
inflammation in CD (Mary & Modigliani, 1989). The CDEIS is complex and cumbersome for 
use in routine clinical practice. A more simplified version of this score, called the Simple 
Endoscopic Score for Crohn’s disease (SES-CD), has been developed and validated (Daperno et 
al., 2004). The SES-CD score has been demonstrated to be highly correlated with the CDEIS, is 
much easier to perform and therefore feasible for use in clinical practice (Schoepfer et al., 2008).  
However, measuring endoscopic response can be difficult without a clear consensus on the SES-
CD or CDEIS definition for endoscopic remission or response (Björkesten et al., 2012; Mary & 
Modigliani, 1989; Schoepfer et al., 2010; Sipponen et al., 2008). On the other hand, the CDAI 
recognizes clinical remission as a score less than 150, and clinical response, as a decrease of 100 
in score from baseline (Vermeire, Schreiber, Sandborn, Dubois, & Rutgeerts, 2010). In our 
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study, the SES-CD was used as the independent variable, and gold standard measure of intestinal 
inflammation, against that model variables were compared.  
 
Advances in disease assessment and monitoring have led to the development of non-
invasive, objective biomarkers of inflammatory disease activity. A biological marker 
("biomarker") is a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention (Biomarkers Definitions Working Group, 2001).  Numerous biomarkers have been 
evaluated as potential surrogate markers of intestinal inflammation. However, FC, IL-6, and CRP 
have the most promise, with FC demonstrating the highest sensitivity, specificity and positive 
and negative predictive values (Andre et al., 1981; Boirivant et al., 1988; Brignola et al., 1986; 
Fagan et al., 1982; Niederau et al., 1997; Poullis et al., 2002; Røseth et al., 1992; Schoepfer et 
al., 2008; Sugi et al., 1996; Teahon et al., 1997; Van Assche et al., 2010; van der Sluys Veer et 
al., 1999; Vermeire et al., 2004; von Roon et al., 2007; Walker et al., 2004). IL-6 and CRP are 
acute phase proteins that play a vital role in the inflammatory response process (Vermeire et al., 
2004). IL-6 is a pro-inflammatory cytokine released by T cells and macrophages originating at 
the site of inflammation that stimulates hepatocytes to produce CRP. IL-6 is elevated in patients 
with CD, correlates to clinical disease activity, and is predictive of relapse (Mahida, Kurlac, 
Gallagher, & Hawkey, 1991; Mitsuyama et al., 1991; Tilg, Dinarello, & Mier, 1997).  CRP is 
produced almost exclusively by hepatocytes in the liver, although extra-hepatic production has 
been demonstrated (Henriksen et al., 2008). Following an acute phase reaction CRP is rapidly 
produced, with potential for peak levels reaching between 350-400 mg/L. Normal CRP values 
fall within 0 – 7.0 mg/L.  Serum levels of CRP during the inflammatory process, when an 
individual is capable of mounting a CRP response, are useful for assessing a patient’s risk of 
relapse and response to medication (Van Assche et al., 2010; Vermeire et al., 2004). Recently, 
the assessment of hsCRP, that can detect lower concentrations of serum CRP, suggest a stronger 
association with intestinal disease activity. Ultimately, the specificity of CRP limits its use as a 
biomarker in CD.  
 
 An ideal biomarker would be specific for gastrointestinal inflammation with the potential 
to supplant endoscopic evaluation in defined circumstances in CD (i.e. monitoring response to 
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therapy and prediction of disease flare). The inflamed intestinal mucosa is populated with a large 
number of neutrophils that are in direct contact with the fecal stream. Neutrophil derived 
proteins, such as FC and lactoferrin, are specific to intestinal inflammation (Abraham & Kane, 
2012; Kane et al., 2003; Røseth et al., 2004, 1997, 1992; Tibble et al., 2000; Tibble & Bjarnason, 
2001). FC, a calcium-binding protein, is found in neutrophils, and to a lesser degree in 
monocytes and macrophages, and comprises a large portion of cytosolic (60%) and total (~5%) 
protein of these cells (Dale et al., 1985; Fagerhol et al., 1990; Røseth et al., 1992). FC plays a 
regulatory role in the inflammatory process and has bacteriostatic and fungistatic properties. 
Increased levels of FC have been consistently observed in IBD, colorectal carcinoma, and 
nonsteroidal enteropathy patients (Kristinsson et al., 1998; Meling et al., 1996; Røseth et al., 
1997, 1992; Teahon et al., 1997; Tibble et al., 2001; Tibble et al., 1999).  FC values in the non-
inflamed intestine have been validated to fall below 50 µg/g. FC has been shown to be superior 
to serological markers (i.e. CRP) in its ability to diagnose IBD (von Roon et al., 2007). A meta-
analysis evaluating the operating characteristics of FC in diagnosing IBD demonstrated pooled 
sensitivity and specificities of 93% and 96%, respectively (van Rheenen et al., 2010).  FC also 
correlates positively with endoscopic activity (i.e. SES-CD), with correlation coefficients 
ranging from 0.48–0.73, sensitivities ranging from 81%–91%, and specificities from 58%–100% 
(D’Incà et al., 2007; Schoepfer et al., 2010; Sipponen et al., 2010).  In a recent study, FC not 
only demonstrated a strong relationship with endoscopic disease, but was observed to predict the 
presence of large ulcers with a sensitivity of 60.4% and a specificity of 79.5% (250 µg/g cut-off 
value) (D’Haens et al., 2012). Additionally, normal FC concentrations have been shown to be a 
consistent surrogate markers for endoscopically and histologically inactive disease (Jones, 
Loftus, Panaccione, Chen, Peterson, McConnell, et al., 2008; Sipponen et al., 2010; Sipponen, 
Kärkkäinen, et al., 2008). The measurement of fecal biomarkers, in combination with other 
factors that influence inflammation, may aid in the development of non-invasive indices of 
disease activity.   
 
Many patient-specific and environmental factors impact disease activity in CD. Although 
not included in existing indices, the impact of these factors on endoscopic disease activity 
warrants further investigation. Cigarette smoking has been shown to be an independent risk 
factor for clinical, surgical and endoscopic recurrence in CD, with further influence on disease 
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activity after surgery (Loftus, n.d.; Somerville et al., 1984; Sutherland, Ramcharan, Bryant, & 
Fick, 1990; Tobin, Logan, Langman, McConnell, & Gilmore, 1987). Other anthropometric 
measures, particularly body composition, could influence disease activity. Alterations to body 
composition could impact disease course and response to therapy in CD (Bryant, Trott, 
Bartholomeusz, & Andrews, 2013). Recently, obesity in CD patients has been associated with a 
more severe disease course as well as higher concentrations of inflammatory biomarkers (Fink, 
Karagiannides, Bakirtzi, & Pothoulakis, 2012; Hass, Brensinger, Lewis, & Lichtenstein, 2006). 
The accumulation of mesenteric white adipose tissue (WAT), central in CD and obesity, will 
increase the secretion of cytokines from adipose tissue ("adipokines"). Alterations to levels of 
circulating adipokines may impact the pathogenesis and disease course of IBD (Karmiris, 
Koutroubakis, & Kouroumalis, 2008). The rate of surgical resection, a common occurrence in 
the first three years of CD, may offer prognostic value (i.e. patients that underwent surgery had 
more severe disease) in stratifying disease activity (Sands et al., 2003). Dietary factors may also 
impact disease activity. Therefore, smoking status, surgical resection and BMI were assessed in 
our study.  
4.2  Objectives 
The aim of this study was to determine the relationship between individual components 
of the CDAI (using both PRO- and biomarkers variables) and other disease activity variables and 
the SES-CD, in the effort to create a sensitive and specific model (including a PRO-exclusive 
model) to predict endoscopic disease activity. 
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4.3  Materials and Methods 
This was a cross-sectional observational study conducted between 2004 and 2006.  One 
hundred and sixty-four consecutive adults with an established diagnosis of Crohn’s disease, 
undergoing clinically indicated ileocolonoscopy were recruited to participate in this study (Jones, 
Loftus, Panaccione, Chen, Peterson, McConnell, et al., 2008). Recruitment was held at two 
tertiary care centers, the University of Calgary, Calgary, AB, Canada and the Mayo Clinic 
College of Medicine, Rochester, MN, USA. Patients were excluded if they had an alternate 
condition that could elevate CRP or FC concentrations including associated autoimmune 
diseases, active infection, cancer, ileostomy, or evidence of a small bowel obstruction. Clinical, 
endoscopic, serologic and fecal inflammatory biomarker measurements were collected 
prospectively. Data collection was performed through performance of patient interviews, 
colonoscopy, and laboratory measures. CDAI was used to determine clinical disease activity that 
relies on a 7-day patient recall (Frenz, Dunckley, Camporota, Jewell, & Travis, 2005). Patients 
with a CDAI score > 150 points were considered to have active disease. Those with CDAI score 
< 150 were considered to be in clinical remission. Since the CDAI uses ideal body weight as an 
indication of changes in body composition, scores for this variable can be both positive and 
negative (and therefore add to or subtract from the total score). The conventional practice when 
calculating the CDAI is to truncate negative scores at 10. The variables used to diagnose and 
assess disease activity in CD are summarized in Table 4.1.  
Table 4.1 Variables potentially predictive of disease activity in CD 
 
Patient reported outcome 
(PRO) 
Clinical Laboratory Endoscopic 
Number of liquid stools Disease Complications Hematocrit Presence and size of ulcers^ 
Abdominal pain Ideal Body Weight hsCRP Extent of ulcerated surface^ 
General well-being Opiate use FC Extent of affected surface^ 
 Abdominal mass IL-6 Presence and type of 
narrowing^ 
 BMI Histology  
 Smoking status Lf  
 Surgical resection   
BMI, body mass index, hsCRP, high sensitivity C - reactive protein, FC, fecal 
calprotectin, IL-6, interleukin-6, Lf, lactoferrin, Hematocrit, italics denotes CDAI parameter, ^ 
denotes simple endoscopic score – Crohn’s Disease (SES-CD) parameter.  
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Endoscopic disease activity was scored by colonoscopists who were blinded to the 
laboratory and CDAI results using the SES-CD. A SES-CD score of > 7 points was indicative of 
active disease.  Serum concentrations of hsCRP were measured on a Hitachi 912 (Roche 
Diagnostics Corp, Indianapolis, IN) automated chemistry analyzer using a high-sensitivity 
polystyrene particle–enhanced immunoturbidimetric assay from DiaSorin (Stillwater, MN). 
Serum concentrations of IL-6 were measured by quantitative, 2-site sandwich enzyme 
immunoassay (R&D Systems, Minneapolis, MN). Fecal concentrations of FC were measured by 
a quantitative enzyme immunoassay using polyclonal rabbit antibodies (Phi-Cal; Genova 
Diagnostics, Asheville, NC). Fecal concentrations of Lf were measured by a quantitative enzyme 
immunoassay (IBD-SCAN, TechLab, Inc, Blacksburg, VA). Specific information on the 
analytical performance of these laboratory tests, along with characteristics of these biomarkers, 
can be found in the original article (Jones, Loftus, Panaccione, Chen, Peterson, McConnell, et al., 
2008).  
  
In our study, the SES-CD score was the independent variable. Our analysis included the 
eight original CDAI variables along with six new variables: BMI, smoking status, surgical 
resection, FC, IL-6, and hsCRP (Table 4.2). Since biomarkers are not observed as normally 
distributed but rather with skewed distribution they were log-transformed. These variables were 
analyzed, in univariate analysis, and then in multivariate models for the prediction of SES-CD.  
Simple Poisson regression was performed on each of the variables to identify those that may 
have an effect on the SES-CD. From this analysis, variables that correlated well with the SES-
CD were included in our new model. Akaike information criterion (AIC) values were used to 
compare similar variables (i.e. BMI and ideal body weight).  To create a new predictive model, a 
robust, multivariate Poisson regression model, named PRO+, was built using a cross-validated 
bootstrapping approach (bagging). 
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Table 4.2 Variables found in study models 
 
CDAI PRO+ PRO-exclusive  
Number of liquid stools Number of liquid 
stools 
Number of liquid stools 
Abdominal pain Abdominal pain Abdominal pain 
General well-being General well-being General well-being 
Symptom Categories Symptom Categories Symptom Categories 
Opiate use Hematocrit BMI 
Abdominal mass hsCRP  
Hematocrit FC  
Ideal Body Weight BMI  
BMI, body mass index, hsCRP, high sensitivity C - reactive protein, FC, fecal 
calprotectin. Non-CDAI variables included in the model are in bold.   
 
To evaluate the operating characteristics of PRO+, a receiver operating characteristic 
(ROC) curve was used to evaluate the prediction of active disease using SES-CD at two levels 
(SES-CD of ≥7 versus ≤ 6, for moderate disease SES-CD >1). The ROC curve provided 
sensitivity, specificity and area under the curve (AUC) values for our CDAI, FC, PRO+ and pro-
exclusive models.   
 
4.4  Results 
One hundred and eighty patients were screened for potential enrolment and 164 were 
subsequently enrolled (see Section 4.3 for inclusion/exclusion criteria). The demographic 
characteristics of the patients are shown in Table 4.3. The mean age of the patients was 41 years 
(range 18 - 75) and the mean duration of disease was 12 years (range 0.5 - 40). Notably, 23% of 
patients were receiving medications that have been shown previously to decrease CRP 
concentration including statins and nonsteroidal anti-inflammatory drugs. Forty-four percent of 
patients had ileocolonic disease, with 32 and 24% being restricted to the ileum and colon, 
respectively. Sixty percent of patients had inflammatory (nonstricturing, nonpenetrating) disease, 
while 35% and 5% had stricturing and penetrating disease, respectively.   Seventeen percent of 
patients were receiving anti-TNF therapy with infliximab or adalimumab and 30% of patients 
were receiving corticosteroids. 
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Table 4.3 Clinical and Demographic Characteristics (n=164) 
 
 Frequency (%) 
Sex   
     Male 68 40 
     Female 97 59 
Smoking Status   
     Smoker 26 16 
     Non-smoker 134 82 
     Missing 4 2 
Medications   
     Anti-TNF 29 17 
     Steroids 51 30 
     Immunosuppressants 81 49 
     NSAIDs 20 20 
     Statins 5 3 
Montreal 
Classification 
  
    Ileal 53 32 
    Ileocolonic 72 44 
    Colonic 40 24 
    Stricturing 57 35 
    Penetrating 8 5 
    Nonstricturing,                                                    
nonpenetrating 
99 60 
Age of diagnosis (y)   
    < 16 23 14 
    17 - 40 114 69 
    > 40 29 17 
NSAIDs, non-steroidal anti-inflammatory drugs, Anti-TNF, anti-tumour necrosis factor. 
 
 A poor relationship was observed between CDAI and SES-CD (Figure 4.1). Univariate 
pre-screening revealed that antidiarrheal/opiate use, smoking status and presence of resection 
correlated poorly with the SES-CD score and were dropped from the model (Table 4.4).  
Additionally, abdominal mass (a localized enlargement or swelling found in the abdomen) was 
not present in any of the subjects and was dropped from the model. Both hsCRP and IL-6 were 
found to correlate well with SES-CD, but their collinearity precluded including both in the 
model. As hsCRP is more clinically accessible and has a slightly stronger relationship with SES-
CD, IL-6 was excluded from the multivariate model. BMI and ideal bodyweight had similar AIC 
values, but again due to collinearity could not both included in the model. BMI was selected for 
the model since it has been more recently used in work exploring associations between obesity 
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and disease activity in IBD. Neither variable contributed significantly to the final prediction in 
the multivariate model. 
 
 
 
Figure 4.1 Relationships between CDAI and SES-CD. Plot showing weak relationship between 
the Crohn’s disease Activity Index (CDAI), a tool typically used in clinical trials, with the gold 
standard for assessing disease activity in Crohn’s disease (CD), the Simple Endoscopic Score for 
Crohn’s disease (SES-CD).  
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Table 4.4 Results of univariate Poisson modelling (n=164) 
 
 p value AIC 
Existing Variables   
     (1) number of liquid stools <0.0001 1401.6 
     (2) abdominal pain 0.0015 1447.5 
     (3) general well-being <0.0001 1432.7 
     (4) symptom categories <0.0001 1390.6 
     (5) lomotil/opiate use 0.9067 1444.5 
     (6) abdominal mass 0.0019 1434.9 
     (7) hematocrit <0.0001 1408.6 
     (8) % from standard weight 0.0013 1448.8 
New Variables   
     BMI <0.0001 1351.7 
     Smoker 0.0794 1462.3 
     abdominal resection 0.8763 1455.8 
     (log) FC <0.0001 1020.6 
     (log ) IL-6 <0.0001 1161.0 
     (log) hsCRP <0.0001 1158.1 
BMI, body mass index, (log), logarithmic scale, FC, fecal calprotectin, IL-6, interleukin-
6, hsCRP, high sensitivity C-reactive protein, AIC, Akaike information criterion.  
 
The remaining variables were used to model PRO+ (Table 4.5). Three variables were 
significantly and consistently correlated to SES-CD in the multivariate Poisson regression 
model: number of liquid or soft stools, FC and hsCRP.  
Table 4.5 Summary of Multivariate Poisson Regression Bootstrapping  
 
PRO-exclusive median p value PRO+ median p value 
Existing Variables  Existing Variables  
     (1) number of liquid   
stools 
0.0018      (1) number of liquid 
stools 
<0.0001 
     (2) abdominal pain 0.0846      (2) abdominal pain 0.0520 
     (3) general well-being 0.0053      (3) general well-
being 
0.2404 
     (4) symptom 
categories 
0.0001      (4) symptom 
categories 
0.2283 
     (7) hematocrit 0.0024      (7) hematocrit 0.1261 
New Variables  New Variables  
     BMI 0.0147      BMI 0.2103 
       (log) FC <0.0001 
       (log) hsCRP <0.0001 
BMI, body mass index, (log), logarithmic scale, IL-6, interleukin-6, hsCRP, high 
sensitivity C-reactive protein. 
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For the prediction of endoscopic disease activity (SES-CD ≥7 versus ≤ 6), the AUC for 
PRO+ was 0.81 AUC (95% CI: [0.802 0.817]) with sensitivity and specificity of 66.0% and 
87.2%. In comparison, the CDAI AUC was 0.54 (95% CI [0.534, 0.552]) with sensitivity and 
specificity of 58.8% and 58.9%, the PRO-exclusive was 0.62 AUC (95% CI: [0.609, 0.628]) 
with sensitivity and specificity values of 62.7% and 60.6%, and FC was 0.74 AUC (95% CI: 
[0.732, 0.749]) with sensitivity and specificity values of 76.5% and 45.2%. The ROC used in 
predicting active disease between these four models is shown in Figure 4.2.  
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Figure 4.2 Receiver Operating Curve (ROC) for predicting SES-CD in CD. Calprotectin (FC), 
PRO+ and pro-exclusive models (a) SES-CD of ≥7 versus ≤ 6. PRO+: 0.81 AUC, 66.0% 
sensitivity, 87.2% specificity, PRO-exclusive: 0.62 AUC, of 62.7% sensitivity, 60.6% 
specificity, CDAI: 0.54, 58.8% sensitivity, 58.9% specificity, FC: 0.74 AUC, 76.5% sensitivity, 
45.2% specificity. (b) For moderate disease SES-CD ≥1 versus ≥2. PRO+: 0.66 AUC, 35.1% 
sensitivity, 93.5%, PRO-exclusive: 0.60 AUC, of 78.3% sensitivity, 44.7% specificity, CDAI: 
0.54, 56.8% sensitivity, 60.0% specificity, FC: 0.67 AUC, 60.2% sensitivity, 74.3% specificity. 
 
 
4.5  Discussion 
Our understanding of what drives clinical symptoms in patients with IBD has evolved. 
The recognition that non-inflammatory mechanisms can cause symptoms that may resemble 
those experienced by patients with active intestinal inflammation has led to an agnostic re-
evaluation of commonly used measurement tools of CD disease activity.  Inconsistencies 
observed in the associations between clinical symptoms and endoscopic disease severity in CD 
are well documented (Jones et al., 2008). Despite this, the CDAI, a composite disease activity 
measure, is the most commonly used scoring tool for assessing disease activity in clinical trials 
(Sandborn et al., 2002). This study confirmed the lack of accuracy of the CDAI for assessment of 
endoscopic disease activity and evaluated the ability of a new model to predict endoscopic 
inflammatory disease activity.  The weak correlation observed between the CDAI and SES-CD 
scores (Figure 4.1) may exist for many reasons.  The CDAI includes the use of different disease-
related symptoms, some of that are less specific for intestinal inflammation by virtue of the fact 
that they are more subjective in nature.  Additionally, the CDAI includes variables that are not 
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applicable to a number of subgroups of CD patients. For example, CD patients in objective 
remission (clinically and endoscopically) with IBS symptoms have a greater likelihood of being 
misclassified as having active CD given symptomatic overlap between selected subtypes of IBS 
and IBD (i.e. diarrhea and abdominal pain). Likewise, the CDAI includes other subjective, non-
specific symptoms that may be caused by systemic factors or diagnoses that are unrelated to 
IBD.  For example "general well-being", included in the CDAI could be influenced by several 
factors that are not IBD related.  These factors limit the utility and accuracy of the CDAI, and 
although validated, make it an unreliable surrogate measure of endoscopic disease activity 
(Figure 4.2).  
 
 Inclusion of biomarkers, such as FC and hsCRP, into disease activity scores improves the 
prediction of endoscopic disease activity (Figure 4.2) (Björkesten et al., 2012; Langhorst et al., 
2008; Schoepfer et al., 2010). However, the published literature pertaining to the creation of non-
invasive composite scoring models is limited. Similar to our study, Khanna et al. (2015) showed 
the use of 2- or 3-item PRO derived from CDAI diaries (stool frequency, abdominal pain, and 
general well-being) were suitable to predict CDAI-defined outcomes and responsiveness to 
medical therapy. Bjorkesten et al. (2012) observed that FC alone was effective in predicting 
endoscopic remission with sensitivity and specificity values of 84% and 74%, respectively. They 
also showed that FC combined with the HBI was superior to FC alone as a surrogate measure of 
endoscopic disease activity.   However these observations did not reach statistical significance. 
Langhorst et al. (2008)  observed the performance of the CDAI, CRP and three fecal biomarkers 
(FC, lactoferrin and polymorphonuclear neutrophil elastase concentrations) in distinguishing 
active and inactive CD. Their analysis showed no singular fecal biomarkers was consistently 
reflective of endoscopic inflammation and that they all performed similarly in terms of their 
operating characteristics (AUC, sensitivity and specificity for lactoferrin was 0.87, 85% and 
77.2%, for FC 0.89, 100% and 36.7%, and 0.75, 60.7% and 75.9%, for CRP).  However, all fecal 
biomarkers were superior to serum CRP concentration in their prediction of endoscopic disease 
activity.  Also, this group created a categorical (positive or negative) comprehensive index, that 
included three stool biomarkers (marked positive if two of three stool parameters were above 
respective cut-offs), CRP, and the disease-specific activity index (CAI for UC and CDAI for CD) 
(Langhorst et al., 2008). This index was rated positive if two of three categories were observed 
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positive and expressed as a percentage correspondence for active and inactive disease status. 
This index had a 76.7 and 95.3% diagnostic accuracy in CD and UC patients, respectively 
(Langhorst et al., 2008). This composite scoring index outperformed both serum CRP 
concentration and the CDAI, but not FC concentration for estimation of endoscopic disease 
activity in CD. This observation may be reflective of the fact that CD is a very heterogeneous 
disease comprised of differences in disease location, extent and phenotype, all of which alter the 
observed concentration of FC. Unlike CD, UC is a much more homogeneous disease entity 
characterised by universal rectal involvement with a continuous pattern of inflammation of 
various extent. There is further evidence to suggest that FC concentration is dependent on the 
location of inflammation within the intestine (af Björkesten et al., 2012; Schoepfer et al., 2010). 
Schoepfer et al. (2010) analyzed the relationship between FC and disease location (ileum, colon, 
and ileocolonic) in CD, observing the strongest correlation between FC and SES-CD in 
ileocolonic disease (r=0.795, p<0.001). This is direct evidence that extent and location of 
inflammatory disease influences FC concentration.  Additional studies should stratify subjects by 
subgroups of CD based on disease location (colonic vs. ileocolonic), disease extent and disease 
behaviour (inflammatory vs. stricturing vs. penetrating). Such stratification would allow the 
development and validation of such models specific to CD subgroups and generation of results 
that will be more applicable to a heterogeneous patient population.  
 
The PRO+ model out-performed both the CDAI and PRO-exclusive model in predicting 
the SES-CD in a heterogeneous sample of CD patients.  Although an improvement over the 
existing CDAI, the new model could still be more accurate. Additionally of note, the use of only 
FC to predict SES-CD was more accurate than the PRO-exclusive model. A full calculator can 
be found in Figure 4.3. Previous studies have shown better operating characteristics with fecal 
biomarkers alone, although none of these studies attempted to include PRO (D’Incà et al., 2007; 
Schoepfer et al., 2010; Sipponen et al., 2010). The inclusion of PRO may address more global, 
patient specific aspects of disease activity that biomarkers fail to capture, leading to a more 
accurate model. Additionally, the PRO-exclusive model, including number of liquid stools and 
abdominal pain, still out performed the CDAI. This observation draws attention to parameters of 
the CDAI that may no longer be useful, and could actually detract from the score’s accuracy. 
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This observation raises questions about the ongoing utility and applicability of the CDAI for 
disease assessment in CD.  
 
 In contrast to previously performed studies evaluating the associations between 
inflammatory biomarkers and endoscopic disease activity, we included a larger number of 
clinical variables in addition to biomarkers of inflammation (Denis, Reenaers, Fontaine, 
Belaïche, & Louis, 2007; Solem et al., 2005). Modest correlations between the SES-CD and 
serological and fecal biomarkers have been observed in previous studies, suggesting that one 
biomarker alone may not be reliable as a surrogate biomarker of endoscopic disease activity. 
This highlights issues related to both inter and intra-individual biomarker concentration 
variability in CD populations. Therefore, the inclusion of additional validated variables were a 
methodological strength in our study, since we could evaluate each variable individually, and 
then as part of remodelled score.  
 
The results of the PRO+ model highlight the importance of including variables that are 
both objective and patient-derived in nature. The combination of these variables appears to out-
perform traditional validated measures as well as measures using solely objective biomarkers of 
intestinal inflammation. Of the five variables included, three (number of liquid stools, abdominal 
pain, and symptom/complication categories) were included in the original CDAI tool. Number of 
liquid stools and presence and severity of abdominal pain are considered PRO-variables. The 
other two variables, hsCRP and FC, are biomarkers, surrogate markers of inflammation. FC, a 
neutrophil derived inflammatory marker, has been shown perhaps to be the most sensitive and 
specific surrogate marker of mucosal inflammation (D’Haens et al., 2012).  Our study confirms 
the import relationship between fecal biomarkers and the presence of active endoscopic disease.  
 
Interestingly, variables hypothesized to impact endoscopic disease activity, such as 
smoking status, body composition and surgical resection, did not contribute and were dropped 
from the model.  Some of the CDAI variables, such as presence of an abdominal mass, weren't 
present in this study population.  Since, our study was limited in size (n=164), future validation 
studies should confirm this relationship. Additionally, although the use of BMI did not improve 
the prediction of endoscopically active disease, this may be due the inaccuracy of BMI as a 
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marker of body fat composition, and should not dismiss the relationship between white adipose 
tissue (WAT) and disease activity.  Future research should include more accurate, prospectively 
collected measurements of body composition and fat mass, such as dual-energy x-ray 
absorptiometry.  
 
The new model has limitations. With the inclusion of biomarker concentrations, the new 
model still requires the collection and testing of fecal and serum samples. Thus, the avoidance of 
diagnostic testing is not averted as it would be with a PRO. However, the inclusion of 
biomarkers also provides an accurate surrogate measure of disease activity, which is less costly 
and invasive than colonoscopy. The use of this type of model has far reaching implications; an 
accurate scoring index would limit the need for colonoscopy in clinical practice, therefore, 
reducing the burden on the health care related to monitoring of CD disease activity and provide 
less expensive and more accessible primary outcomes for clinical trials. 
 
4.6  Conclusion 
Biomarker enhanced CD disease activity models provide clinicians with a relatively non-
invasive, and inexpensive surrogate measure of endoscopic disease activity, with greater 
predictive accuracy. These attributes give biomarkers ideal clinical utility. The inclusion of 
biomarkers in scoring models could influence patients that are selected for clinical trials, and 
could improve the ability to predict disease relapses and response to therapy in clinical practice. 
Some PRO still possess clinical utility and their use should be continued.  . Our study showed the 
poor relationship between the CDAI and the SES-CD. Incorporation of inflammatory biomarkers 
into models improved accuracy for endoscopically active disease. 
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The long PRO+ model can be calculated as follows:  
 
 
USASK = e^[0.473 -0.002(BMI) + 0.214 (FC) + 0.195 (hsCRP) + 
0.007 (# of liquid stools) -0.016(abdominal pain) + 0.004 (general well being) + 0.054 
(symptom/complications) - 0.003(HCT)] 
 
 
The simplified model, PRO+, can be calculated as follows:  
 
 
USASK = e^[0.473  + 0.214 (FC) + 0.195 (hsCRP) + 
0.007 (# of liquid stools))  + 0.004 (general well being) + 0.054 
(symptom/complications)] 
 
 
 
Figure 4.3 PRO+ full scoring model  
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CHAPTER 5 
BIOMARKERS ARE PREDICTIVE OF DISEASE ACTIVITY AND 
ASSOCIATED WITH MEASURES OF CARBOHYDRATE QUALITY IN 
NEWLY DIAGNOSED IBD PATIENTS 
 Marc W. Morris, Gordon A. Zello, Samuel A. Stewart, Sharyle Fowler, Jane Alcorn, 
Jennifer L. Jones  
 Not yet published 
 Clinicians in IBD apply a combination of symptom scoring, clinical examination, 
laboratory indices, and radiology, to the “gold-standard” of endoscopy with biopsy, to make key 
decisions, such as diagnosis, assessment of disease severity, medical therapy and outcome. The 
use of biological markers ("biomarker"), objective characteristics of normal or pathogenic 
processes, could improve decision making at these times, particularly in lieu of endoscopic 
information. However, previous IBD cohorts exploring predictors of disease activity and course 
have been limited by heterogeneity and confounding effects within the sample population. This 
chapter focuses on a newly diagnosed cohort of IBD patients, which may remove some of the 
limitations of previous cohort studies, including disease onset and patient heterogeneity. 
Additionally, though frequently implicated in pathogenesis and treatment, there is limited 
evidence regarding the influence of diet and nutritional interventions in IBD. Observing 
nutritional trends in the period around diagnosis may shed light in this area. To the best of our 
knowledge, no nutritional assessments have been conducted in newly diagnosed IBD patients in 
Canada. Observation of nutritional trends, in addition to the novel study of fecal biomarkers in 
this cohort, makes this study distinctive.   
Author role: I completed the lab analysis, statistical analysis and manuscript preparation 
and writing for this chapter.  
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5.1 Introduction 
 IBD encompasses a multisystem group of disorders, with underlying chronic 
inflammation and specific clinical and pathological features, that primarily affects the GI tract 
(Burri & Beglinger, 2012). Classical IBD consists of two main forms: CD and UC. Although 
generally grouped together, CD and UC differ with respect to some important clinical, 
immunophenotypic and pathologic characteristics, including disease location, complications and 
select histopathological features (Bamias et al., 2005; Podolsky, 2002). Chronic inflammation 
leads to IBD related symptoms. Therefore, clinical assessment of inflammation is key to the 
diagnosis and monitoring of IBD (Konikoff & Denson, 2006). Since inflammation may be 
subclinical, and thus difficult to observe and assess by patients or physicians, various techniques 
and systems have been developed to quantify the severity and extent of this inflammation 
(Konikoff & Denson, 2006). Clinicians apply a combination of symptom scoring, clinical 
examination, laboratory indices, and radiology, in addition to the current gold- standard of 
endoscopy with biopsy to make a diagnosis, assess severity and predict the outcome of disease 
(Vermeire et al., 2006). 
 
The clinical symptoms of IBD, particularly CD, are not specific and unfortunately no 
hallmark sign or symptom exists (Burri & Beglinger, 2012). There is considerable overlap in the 
symptoms found in functional disorders, such as IBS and organic diseases like IBD. Thus, 
differentiating between the organic and functional disease is difficult and often requires a 
colonoscopy with histology. Laboratory markers that are specific to IBD and could accurately 
detect inflammation and monitor disease would be useful clinically (Abraham & Kane, 2012).  A 
biological marker ("biomarker") is a characteristic that is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to 
a therapeutic intervention (Biomarkers Definitions Working Group., 2001). A biomarker, or set 
or markers, to fulfill this role would provide an objective measure of inflammation and disease 
activity while avoiding invasive and expensive procedures (Vermeire et al., 2006).  
 
CRP is a vital acute phase proteins in humans (Vermeire et al., 2004). Following an acute 
phase reaction, such as gut inflammation, CRP is rapidly produced, with potential for peak levels 
reaching between 350-400 mg/L. However, since it may be affected by other non-IBD related 
  
72 
 
 
phenomena, the utility of CRP in IBD is limited. Historically, a notable difference exists between 
the strong CRP responses in CD compared with the moderate, weak or absent CRP responses in 
UC, despite active inflammation (Vermeire et al., 2006). hsCRP was observed to be more 
effective (100% sensitivity/67% specificity) in differentiating between functional and new IBD 
diagnoses (Poullis et al., 2002). Unfortunately, the correlation between CRP and disease activity 
in IBD has been inconsistent (Andre et al., 1981; Boirivant et al., 1988; Brignola et al., 1986; 
Buckell et al., 1979; Fagan et al., 1982; Niederau et al., 1997). The more recent assessment of 
hsCRP in CD patients, though, suggests a stronger association with disease activity. 
Additionally, serum levels of CRP (when an individual mounts a CRP response) are useful for 
assessing a patient’s risk of relapse and response to medication (Van Assche et al., 2010; 
Vermeire et al., 2004).  
 
 Although serum markers are useful in assessing active inflammation, they are non-
specific and elevated in conditions unrelated to IBD. The inflamed intestinal mucosa is populated 
with a larger number of neutrophils that are in direct contact with the fecal stream. Neutrophil 
derived proteins, calprotectin and lactoferrin being the most widely studied, present the most 
ideal type of biomarkers in the study of gut inflammation (Abraham & Kane, 2012). 
Concentration of FC is consistently increased in IBD, colorectal carcinoma, and nonsteroidal 
enteropathy patients (Kristinsson et al., 1998; Meling et al., 1996; Røseth et al., 1997, 1992; 
Teahon et al., 1997; Tibble et al., 2001; Tibble et al., 1999). Similar to FC, lactoferrin has been 
observed to be very accurate in diagnosing IBD. In discriminating from IBS, Schoepfer and 
colleagues (2008) found that lactoferrin was 91% accurate. Overall accuracy for discrimination 
of IBS from patients with CD in remission (CDAI<150) was 90% for both lactoferrin and FC 
(Schoepfer et al., 2008). A meta-analysis conducted by von Roon and colleagues (2007) found 
FC to be superior to serological markers (i.e. CRP, ESR) in its ability to diagnose IBD (von 
Roon et al., 2007). FC displays modest to good correlation with endoscopic activity (Burri & 
Beglinger, 2012). Additionally, levels of fecal lactoferrin are increased in active UC and CD. 
Lactoferrin is also elevated in inactive IBD, above levels from IBS patients and healthy controls. 
Furthermore, fecal lactoferrin concentration has a 93% correlation with measures of disease 
activity (Sugi et al., 1996; van der Sluys Veer et al., 1999; Walker et al., 2004). The use of fecal 
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biomarkers as surrogate markers of inflammation and their clinical utility holds promise, thus, 
warrants further investigation.  
The study of nutrition and IBD can be divided into three main categories: specific dietary 
components in pathogenesis, malnutrition or nutritional deficiencies in disease course, and 
nutritional therapy in response to the disease (Geerling, Stockbrügger, et al., 1999). Nutritional 
deficiency in IBD is well documented, largely due to the use of objective markers of nutritional 
status (micronutrients in bloodstream etc.) in a relatively homogeneous patient population (active 
disease, inpatients) (Geerling et al., 2000; Han et al., 1999; Vagianos et al., 2007). However, the 
influence of diet in the pathogenesis and treatment of IBD is not well known. Studying newly 
diagnosed patients, whilst collecting endoscopic and biological markers of inflammation, may 
remove some of the limitations of previous cohort studies, including disease onset and patient 
heterogeneity.  
 Dietary carbohydrates, the principal dietary constituents that control the rise in blood 
glucose (postprandial glycemia) and insulin secretion after a meal, have been long implicated in 
the development of IBD (Brand-Miller, 2004). In observational studies, an increase in dietary 
sugar consumption has been consistently reported in IBD. (Geerling, Stockbrügger, et al., 1999; 
Järnerot, Järnmark, & Nilsson, 1983; Kasper & Sommer, 1979; Martini & Brandes, 1976; 
Mayberry et al., 1981; Mayberry, Rhodes, & Newcombe, 1978, 1980; Miller et al., 1976; Penny 
et al., 1983; Rawcliffe & Truelove, 1978; Silkoff et al., 1980; Thornton, Emmett, & Heaton, 
1979). However, clinical trials testing the therapeutic effect of a low-refined carbohydrate, high-
fibre diet in the treatment of IBD produced conflicting results (Jones et al., 1985; Lorenz-Meyer 
et al., 1996; Ritchie et al., 1987). Recently, the consumption of wheat-bran had no adverse 
effects in CD, while increasing QOL and GI function (Brotherton, Taylor, Bourguignon, & 
Anderson, 2014). However, a systematic review in the area showed limited weak evidence for 
the effectiveness of fibre in improving disease outcomes (Wedlake, Slack, Andreyev, & Whelan, 
2014). The GI is used to quantify the glycemic response to carbohydrate-containing foods 
(Jenkins et al., 1981). The GL of a food is the product of the GI and the amount of carbohydrate 
in the food. In recent years, the values of GI and GL in the human diet have increased, mainly 
due to increases in carbohydrate consumption and advances in food processing (Ludwig, 2002). 
Excess postprandial blood glucose has been implicated as a developmental risk factor for 
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cardiovascular disease and diabetes in prospective observational studies, but has never been 
studied in IBD (Beulens et al., 2007; Schulze et al., 2004).  To the best of our knowledge, no 
nutritional data in newly diagnosed Canadian IBD patients exists.  
5.2  Objectives 
 Previous cohort studies in IBD exploring predictors of disease course have had 
limitations due to the heterogeneity and confounding effect of numerous subject and disease-
related characteristics of the subjects within the sample population. When studying a population 
of patients with long-established disease, patients are subject to different medications, 
complications and surgeries distorting the usefulness and calculation of biomarker concentrations 
and measures of disease activity. Thus, studying newly diagnosed patients is important for 
observing a homogenous sample population; consequently limiting confounders. 
 
 Biomarkers, together with endoscopic appearance, have never been evaluated together for 
their joint predictive ability in disease course. The primary objective of this research is to 
develop a single-center, prospective cohort of newly-diagnosed adults with IBD, in the effort to 
evaluate the predictive performance of select endoscopic, serologic, and fecal biomarkers in 
long-term disease course and response to therapeutics. A secondary objective of this study is to 
provide a nutritional assessment in newly diagnosed patients, observing nutrient intakes during 
the onset of IBD 
 
5.3  Materials and methods 
 Patient recruitment: Eligible subjects were those having a new diagnosis of IBD within 
the past 12 months by treating physicians at the Royal University Hospital and the Saskatoon 
area. Individuals ages 18 and older with a diagnosis of IBD based on standard criteria and able to 
provide written informed consent were eligible to participate in the study conducted from 
November 2012 to July 2014 (Lennard-Jones, 1989).  Exclusion criteria in this cohort consisted 
of patients with infectious diseases, end-stage renal, cardiovascular or hepatic disease or who are 
pregnant. This study was approved by the University of Saskatchewan’s Biomedical Research 
Ethics Board (Bio-REB) (Bio# 09-26).  
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Experimental design: Patient demographics (age, gender, disease type, location, 
medication therapy, smoking status) and anthropometric characteristics (height, weight, BMI) 
were collected from all participants. A nutritional assessment was conducted at baseline by a 
FFQ. At baseline and follow-up (3 – 6 months), detailed endoscopic and clinical disease activity 
measures were calculated. At baseline and follow-up visits (3 – 6 months depending on disease 
activity) over a two-year period, blood and fecal samples were collected for biomarker 
determination.  
Blood was drawn by trained Royal University Hospital personnel and used for hsCRP 
determination. Fecal samples (two 50-gram aliquots) were collected in sterile containers, one left 
thawed for biomarker determination, and one frozen immediately and delivered to the Mary 
Irwin Laboratory of Nutrition at the University of Saskatchewan for analysis found in Chapter 
7.  
Disease Activity: Clinical disease activity was scored using the CDAI and HBI for CD 
and partial Mayo (pMayo) and PT score for UC. CDAI was categorized as active ≥ 150, inactive 
< 150 and HBI as remission ≤ 2, active 3-7 and severe ≥ 8. Partial Mayo was categorized as 
inactive ≤2, mild 3-4, moderate 5-6, and severe 7-9. The PT score was only used in the 
longitudinal analysis and, therefore, not categorized. Endoscopic disease activity was scored by 
colonoscopists using the SES-CD and Mayo Score for UC. SES-CD was categorized as inactive 
0-2, mild 3-6, moderate 7-15, severe ≥ 16 and Mayo score as inactive ≤ 2, mild 3-5, moderate 6-
10, severe 11-12.  
Biomarker analysis: hsCRP was tested using the high sensitivity CRP (latex) reagent on 
the c501 analyzer (Roche Diagnostics Canada, Laval, QC) using the manufacturer’s reagents and 
calibrators (Sánchez et al., 2002). Analysis was completed by the Saskatoon Health Region.  
FC was determined using a Quantum Blue® FC High Range Rapid Test using the 
Quantum Blue Reader® point-of-care (POC) desk-top reader (ALPCO Immunoassays, Salem, 
NH). Approximately 30 mg of fecal sample was pressed into a base cap and fitted on the 
extraction tube. This device was filled with 4 mL of extraction buffer and homogenized by 
vortex for 1 minute. A 1:16 dilution was performed with chase buffer and 80 µl was positioned 
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into the test cartridge for analysis. Each run took 15 minutes to complete and results were 
displayed in micrograms per gram (µg/g) on the POC display.  
Lf was determined using IBD-SCAN® (TechLab, Inc, Blacksburg, VA). Approximately 
450 mg of fecal sample was weighed in an Eppendorf tube and diluted at 1:100 to 1:10,000. Test 
samples, standards and quality controls were plated in a 96-well plate provided with the kit. The 
plate was read at 450/620 nanometres wavelength with a microplate reader and results were 
calculated in micrograms per millilitre (µg/mL).  
Nutritional Assessment: Dietary information was captured using a FFQ, the 98 Block 
Questionnaire (Block 98.2 FFQ; Block Dietary Data Systems, Berkeley, CA, USA). Patients 
completed the questionnaires during the baseline study period (at or within 1-week of the 
baseline visit). The study coordinator was available for questions regarding the FFQ, but 
generally patients completed the questionnaires alone. The full length (110 food items) 
questionnaire was designed to estimate usual and customary intake of a wide array of nutrients 
and food groups. This questionnaire has been validated in various studies (Block, Hartman, & 
Naughton, 1990; Johnson, Herring, Ibrahim, & Siega-Riz, 2007) and more recently in a sample 
population of Canadian women (Boucher et al., 2006). A customized version of this 
questionnaire, modified to reflect fortification in the Canadian diet, was used in this study 
(Chilibeck et al., 2013). This food-frequency has been validated for assessment of glycemic 
index and glycemic load (Barclay et al., 2008; Liu et al., 2001). The overall dietary glycemic 
load is calculated as the cumulative glycemic load of each food item multiplied by the frequency 
of consumption over all food items. Dietary glycemic index is calculated by dividing dietary 
glycemic load by the total amount of carbohydrate consumed. Each unit of dietary glycemic load 
represents the overall quality of carbohydrate in the diet matched to 1 gram of glucose or white 
bread. Completed questionnaires were scanned and analyzed to determine nutrient values 
(Nutrition Quest, Berkeley, CA, USA; www.nutritionquest.com). Analysis was completed in 
grams of macronutrient and alcohol intakes, % of energy intake, food servings (based on 2005 
Food Pyramid values), and GI and GL (United States Department of Agriculture, 2005). A 
comparison of the 2005 USDA Food Pyramid and Eating Well with Canada’s Food Guide is 
found in Table 5.1.   
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Table 5.1 USDA Food Pyramid and Eating Well with Canada’s Food Guide  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison table of USDA Food Pyramid and Eating Well with Canada’s Food guide. y, years. 
USDA Food Pyramid, (United States Department of Agriculture, 2005) , EWCFG, Eating Well 
with Canada’s Food Guide(Health Canada, 2011).  
  
Statistical analysis: Descriptive statistics were used to describe patient demographics and 
biomarker concentrations. Data are presented as mean ± standard deviation unless otherwise 
noted. Biomarkers are presented as median values with interquartile ranges (not normally 
distributed). All analysis was completed on SPSS unless otherwise noted (IBM SPSS Statistics 
for Windows, 2013) 
A linear regression model was used to determine biomarkers performance at baseline 
using R (R: A language and environment for statistical computing, 2008)  
 Descriptive statistics were used to describe the nutritional assessment. Data are presented 
as mean ± standard deviation unless otherwise stated. A one-way ANOVA was used to detect 
significant differences between quartiles of glycemic index and glycemic load.  
For repeated biomarker measures, generalized estimating equations (GEE) were used to 
test for an association between disease activity measures over time (i.e. The CDAI and PT index 
for the CD and UC, respectively) and predicting variables (i.e. therapy, gender, and age, along 
with hsCRP, FC, and Lf). The identity link function was used given that the dependent variables 
were continuous. An exchangeable correlation structure for the repeated measures was specified 
USDA Food Pyramid (2005) 
Category Recommendation (servings) 
Bread, pasta, rice 6-11 
Vegetables 3-5 
Fruits, fruit juices 2-4 
Milk, cheese 
yogurt 
2-3 
 Meat, eggs, beans 2-3 
Very little Fats, oil, sweets 
EWCFG (2011) 
Category Recommendation (19-50y) (servings) 
 Female Male 
Vegetables and 
fruit 
7-8 8-10 
Grain products 6-7 8 
Milk/alternatives 2 2 
Meat/alternatives 2 3 
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in the GEE (Dohoo, Martin, & Stryhn, 2012). First, unconditional analyses were performed to 
evaluate associations between disease activity and each of the predictors (therapy, gender, visit 
number, age, hsCRP, FC, and Lf), obtaining unadjusted beta estimates with corresponding 95% 
confidence intervals (95% CI). The linearity assumption of the continuous independent variables 
was tested using a quadratic term. Then, a manual backward selection strategy was used to build 
two multivariate models, one for CD and another one for UC, removing variables with p-value ≥ 
0.05. Variables removed from the models were evaluated as confounding factors, considering 
them as confounders if a 10% or more change in the estimates of the predictors in the model was 
observed. In the final model, independent, exponential, and autoregressive correlation structures 
were tested. The quasi-likelihood under the independence model criterion (QIC) was used to 
evaluate goodness of fit of the models. Estimates and corresponding 95% CI were reported for 
the final models. The repeated measure analyses were completed using the xtgee and qic 
commands in STATA (Stata Statistical Software, 2015). 
5.4 Results 
 Baseline: During recruitment, 70 patients were screened for potential enrolment. Of these 
42 participants who met the inclusion and exclusion criteria were subsequently enrolled. The 
cohort was split between 50% male and 50% female, with a mean age of 38.3 years, ranging 
between 19 and 70. Thirty-six percent of patients were receiving an ASA-agent, 38% receiving 
immunomodulators, and 19% of patients were receiving an anti-TNF agent, in addition to 7% not 
receiving any therapy. Only 19% of patients were smokers. The demographic characteristics of 
the total cohort are shown in Table 5.2 as well as each specific cohort [CD;UC] Appendix B. 
The clinical characteristics of this cohort are shown in Table 5.3. Of the 26 CD patients, 46% 
had ileocolonic disease.  
At enrolment, the median hsCRP concentration was within normal range 5.0 mg/L 
(normal 0 – 7.0 mg/L). However, the fecal biomarkers were elevated. The median FC 
concentration was 729 μg/g (normal <50 μg/g), and median fecal Lf concentration was 146.0 
µg/mL (normal 0 - 7.24 μg/mL) (Table 5.4). 
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Table 5.2 Demographics and anthropometry of a newly diagnosed IBD cohort (n=42) 
 Mean ± SD Range Freq (%) 
Age (y)  38.3 ± 12.1 19 - 70   
Gender     
     Male   21 50 
     Female   21 50 
Smoking Status     
     Smoker   8 19 
     Non-smoker   31 74 
     Missing   3 7 
Ethnicity     
     Caucasian   39 93 
     Aboriginal    3 7 
Therapy     
    ASA Agent   15 36 
    Immunomodulators   16 38 
    Anti-TNF Agent   8 19 
    None   3 7 
Anthropometry     
    Weight (kg) 81.2 ± 20.8 47.3 – 129.1   
     Height (cm) 172.4 ± 8.2 157.5 – 188.0   
     BMI 26.9 ± 6.0 18.0 – 41.9   
Freq, frequency, ASA, amino-salicylic acid, Anti-TNF, anti-tumour necrosis factor, y, 
years, BMI, body  
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Table 5.3 Endoscopic assessment of disease location of the newly diagnosed cohort (n=42) 
 CD, n=26 UC, n=16 
 Frequency (%) Frequency (%) 
Disease Location (CD)     
    Ileal 8 31   
    Ileocolonic 12 46   
    Colonic 6 23   
Disease Location (UC)     
     Pan-colonic   10 63 
     Left-sided   4 25 
     Proctosigmoditis   2 13 
 Disease location of 42 newly diagnosed IBD patients (n=42), divided into 
Crohn’s disease (n=26) and ulcerative colitis (n=16).  
 
Table 5.4 Biomarker characteristics in a newly diagnosed cohort (n=42) 
  Median IQR Q1 - Q3  Normal Range 
Biomarker         
    hsCRP (mg/L) 5.0 17.0 2.0 - 19.0 0 - 7.0 
    FC (μg/g) 729 1126 330.3 - 1455.8 < 50 
    Lf (μg/mL) 146.0 290.0 6.0 - 298.0 0 - 7.24 
Results of biomarker concentrations in full cohort of 42 IBD patients. Results are 
expressed as median values. One value was missing from hsCRP analysis. IQR, Interquartile 
range, Q1, quartile 1, Q3, quartile 3, hsCRP, high sensitivity C-reactive protein, FC, 
calprotectin, Lf, lactoferrin.  
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The anthropometric characteristics of the newly diagnosed cohort are found in Table 5.2. 
The mean weight of the cohort was 81.2 ± 20.8 kg and height was 172.4 ± 8.2 cm. BMI for the 
newly diagnosed cohort was 26.9 ± 6.0, falling into the “overweight” category (National Institute 
of Health, 2015).   
The box and whisker plots shown in Figures 5.1 - 5.4 display the relationship between 
disease activity and biomarker concentration. When stratified in relation to clinical and 
endoscopic disease activity of CD (CDAI, HBI and SES-CD), median values of FC, Lf, and 
hsCRP increase with increases in disease severity (Figure 5.1, 5.2). This trend is also observed 
between biomarkers and disease activity (pMayo, Full Mayo) in UC (Figure 5.3, 5.4).  
 
Figure 5.1 Fecal biomarkers, calprotectin and lactoferrin, stratified by disease activity in Crohn’s 
disease. (CDAI: active > 150, inactive > 150, HBI: remission ≤ 2, active 3-7, severe ≥ 8 SES-
CD: inactive 0-2, mild 3-6, moderate 7-15, severe ≥ 16). CDAI, Crohn’s disease Activity Index, 
HBI. Harvey Bradshaw Index, SES-CD, Simple Endoscopic Score for Crohn’s disease.                
o indicates an outlier.   
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Figure 5.2 High sensitivity C-reactive protein stratified by disease activity in Crohn’s disease 
(CDAI: active > 150, inactive > 150, HBI: remission ≤ 2, active 3-7, severe ≥ 8 SES-CD: 
inactive 0-2, mild 3-6, moderate 7-15, severe ≥ 16). CDAI, Crohn’s disease Activity Index, HBI. 
Harvey Bradshaw Index, SES-CD, Simple Endoscopic Score for Crohn’s disease, CRP, C - 
reactive protein. o indicates an outlier. 
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Figure 5.3 Fecal biomarkers, calprotectin and lactoferrin, stratified by disease activity in 
Ulcerative colitis. (partial Mayo (pMayo): inactive ≤ 2, mild 3-4, moderate, 5-6, and severe 7-9. 
Mayo: inactive ≤ 2, mild 3-5, moderate 6-10, severe 11-12). pMayo, partial mayo score.                
o indicates an outlier. 
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Figure 5.4 High sensitivity c-reactive protein stratified by disease activity in Ulcerative colitis 
(partial Mayo (pMayo): inactive ≤ 2, mild 3-4, moderate, 5-6, severe 7-9 , Mayo: inactive ≤ 2, 
mild 3-5, moderate 6-10, severe 11-12). pMayo, partial mayo score. 
The relationship between biomarkers and disease activity scores are presented by a 
simple linear regression found in Table 5.5. In CD, a modest correlation between the biomarkers 
and the markers of disease activity was found, with the strongest relationship between FC and 
SES-CD (r = 0.62). This relationship was not as strong with CRP or lactoferrin. In UC, the 
strongest relationship was also shown to be between FC and the Full mayo score (r = 0.61). 
Figure 5.5 displays the relationship between BMI, biomarkers and glycemic index and glycemic 
load.  
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Table 5.5 Simple linear modelling scores in a newly diagnosed IBD cohort (n=42)  
  FC (µg/g) Lf (µg/mL) hsCRP (mg/L) 
 r p-value  r p-value  r p-value 
CD, n=26       
HBI 0.36 0.0810 0.10 0.6407 0.41 <0.05 
CDAI 0.31 0.1357 0.13 0.5242 0.32 0.1133 
SES-CD, n=17 0.62 <0.01 0.37 0.1415 0.13 0.6283 
UC, n=16       
PTI 0.20 0.4844 0.30 0.2649 0.29 0.3009 
Partial Mayo 0.21 0.4744 0.54 <0.05 0.43 0.1249 
Full Mayo, n=9 0.61 <0.01 0.36 0.3364 0.48 0.1950 
Results of a linear regression model in a full cohort of 42 newly diagnosed IBD patients. 
hsCRP, high sensitivity C-reactive protein, FC, calprotectin, Lf, lactoferrin, CD, Crohn’s 
disease, UC, Ulcerative colitis, HBI, Harvey Bradshaw Index, CDAI, Crohn’s disease Activity 
Index, SES-CD, Simple Endoscopic Score - Crohn’s disease, PTI, Powell Tuck Index.   
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Figure 5.5 Correlation between biomarkers, body mass index (BMI) and measures of 
carbohydrate quality, glycemic index (GI) and glycemic load (GL) in a newly diagnosed IBD 
cohort (n=41). Lf, lactoferrin, FC, fecal calprotectin.   
 
.
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Table 5.6 Mean daily intake of nutrients in newly diagnosed IBD (n=41) 
 CD, n=25 UC, n=16 All, n=41  
 Mean (SD) Range Mean (SD) Range Mean (SD) Range AMDR 
Energy (kcal) 1556 (545) 637 – 2750 
 
  
1761 (683) 527 – 3139 1636 (603) 527 - 3139 
 
 
 
 
 
Protein (g) 61 (25) 20 – 118   66 (31) 6 – 144 63 (27) 6 – 144  
  % of NRG 16 (3) 11 – 25  15 (4) 5 – 21  15 (3) 5 – 25 10 – 35 
Fat (g) 67 (28) 21 – 124 74 (31) 11 – 140  70 (29) 11 – 140  
  % of NRG 38 (7) 18 – 53  37 (6) 19 – 43  37 (6) 18 – 53 20 – 35 
Carbohydrate (g) 
 
175 (61) 76 – 356  205 (81) 104 – 387  187 (70) 76 – 387  
 % of NRG 46 (9) 32 – 78  48 (9) 31 – 79  47 (9) 32 – 79 45 – 65 
Alcohol (%) 4 (5)  0 – 17 4 (5) 0 - 14 4 (5) 0 – 17  
Fibre (g) 15 (8) 6 – 38 14 (9) 2 - 39 15 (8) 2 – 39  
GL 
 
 
85 (33) 37 – 179  104 (39) 51 - 186 92 (36) 37 – 186  
GI  
 
53 (4) 42 - 59 55 (3) 50 - 59 53 (4) 42 – 60  
       Mean daily nutrient intake for 38 newly diagnosed (n=38) IBD patients. Data are expressed as mean (standard deviation) or as 
stated. NRG, energy, GL, glycemic load based on glucose standard, GI, glycemic index based on glucose standard, CD, Crohn’s 
disease, UC, Ulcerative colitis, AMDR, acceptable macronutrient distribution range (Institute of Medicine (U.S.) & Institute of 
Medicine (U.S.), 2005)  
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Table 5.7 Mean daily food servings intake in newly diagnosed IBD (n=41) 
Serving group CD, n=25 UC, n=16 All, n=41 Food Pyramid, 2005 
Vegetable 3.6 ± 2.9 (0.6 – 11.5) 2.6 ± 1.8 (0.2 – 6.6) 3.2 ± 2.5 (0.2 – 11.5) 3 – 5  
 
Grain 3.0 ± 1.7 (0.8 – 6.3) 3.7 ± 1.7 (0.1 – 6.8) 3.3 ± 1.8 (0.1 – 6.8) 6 – 11 
 
Meat 1.7 ± 0.9 (0.4 – 4.4) 1.8 ± 1.1 (0.2 – 4.8) 1.7 ± 1.0 (0.2 – 4.8) 2 – 3  
Dairy 1.3 ± 0.9 (0.0 – 3.5) 1.5 ± 1.0 (0.1 – 3.7) 1.4 ± 0.9 (0.0 – 3.7) 2 – 3 
Fruit 1.5 ± 1.1 (0.2 – 4.0) 1.4 ± 1.1 (0.1 – 4.0) 1.5 ± 1.1 (0.1 – 4.0) 2 – 4 
Fat  2.8 ± 1.5 (0.5 – 5.8) 3.1 ± 1.3 (1.0 – 5.9) 2.9 ± 1.4 (0.5 – 5.9) Very little 
Mean daily food serving intake for 41 newly diagnosed IBD patients. Data are expressed as mean ± standard deviation (range) 
Compared with reference values from the 2005 USDA Food Pyramid (United States Department of Agriculture, 2005). CD vs. UC 
samples were compared using independent t-test (no significant differences were found).  
An assessment of the mean daily nutrient intake for this newly diagnosed cohort is found in Table 5.6. The energy intake for 
this cohort was 1636 kilocalories (kcal) per day. The intake of macronutrients and alcohol (expressed as percentage of energy intake) 
was 15% dietary protein, 37% dietary fat, 47% dietary carbohydrate, and 4% from alcohol. Only dietary fat was found to be slightly 
outside the acceptable macronutrient distribution range (AMDR) (Institute of Medicine (U.S.) & Institute of Medicine (U.S.), 2005), 
although carbohydrate was close to the lower end.  Total dietary fibre was calculated to be 15 grams per day for the entire cohort, 
which when adjusted for energy intake, was 9 g/1000 kcal/day, lower than recommended (14 g/1000 kcal/d) (Institute of Medicine 
(U.S.) & Institute of Medicine (U.S.), 2005). In the full cohort, GI was calculated as 53, GL as 85. In CD, intake of macronutrients and 
alcohol was 16% protein, 38% fat, 46% carbohydrates, and 4% alcohol. GI was calculated at 55, GL was calculated at 104. In UC, 
intake of macronutrients and alcohol was 16% protein, 37% fat, 48% carbohydrates, and 4% alcohol. Dietary fibre was calculated to 
be 14 g/1000 kcal/d, same as the recommendation. GI was calculated at 53, GL was calculated at 92. 
8
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The mean daily food serving intakes of the newly diagnosed cohort is found in Table 5.7. 
The entire cohort was found to consume less grain (3.3 ± 1.8 vs. 6-11), meat (1.7 ± 1.0 vs. 2-3), 
dairy (1.4 ± 0.9 vs. 2-3) and fruit (1.5 ± 1.1 vs. 2-4) compared with 2005 Food Pyramid 
recommendations (n=41). Vegetable consumption was within recommendations (3.2 ± 2.5 vs. 3-
5). Although not statistically significant, vegetable intake was higher in CD patients compared 
with UC (3.6 ± 2.9 vs. 2.6 ± 1.8), with the opposite trend being seen with grain intake (3.0 ± 1.7 
vs. 3.7 ± 1.7, respectively). Meat, dairy, fruit and fat servings were roughly equal (Table 5.7).  
Nutritional assessment and BMI values for individual CD patients, separated by male and 
female, are found in Table 5.8 (n=26, 14 female, 12 male). Male BMI values were higher than 
females, 27.8 to 24.7, respectively. Both male and female CD patients were above the 
recommended dietary allowance (RDA) for protein intake (0.8 g/kg/d) at 0.9 and 0.8 g/kg/d, 
respectively (Institute of Medicine (U.S.) & Institute of Medicine (U.S.), 2005). However, both 
female and male patients fell short of fibre requirements (14 g/ 1000 kcal/d) at 9 and 12 g/1000 
kcal/d, respectively (Institute of Medicine (U.S.) & Institute of Medicine (U.S.), 2005).  
 
Nutritional assessment and BMI values for individual UC patients, separated by male and 
female, are found in Table 5.9 (n=16, 6 female, 10 male). Male and female BMI values were 
similar, 28.5 and 28.0, respectively. Female UC patients were below the RDA for protein intake 
at 0.6 g/kg/day, while male patients were above at 0.9 g/kg/day. (Institute of Medicine (U.S.) & 
Institute of Medicine (U.S.), 2005). Similar to CD patients, both female and male patients fell 
short of fibre requirements at 8 and 7 g/1000 kcal, respectively (Institute of Medicine (U.S.) & 
Institute of Medicine (U.S.), 2005)
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Table 5.8 Nutritional assessment and BMI in a newly diagnosed cohort of female CD patients (n=26) 
Patient  Age Gender BMI  NRG (kcal)   PRO (g)  PRO (g/kg/d) CHO (g) FAT (g) FIB (g) FIB (g/1000kcal) 
CD3 22 F 20.1 2750 104 2.1 356 108 28 10 
CD4 19 F 19.0 1003 39 0.8 116 43 6 6 
CD5 52 F 35.3 655 28 0.3 76 29 8 12 
CD10 48 F 33.2 1067 35 0.4 126 50 8 7 
CD11 47 F 19.5 2069 80 1.4 244 92 21 10 
CD18 20 F 21.7 1575 63 1.2 170 64 13 8 
CD19 25 F 25.3 637 20 0.3 92 22 7 11 
CD20 22 F 21.6 1231 43 0.7 116 65 14 11 
CD21 34 F 22.1 2003 68 1.0 247 84 12 6 
CD22 60 F 26.6 1146 54 0.7 144 40 20 18 
CD23 28 F 19.5 1861 84 1.4 187 86 12 7 
CD24 32 F 21.8 1389 52 0.9 166 60 9 6 
CD25 52 F 30.3 963 45 0.6 122 34 12 12 
CD26 32 F 29.5 1977 68 0.9 223 93 16 8 
FEMALE 35.2  14 24.7 1452 56 0.9 170 62 13 9 
TOTAL 35.9 26 26.1 1556 61 0.8 176 67 15 10 
Baseline demographics in 26 newly diagnosed Crohn’s disease (CD) patients. Summary rows (FEMALE etc.) present mean 
data. BMI, body mass index, NRG, energy, PRO, dietary protein, FAT, dietary fat, CHO, dietary carbohydrate, FIB, dietary fibre, 
n/a, not applicable.  
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Table 5.8 Nutritional assessment and BMI in a newly diagnosed cohort of male CD patients (n=26) (CONTINUED)  
Patient  Age Gender BMI  NRG (kcal)   PRO (g)  PRO (g/kg/d) CHO (g) FAT (g) FIB (g) FIB (g/1000kcal) 
CD1 44 M 21.6 1670 73 1.0 175 59 13 8 
CD2 25 M 26.3 2029 101 1.1 196 84 22 11 
CD6 32 M 18.0 1027 32 0.6 201 21 38 37 
CD7 33 M 24.8 1748 63 0.8 209 74 14 8 
CD8 52 M 27.6 1864 118 1.2 172 70 24 13 
CD9 48 M 27.2 2153 76 0.8 172 104 13 6 
CD12 31 M 21.2 2143 85 1.0 246 97 27 12 
CD13 36 M 33.7 1259 37 0.3 147 50 11 9 
CD14 35 M 35.2 954 44 0.4 102 42 10 10 
CD15 28 M 33.8 n/a  n/a  n/a  n/a  n/a  n/a  n/a  
CD16 52 M 33.9 2127 61 0.6 197 124 14 7 
CD17 24 M 30.4 1599 55 0.6 186 74 12 7 
MALE 36.7 12 27.8 1688 68 0.8 182 73 18 12 
TOTAL 35.9 26 26.1 1556 61 0.8 176 67 15 10 
Baseline demographics in 26 newly diagnosed Crohn’s disease (CD) patients. Summary rows (MALE etc.) present mean data. 
BMI, body mass index, NRG, energy, PRO, dietary protein, FAT, dietary fat, CHO, dietary carbohydrate, FIB, dietary fibre, n/a, not 
applicable.  
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Table 5.9 Nutritional assessment and BMI in a newly diagnosed cohort of UC patients (n=16) 
Patient Age Gender BMI  NRG (kcal)   PRO (g)  PRO (g/kg/d) CHO (g) FAT (g) FIB (g) FIB (g/1000kcal) 
UC1 41 F 28.2 1291 56 0.7 172 41 11 8 
UC5 38 F 22.1 2003 68 1.0 247 84 12 6 
UC7 43 F 41.9 1422 47 0.4 166 69 17 12 
UC10 50 F 25.4 527 6 0.1 104 11 2 3 
UC14 35 F 21.0 1431 69 1.1 155 64 15 10 
UC15 55 F 29.6 1085 40 0.5 145 41 12 11 
FEMALE 43.7  6 28.0 1293 48 0.6 165 52 12 8 
UC2 35 M 36.9 2304 87 0.7 276 95 11 5 
UC3 49 M 22.6 1870 54 0.9 226 79 13 7 
UC4 70 M 28.1 1146 43 0.5 122 48 6 5 
UC6 36 M 30.1 1776 95 1.0 189 73 17 9 
UC8 45 M 33.8 3139 144 1.5 350 140 39 12 
UC9 54 M 27.2 1315 51 0.7 105 63 7 5 
UC11 35 M 37.7 2069 97 0.8 220 81 10 5 
UC12 20 M 25.5 2035 77 0.9 212 95 12 6 
UC13 34 M 18.6 1757 60 1.0 202 82 12 7 
UC16 37 M 24.0 3009 64 0.9 387 117 31 10 
MALE 41.5 10  28.5 2042 77 0.9 229 87 16 7 
TOTAL 42.3 16 28.3 1761 66 0.8 205 74 14 8 
Baseline demographics in 16 newly diagnosed Ulcerative colitis (UC) patients. Summary rows (FEMALE etc.) present mean 
data. BMI, body mass index, NRG, energy, PRO, dietary protein, FAT, dietary fat, CHO, dietary carbohydrate, FIB, dietary fibre 9
2
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A one-way ANOVA was used to determine the relationship between quartiles of GI and 
GL (based on glucose standard) and fecal biomarkers, FC and Lf (presented as median values). 
The concentration of Lf and FC increased across quartiles of glycemic index (µg/mL and µg/g), 
respectively, from the first quartile (n=10, 3.5 and 420.0), to the second (n=11, 695.0 and 91.0), 
third (n=10, 868.5 and 117.0) and fourth (n=10, 1172.0 and 163.5) (Figure 5.6). The 
concentration of Lf and FC did not follow the same trend for quartiles of glycemic load (µg/ml 
and µg/g), respectively, from the 1st quartile (n=10, 118.5 and 776.5), to the second (n=11, 61.0 
and 612.0), third (n=10, 210.0 and 1665.5) and fourth (n=10, 49.0 and 676.0) (Figure 5.7). 
Although a clear trend is observed between quartiles of GI, no statistically significant differences 
in biomarkers between these quartiles 
 
 
Figure 5.6 Relationship between glycemic index (GI) and fecal biomarkers, lactoferrin (blue, 
µg/mL) and calprotectin (green, µg/g) across quartiles in newly diagnosed IBD cohort (n=41). 
Biomarkers are presented as median values. Lf, lactoferrin, FC, fecal calprotectin.   
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Figure 5.7 Relationship between glycemic load (GL) and fecal biomarkers, lactoferrin (blue, 
µg/ml) and calprotectin (green, µg/g) across quartiles in newly diagnosed IBD cohort (n=41). 
Biomarkers are presented as median values. Lf, lactoferrin, FC, fecal calprotectin.   
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 Repeated Measures: For prediction of CDAI among patients with CD, our analyses 
identified therapy (p-value = 0.006), hsCRP (p-value = <0.001), and FC (p-value = <0.001) as 
significant predictors of disease activity over time (see Table 5.10). Age, hsCRP, and FC met the 
assumption of linearity (p-values≥0.05). Lf was excluded during unconditional analysis because 
it was not a significant predictor (p-value = 0.157). In the model building process, therapy, age, 
gender, and hsCRP were removed during the backward selection process, and only FC was 
retained. However, hsCRP was identified as a cofounding variable (using a 10% cut-off for 
precision) and included in the final model. Therefore, the final model including FC and hsCRP 
(Table 5.11) fitted best (QIC=491,637.832) than the null model (QIC=1,093,062.781).  
Table 5.10 Unconditional analysis for repeated measures using Crohn’s disease Activity Index 
(CDAI) (100 observations, n=25) 
 β estimates 95% CI p-value 
Therapy     
   5-ASA 64.8598 1.7829 127.9367 0.044 
   Immuno 77.5797 28.6622 126.4972 0.002 
   Anti-TNF 82.4162 18.1051 146.7274 0.012 
   None ref    
Gender     
   Male -10.1875 -69.9515 49.5766 0.738 
   Female ref    
Age 0.4512 -2.6890 3.5913 0.778 
Lf (80 obs.) 0.0965 -0.0372 0.2303 0.157 
hsCRP (94 obs.) 1.8078 1.0896 2.5261 <0.001 
FC (84 obs.) 0.0351 0.0224 0.0478 <0.001 
Unconditional analysis of repeated measures in predicting CDAI score. 100 observations for 
each variable unless state otherwise. CDAI, Crohn’s disease Activity Index, 5-ASA, amino-
salicylic acid, Anti-TNF, anti-tumour necrosis factor agent, immuno, immunosuppressant, ref, 
reference variable, Lf,  lactoferrin, FC, fecal calprotectin, hsCRP, high sensitivity C-reactive 
protein, obs., number of observations.  
  
  
96 
 
 
Table 5.11 A multivariate general estimating equation for all repeated measures using Crohn’s 
disease Activity Index (CDAI) (79 observations, n=25) 
 β estimates 95% CI p-value 
hsCRP 0.9576 -0.3968 2.3119 0.116 
FC  0.0290 0.0144 0.0433 <0.001 
General estimating equation modelling results of the predictive ability of repeated measures in 
predicting disease activity scores. CDAI, Crohn’s disease Activity Index, FC, fecal calprotectin, 
hsCRP, high sensitivity C-reactive protein.  
 
For prediction of PT among patients with UC, unconditional analyses identified therapy 
(p-value <0.001), hsCRP (p-value = 0.007), and FC (p-value = 0.002) as significant predictors. 
Lf was excluded during unconditional analysis, considering that it was not a significant predictor 
of disease activity (p-value = 0.106) (Table 5.12). There was no evidence that age, hsCRP, and 
FC violated the assumption of linearity (p-values ≥ 0.05). In the multivariable model building, 
therapy and age were removed during the backward selection process, and gender, FC, and 
hsCRP were retained. Therapy was identified as a cofounding variable and included in the final 
model (using a 10% cut-off for precision). 
Table 5.12 Unconditional analysis for repeated measures using Powell Tuck (PT) Index (n=16, 
65 observations) 
 β estimates 95% CI p-value 
Therapy     
   5-ASA -0.9046 -5.7378 3.9286 0.714 
   Immuno 3.9944 -0.3651 8.3539 0.073 
   Anti-TNF -0.8826 -5.4437 3.6784 0.704 
   None ref ref ref ref 
Gender     
   Male 2.0856 -0.1495 4.3207 0.067 
   Female ref    
Age -0.0106 -0.0647 0.0440 0.705 
Lf (38 obs.) 0.0052 -0.0011 0.0115 0.106 
hsCRP (56 obs.) 0.0760 0.0206 0.1314 0.007 
FC (45 obs.) 0.0006 2.5067 4.7097 0.002 
Unconditional analysis of repeated measures in predicting disease activity scores. 65 
observations for each variable unless state otherwise. PT, Powell Tuck Index, 5-ASA, amino-
salicylic acid, Anti-TNF, anti-tumour necrosis factor agent, immuno, immunosuppressant, ref, 
reference variable, Lf,  lactoferrin, FC, fecal calprotectin, hsCRP, high sensitivity C-reactive 
protein, obs., number of observations.  
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The final model predicting PT among patients with UC included FC, hsCRP, gender and 
therapy (QIC=292.564) had a better model fit over the null model (QIC=675.992) (Table 5.13).  
The exchangeable correlation structure provided better QIC than the independent, exponential, 
and autoregressive structures. 
Table 5.13 A multivariate general estimating equation for all repeated measures using Powell 
Tuck (PT) (40 observations, n=16) 
 β estimates 95% CI p-value 
Therapy     
   5-asa -0.8466 -3.8463 2.1530 0.580 
   Immuno 1.5018 -1.3649 4.3685 0.305 
   Anti-TNF -1.0300 -5.1138 3.0539 0.621 
   None ref    
Gender     
   Male 1.9667 0.0315    
3.901859 
3.9019 0.046 
   Female ref    
hsCRP 0.0770 0.0365    
.1175682 
0.1176    
.1175682 
<0.001 
FC  0.0006 0.0003   
.0009249 
0.0009  
.0009249 
<0.001 
General estimating equation modelling results of the predictive ability of repeated measures in 
predicting disease activity scores. PT, Powell Tuck index, FC, fecal calprotectin, hsCRP, high 
sensitivity C-reactive protein, ref, reference variable. 
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5.5  Discussion 
The primary objective of this research was to develop a single-center, prospective cohort 
of newly-diagnosed adults with IBD, in an effort to evaluate the predictive performance of select 
endoscopic, serologic, and fecal biomarkers in long-term disease course. Over 5 years, 42 newly 
diagnosed patients were enrolled in this single-center study. The original goal for recruitment 
was set at 70 patients over 2-years. Poor recruitment limited the statistical power of this study. 
Adequate numbers of newly diagnosed patients in single research center (population ~200,000 
residents) may not be feasible.  
The fecal biomarkers in this study, FC and Lf, acting as surrogate markers of 
inflammation, fell outside the ranges of healthy levels (Table 5.3). The serum marker, hsCRP, 
was within the normal range for healthy individuals. Biomarker concentrations outside of the 
normal ranges are expected in an inflammatory condition like IBD (Vermeire, 2006).  
Clinical measures of disease activity have been criticized for their inclusion of subjective 
variables. However, endoscopic measures of disease activity are invasive and expensive. Ideally, 
fecal biomarkers would be suitable surrogate markers of inflammation for these tests. In CD, a 
modest correlation between the biomarkers and the traditional endoscopic markers of disease 
activity was found, with the strongest relationship between FC and SES-CD (r = 0.62). This 
relationship was not as strong with CRP or lactoferrin. In UC, the strongest relationship was also 
shown to be between FC and the Full mayo score (r = 0.61). A comprehensive overview of the 
relationship between FC and endoscopic activity can be found in Table 2.2 of this document. 
Our results are in agreement with the correlation values presented in the 19 studies reviewed in 
that table (r = 0.48 to 0.87). The results from this study are supported by the observations of 
others (Cellier et al., 1994; Jones et al., 2008; Kane et al., 2003). One major difference between 
those studies and the one presented in this paper is the study population. An advantage of this 
study, is that a newly diagnosed cohort presents a clearer look at the relationship between fecal 
biomarkers and endoscopic disease activity.  
Although the sample size was small, our data suggests that the use of clinical disease 
activity measures in newly diagnosed IBD may be adequate for determining inflammatory 
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burden and for risk stratification. However, this work also confirms the lack of confidence in 
clinical measures of disease activity assessment.  
A secondary aim of this study was to provide a nutritional and anthropometric baseline 
assessment in newly diagnosed patients. Our cohort had an overall BMI of 27.1, that is 
categorized as “overweight” (National Institute of Health, 2015). The energy intake for this 
cohort was calculated at 1636 kcal per day. There is a discrepancy between the reported energy 
intake and BMI in this patient population.  Macronutrients and alcohol as expressed as 
percentage of energy intake was 15% dietary protein, 37% dietary fat, 47% dietary carbohydrate, 
and 4% from alcohol. Only dietary fat fell outside of the AMDR (Institute of Medicine (U.S.) & 
Institute of Medicine (U.S.), 2005). Dietary fibre was inadequate at 9 g/1000 kcal per day of 
intake. In both male and female IBD patients, protein intake was found to be adequate in 
reference to the RDA, however fibre as under the recommended amount (Table 5.8, 5.9).  
Geerling et al. (2000) was the first study to perform a nutritional assessment at IBD 
diagnosis (Geerling et al., 2000). Patients that had been diagnosed with IBD in the previous 6-
months were enrolled in this study. This well designed study assessed disease activity, CRP and 
body composition. Dietary intake was assessed by cross-check dietary history (in-home dietitian 
assessment cross-checked with FFQ).  Of note, this was a multi-center study (3 centers) based in 
The Netherlands, where the sixty-nine patients came from a prospective 71 that been diagnosed 
in the study period (91% enrolment). Sixty-nine age- and sex-matched controls volunteered for 
this study. BMI was found to be 22.2 ± 2.7 in CD (n=23) and 23.1 ± 3.0 in UC (n=46) (mean ± 
SD), far lower than the BMI values found in our study, 26.1 and 28.3, respectively. Energy 
intake was calculated at 11.0 ± 3.4 MJ (2629 ± 813 kcal) for CD patients and 10.3 ± 2.6 MJ 
(2462 ± 621 kcal). However, the authors noted this may because the patients did not have 
strongly elevated disease activity, thus a higher energy intake (Geerling et al., 2000). These are 
significantly higher energy intakes than found in our study (Table 5.6). Macronutrients and 
alcohol were expressed as a percent of energy intake. In CD, 14.7 ± 2.2% calories came from 
protein, 34.0 ± 7.6% from fat, 51.0 ± 7.4% from carbohydrates and 0.9 ± 1.3% from alcohol. 
From the macronutrients, only carbohydrates were statistically higher in CD than controls. 
Compared with our findings, fat and alcohol intake was significantly lower (p-value < 0.01). In 
UC, 14.8 ± 2.5% calories came from protein, 35.2 ± 6.3% from fat, 49.3 ± 7.7% from 
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carbohydrates and 1.8 ± 3.0% from alcohol. From the macronutrients, only protein was 
statistically lower than controls. There were no significant differences compared with our 
findings. In Geerling et al. (2000), both UC and CD, alcohol consumption was statistically lower 
than in healthy controls. Fibre intake was calculated at 1.6 ± 0.5 g/MJ (7 g/1000 kcal/d) for CD 
patients and 1.9 ± 0.5 (8 g/1000 kcal) from UC patients, compared with the 10 and 8 g/1000 
kcal/d  for our CD and UC patients, respectively. Although they did not measure glycemic index 
or load, the intake of mono- and disaccharides, or simple carbohydrates, as a percent of the diet 
was calculated.  In CD, 26.7 ± 6.6 % of energy was from simple carbohydrates, significantly 
more than healthy controls.  
Discrepancies between these two studies are most likely due to the differences in dietary 
intake assessment. In our study, we used a FFQ, assessing the usual consumption of a list of 
foods, compared with the cross-check dietary history used by Geerling et al. (2000). FFQ’s 
capture a variety of information, although at differing levels of accuracy. They are inexpensive 
and feasible to administer in studies where multiple food records or 24-hour food recalls would 
not be possible (Liu, 1994). Additionally, they are appropriate to capture the usual intake of the 
individual, usually retrospectively before a disease develops (Nutrition Quest, 2015). One 
limitation is the recall bias introduced into our study by using a FFQ to retrospectively capture 
dietary information (Molodecky, Panaccione, Ghosh, Barkema, & Kaplan, 2011) 
In this study, our IBD cohort was found to consume less grain, meat, dairy and fruit 
compared with 2005 Food Pyramid recommendations (Table 5.7). Also, as previously noted, 
comparatively our cohort BMI was high and energy intake was low, that may highlight an 
underestimation of food intake by the FFQ.  
In our study, when energy intake was separated into quartiles (not shown in results), the 
most striking observation was that the lowest quartile of energy had the highest intake of 
carbohydrates at 55 ± 13.7%. As energy increased across quartiles, this intake dropped to 44.5 ± 
5.9%, 44.7 ± 4.3%, and 43.7 ± 6.1%. At lower intakes, patients have higher carbohydrates, 
presumably because they are sicker. However, it is unknown if this is the result of the disease 
instead of the cause (Riordan et al. 1998).  
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Another component of our secondary aim was evaluating GI and GL, or “carbohydrate 
quality”, in this newly diagnosed cohort, along with assessing the relationship between these 
measures and fecal biomarkers. Using the glucose standard, GI and GL was measured in our full 
cohort at 53 and 92, respectively. Healthy control GI and GL values of 51 and 120, respectively, 
has been reported elsewhere (n=1503) (Lahmann et al., 2014). The difference in these GI values 
are statistically significant (p-value<0.01). Although not statistically significant, a clear trend 
was observed between GI (measured by glucose standard) and the median concentration of Lf 
and FC (Figure 5.6).  
Furthermore, this study aimed to observe the predictive nature of biomarkers through 
disease course in newly diagnosed IBD. The biomarkers, hsCRP, FC and Lf, along with gender, 
therapy and age were studied as predictors of disease activity. In CD, a final model for predicting 
CDAI included hsCRP and FC (Table 5.11). The beta (β) estimates for hsCRP and FC were 
calculated at 0.9576 and 0.0290, respectively. Meaning for every 1 unit increase in the hsCRP 
and FC, this model predicts CDAI to increase by 0.9576 and 0.0290 points, respectively. In UC, 
a final model for predicting PT among patients included FC, hsCRP, gender and therapy (Table 
5.13). The β estimates for therapy were calculated at -0.8466 (5-ASA), 1.5018 
(immunomodulators), -1.0300 (anti-TNF agents) with no therapy acting as the reference 
category. Thus, PT scores decreased when 5-asa and anti-TNF therapy were used as therapy.  
Also, the β estimates for hsCRP and FC were calculated at 0.0770 and 0.0006, respectively, 
showing that biomarkers have a smaller impact on PT score estimation, although PT scores are 
smaller values.   The clinical scores, CDAI and PT, were used as outcomes due to low number of 
endoscopic measures.  These results agree with the significance of FC and hsCRP in the 
prediction of CDAI found in the previous chapter (Chapter 4) of this thesis. The results from the 
building of these models are supported by others studying the predictive nature of biomarkers on 
disease activity (Björkesten et al., 2012; Langhorst et al., 2008).  
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5.6  Conclusion 
This study observed a strong relationship between biomarkers and disease activity in 
newly diagnosed disease activity. The biomarker, FC, was found to be consistently related to 
measures of disease activity at baseline, particularly endoscopic measures. Both hsCRP and FC 
were found to predict disease activity through newly diagnosed disease course. The major food 
groups and dietary fibre intake were shown to be lower in this patient population compared with 
reference intakes. However, protein intake was shown to be adequate. Lastly, GI has a strong, 
positive correlation with fecal biomarkers. Fecal biomarkers have been observed to be predictive 
of disease activity in newly diagnosed IBD and should be included in future studies as surrogate 
markers of inflammation whenever possible.  
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CHAPTER 6 
CALCULATION AND FEASIBILITY OF FECAL CALPROTECTIN IN HEALTHY 
AND IBD PREGNANCY 
 Marc W. Morris, Jennifer L. Jones, Gordon A. Zello, Jane Alcorn, Juan Nicolás Peña-
Sánchez, Sharyle A. Fowler   
 Not yet published 
 IBD has a peak incidence between 18 – 35 years of age, making management during 
pregnancy very common. The gold standard for assessing disease activity is endoscopic 
procedures, which can be unpleasant and painful for patients, and time-consuming and expensive 
to perform. Even though endoscopy can be safely performed in pregnancy, patients and 
clinicians prefer to avoid invasive procedures during this time, making assessment through non-
invasive surrogate markers desirable. FC, a neutrophil derived protein, is a promising biomarker 
in the study of intestinal inflammation. Studies have shown FC to be successful in distinguishing 
between IBD and irritable bowel syndrome, in addition to having a strong relationship with 
endoscopic disease activity. However, many studies have excluded the recruitment of pregnant 
patients. The objective of this study was to establish FC reference values for healthy pregnant 
patients. Also, FC was analyzed in pregnant patients with IBD, to assess the utility of measuring 
this biomarker in this important clinical subpopulation. This work adds to the evidence 
suggesting biomarkers demonstrate utility and predictive ability in IBD.  
Author role: I completed the lab analysis, most of the statistical analysis and manuscript 
preparation and writing for this chapter.  
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6.1  Introduction 
 FC is a promising fecal biomarker in the study of intestinal inflammation.  FC is a 
neutrophil-derived protein released locally in the gut in response to inflammation (Røseth, 
Schmidt, & Fagerhol, 1999).  FC resists metabolic degradation by intestinal bacteria and is stable 
in stool samples for up to one week at room temperature (Røseth et al., 1992). Numerous studies 
have shown FC to be effective in distinguishing inflammatory vs. non-inflammatory conditions  
(IBD vs. IBS) with high sensitivity (93%, 95% CI 85-97%) and specificity (96%, 95% CI 79-
99%) (van Rheenen et al., 2010). Additionally in patients with IBD, the concentration of FC has 
been shown to correlate significantly with endoscopic disease activity in both UC and CD 
(Schoepfer et al., 2009; Sipponen et al., 2008). Previous studies studying FC have excluded 
pregnant patients.  The normal physiologic changes of pregnancy are known to affect 
biomarkers, such as hemoglobin, white blood cell and platelet counts, CRP and ESR, 
demonstrating the need for FC reference values in pregnancy (Belo et al., 2005; Larsson, Palm, 
Hansson, & Axelsson, 2008; Milman, Bergholt, Byg, Eriksen, & Hvas, 2007; van den Broe & 
Letsky, 2001).  
6.2  Objectives 
 This work aims to establish reference values for FC throughout healthy pregnancy (HP). 
A secondary objective is to assess the utility of FC for measuring intestinal inflammation in 
pregnant patients with pre-existing IBD (IBDP).    
6.3  Materials and methods 
Patient recruitment:  HP patients were recruited as part of a prospective, observational 
cohort study. Patients were recruited from obstetric clinics in the Saskatoon Health Region, 
Saskatchewan. Pregnant women greater or equal to 18 years of age with no history of 
gastrointestinal disorders were eligible for the study.  Patients with a history of IBD, 
gastrointestinal bleeding, gastrointestinal neoplasia, familial adenomatous polyposis and 
hereditary nonpolyposis colorectal cancer syndromes, history of colonic surgery, and intake of 
nonsteroidal anti-inflammatory drugs, aspirin and anticoagulants within the previous month were 
excluded.  IBDP were recruited as part of a prospective, observational cohort by 
gastroenterologists from the Multidisciplinary Inflammatory Bowel Disease Clinic (MDIBDC) at 
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the University of Saskatchewan. Pregnant women greater or equal to 18 years of age, with IBD 
(based on standard clinical, radiologic, endoscopic, and histologic criteria) were eligible for the 
study.    
Data collection: Baseline demographic (age, smoking status) and medical information 
(comorbid medical conditions, medications) was recorded.  Gastrointestinal symptoms 
(abdominal pain, stool frequency, stool consistency using the Bristol Stool Scale, presence of 
rectal bleeding) (Lewis & Heaton, 1997) in the 3 days prior to stool sample collection was 
recorded. Disease activity was assessed at baseline and at each clinic visit using the Simple 
Clinical Colitis Activity Index for UC and the Harvey Bradshaw Index for CD (Harvey & 
Bradshaw, 1980; Walmsley, Ayres, Pounder, & Allan, 1998).  Blood work was completed as per 
routine care, and if clinically indicated, endoscopic and radiologic tests were performed. Fecal 
samples were obtained during each trimester and within 1 - 6 months post-partum.  Longitudinal 
assessment of FC was performed throughout pregnancy during each trimester (Trimester 1 [T1]: 
1-13 weeks, Trimester 2 [T2]: 14-26 weeks, Trimester 3 [T3]:27-40 weeks) and within 6 months 
post-partum. This study was approved by the University of Saskatchewan’s Biomedical Research 
Ethics Board (Bio-REB) (Bio# 13-194, 13-238). 
Calprotectin analysis: FC was determined using a Quantum Blue® FC High Range 
Rapid Test using the Quantum Blue Reader® point-of-care (POC) desk-top reader (ALPCO 
Immunoassays, Salem, NH). Approximately, 30 mg of fecal sample was pressed into a base cap 
and fitted on the extraction tube. This device was filled with 4 mL of extraction buffer and 
homogenized by vortex for 1 minute. A 1:16 dilution was performed with chase buffer and 80 
µL was positioned into the test cartridge for analysis. Each run took 15 minutes to complete and 
results were displayed in micrograms per gram (µg/g) on the POC display. Samples from HP 
patients were run with Rapid Test kits (30 - 300 µg/g) with a quantitation limit (QL) of 30 µg/g. 
Samples from IBDP patients were analyzed with High Range test kids (100 - 1800 µg/g) with a 
QL of 100 µg/g. Parameters that were detectable but below the QL were assigned a value of half 
the QL (15 µg/g for HP, 50 µg/g for IBDP).  
Statistics: Descriptive statistics were used to describe patient demographics and FC 
concentrations. Data is presented as mean ± standard deviation (SD), unless otherwise noted. 
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Since biomarkers are not normally distributed, some results are presented as medians with 
interquartile ranges (IQR). The Mann-Whitney U test was used to identify significant median 
differences in the FC values between the healthy and IBD pregnant patients. The Friedman’s 
ANOVA test was used to determine rank differences across the four FC measures (T1-T3, as 
well as post-partum). Wilcoxon Matched-Pairs Signed Rank tests were also used to identify 
median differences between the four measurements of FC. Statistical analyses were performed 
using the IBM SPSS Statistics software, version 23 (SPSS Inc. Chicago, IL). 
6.4  Results 
 Between February 2014 and June 2015, over 80 pregnant patients were screened for 
potential enrolment and 46 healthy pregnant participants who met the inclusion and exclusion 
criteria were enrolled. Seventeen patients withdrew from the study. Similarly, 15 patients with 
established IBD were enrolled. Three IBD patients withdrew from the study. The average age in 
the healthy pregnant cohort was 33.4 ± 4.0 years. In the HP group, 121 FC samples were 
collected. The average age of the IBD pregnancy was 30.5 ± 3.9 years. In the IBD group, 35 FC 
samples were collected. Seventy-eight percent of healthy pregnant patients reported never 
smoking, with 15% being former and 4% current smokers (Table 6.1). Seventy-three percent of 
IBD pregnancy patients reported never smoking, while the remaining 27% reported as former 
smokers. In the IBD group, 60% had established CD, with 40% having UC (Table 6.1).  
Baseline bowel habits were assessed. The majority of HP patients reported no issues with bowel 
habits at baseline (98% had no abdominal pain or rectal bleeding). More than two thirds of IBD 
pregnancy patients reported no abdominal pain or rectal bleeding.
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Table 6.1 Healthy and IBD pregnant patient demographics (n=46, n=15, respectively) 
 Healthy Pregnancy (n=46) IBD pregnancy (n=15) 
 Mean ± SD (range) Frequency (%) Mean ± SD (range) Frequency (%) 
Age 33.4 ± 4.0 (24 - 44)   30.5 ± 3.9 (25 - 38)   
FC samples  121   35  
Smoking Status       
Never  36 78  11 73 
Former  7 15  4 27 
Current  2 4  0 0 
Missing  1 2  0 0 
Disease Type       
CD     9 60 
UC     6 40 
 Baseline demographics in 46 healthy and 15 IBD pregnant patients. FC, fecal calprotectin, wk, weeks, CD, Crohn’s 
disease, UC, ulcerative colitis. 
1
0
8
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In healthy pregnancy, FC values below the limit of detection were found across each 
assessment period, with an IQR of 37, 30, 44, and 115 for T1-T3 and post-partum, respectively 
(Table 6.2). The overall median for HP was 15 µg/g with an IQR of 38.  
In IBD pregnancy, median FC values of 477, 337, 469, and 439 µg/g were found in T1-
T3 and post-partum, respectively. The IQR for T1-T3 were 571, 857, and 281, with no IQR for 
the postpartum measurement in this group (Table 6.3). The overall median for IBDP was 416 
µg/g with an IQR of 516. Results of the non-parametric analysis in IBD patients are not shown 
since comparisons cannot be made. 
Results of the non-parametric analyses for HP patients throughout pregnancy and post-
partum are shown in Table 6.4 (n=12). The Friedman’s ANOVA test did not identify significant 
differences across the four measurements, χ2(3)=1.657, p=0.647. The pair-wise comparisons, 
Wilcoxon Matched-Pairs Signed Rank tests, showed no significant differences among the FC 
measures (T1-T3, and post-partum medians) (Table 6.5). Figure 6.2 presents box-plots of the 
four measures.  
The Mann-Whitney U test identified significant median differences in the calprotectin 
values between the healthy and IBD pregnancy patients (U=203.5, z=−8.474, p<0.001), see 
Figure 6.1(b).
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 (a)   
(b)  
Figure 6.1 (a) Histograms of fecal calprotectin for the healthy and IBD group. (b) Box plots depicting different distributions of 
calprotectin levels of the healthy pregnancy and IBD groups. The circles and asterisks represent outliers and extreme outliers, 
respectively. 
1
1
0
 
  
111 
 
 
Table 6.2 Fecal calprotectin in healthy pregnant patients (n=46) 
 Trimester 1 
(n=46) 
Trimester 2 
(n=37)   
Trimester 3 
(n=24) 
Postpartum 
(n=14)    
Total  
(n=121)    
Median 15 15 15 15 15 
Mean ± SD 44 ± 59 44 ± 57 38 ± 36 81 ± 99 47 ± 61 
Range 15 - 362 15 - 273 15 - 152 15 - 288 15 - 288 
IQR 37 30 44 115 38 
Fecal calprotectin measurements in healthy pregnant patients. Analysis limit of detection 
was <30 µg/g. Readings of <30 µg/g (below detection limit), <50 µg/g (no inflammation), 50 - 
200 µg/g (mild inflammation), >200 µg/g (active organic disease). SD, standard deviation, IQR, 
interquartile range  
 
Table 6.3 Fecal calprotectin in IBD pregnant patients (n=12) 
 Trimester 1 
(n=12) 
Trimester 2 
(n=13)   
Trimester 3 
(n=9) 
Postpartum 
(n=1)    
Total      
(n=35) 
Median 477 337 469 439 416 
Mean ± SD 537 ± 383 535 ± 436 504 ± 262 439 525 ± 362 
Range 15 - 477 50 - 1180 183 - 1082  15 – 1180 
IQR 571 857 281  516 
Fecal calprotectin measurements in IBD pregnant patients. Analysis limit of detection 
was <100 µg/g. Readings of <30 µg/g (below detection limit), <50 µg/g (no inflammation), 50 - 
200 µg/g (mild inflammation), >200 µg/g (active organic disease). SD, standard deviation, IQR, 
interquartile range. 
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Table 6.4 Non-parametric fecal calprotectin statistics during health pregnancy (n=12) 
 Mean (µg/g) SD   Range Median Mean Ranka 
1st Trimester 24 19 15 – 78 15 2.21 
2nd Trimester 30 18 15 – 64 23.5 2.5 
3rd Trimester 38 42 15 – 152 15 2.63 
Post-partum 51 69 15 – 247 15 2.67 
Fecal calprotectin measurements in HP pregnanct patients. Analysis limit of detection 
was <100 µg/g. Readings of <30 µg/g (below detection limit), <50 µg/g (no inflammation), 50 - 
200 µg/g (mild inflammation), >200 µg/g (active organic disease). SD, standard deviation. a. 
Friedman Test Ranks.  
 
Table 6.5 Wilcoxon Signed Ranks Test among healthy pregnancy trimesters (n=12) 
 1st T - PP 2nd T - PP  3rd T - PP 2nd T – 1st T 3rd T – 1st T 3rd T – 2nd T 
Z 
-1.960b -1.542b -.734b -.514b -.095b -.369b 
p-value 0.05 0.123 0.463 0.607 0.925 0.712 
Results of the Wilcoxon Matched-Pairs Signed Rank Analysis among HP trimesters. SD, 
standard deviation, 1st  T, first trimester, 2nd  T, second trimester, 3rd  T, third trimester, PP, post-
partum. a.Wilcoxon Signed Ranks Test b. Based on negative ranks 
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Figure 6.2 (a) Box plots depict distributions of measured calprotectin levels through pregnancy among health pregnant women. The 
asterisks and circles represent outliers.
1
1
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6.5  Discussion 
Most commonly measured laboratory tests change during healthy pregnancy, making it 
important to study FC in pregnancy and generate special reference values for this period 
(Larsson et al., 2008). In this study, we found FC to be elevated in IBD pregnancy patients and 
below the limit of detection in healthy pregnancy patients; thus FC is a useful biomarker in IBD 
during pregnancy. 
The presence of FC in healthy patients is known. Costa et al. (2003) reported a median 
value of 11 µg/g in healthy, non-pregnant patients (n=34) (Costa et al., 2003). In our study, FC 
values in HP patients were shown to have a median value of 15 µg/g at each trimester and post-
partum (n=46, 121 observations). To be noted, values in this study under the limit of detection 
(<30 µg/g) were recorded as 15 µg/g, thus, the value is likely to be lower.  
Jost et al. (2014) presented FC values in pregnancy, with a mean of 18.8 ± 6.1 µg/g and  
no significant differences in levels throughout the perinatal (i.e. around the time of birth) period, 
as assessed by ELISA (n=7) (Jost, Lacroix, Braegger, & Chassard, 2014). The authors inferred 
these values may represent low-grade signs of intestinal inflammation, an observation shown 
elsewhere by increased pro-inflammatory cytokines in stool during the third trimester of 
pregnancy (Koren et al., 2012). Additionally, Urwin et al. (2014) observed a median FC 
concentration of 4.7 µg/g at in healthy pregnany controls at Week 38 gestation (Urwin et al., 
2014). In this study, we calculated an overall mean FC value of 47 ± 61 µg/g (median 15 µg/g) 
(Table 6.2). Non-parametric analysis found no significant differences between assessment 
periods (Table 6.4, 6.5). In Jost et al. (2014), maternal feces was collected at four sampling 
points, 3–7 weeks prepartum and at days 3–6, 9–14, and 25–30 postpartum. In this study, 
longitudinal assessment of FC was performed throughout during each trimester (1-13 weeks, 14-
26 weeks, 27-40 weeks) and within 1-6 months post-partum. Differences in the FC values 
between studies may be attributed to the differences in these sampling periods.  
The concentration of FC in IBD pregnancy patients isn’t well known. Median FC values 
were found to be elevated throughout T1-T3 and post-partum, 477, 337, 469 and 439 µg/g, 
respectively (Table 6.4). This indicates active organic inflammation in these patients, 
comparable to studies with other non-pregnant IBD patients (Costa et al., 2003). Non-parametric 
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analysis was not performed due to the post-partum sample size (n=1). These results show that FC 
is useful in detecting active inflammation in IBD pregnancy. Additionally, recruiting 17 total 
patients in this study group displays feasibility in this measurement.  
The Mann-Whitney U test identified significant median differences in the FC values 
between the healthy and IBD pregnancy patients (U=203.5, z=−8.474, p<0.001). This finding 
demonstrates that unlike other biomarkers (CRP, ESR, etc), FC is not affected by pregnancy and 
can be used in this patient population.  
Future work should calculate FC reference values based on fulfilling the 
recommendations of the International Federation of Clinical Chemistry’s statistical treatment of 
reference values (Larsson et al., 2008). Specifically in IBD, future work should study the 
relationship between FC and pregnancy-related outcomes, such as pre-term birth, low birth 
weight, spontaneous abortion and mode of delivery.  Also, the relative risk of adverse clinical 
outcomes amongst those with elevated FC compared with those without elevated levels should 
be calculated. Finally, since the gut microbiota is profoundly altered during pregnancy, future 
work should focus on the relationship between non-invasive biomarkers and gut microbiota 
(Koren et al., 2012). 
6.6  Conclusion 
 This study established reference values for FC in healthy and IBD pregnancy, showing 
statistically significant differences between the groups, while touching on the feasibility of this 
analysis in this patient population.   
Acknowledgements: Healthy pregnancy recruitment was conducted by Susan Kuling in 
the clinic of Drs. Martel and Mytopher from the Saskatoon Obstetrics and Gynecologic 
Consultants in Saskatoon, Saskatchewan. IBD pregnancy recruitment was conducted by Drs. 
Jones and Fowler from the MDIBDC at the University of Saskatchewan. 
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CHAPTER 7 
FECAL MICROBIOTA AND SHORT CHAIN FATTY ACIDS IN NEWLY 
DIAGNOSED IBD PATIENTS 
 Marc W. Morris, Jennifer L. Jones, Samuel A. Stewart, Sharyle Fowler, Jane Alcorn, 
Gordon A. Zello 
 Not yet published 
 
 The relationship between mucosa and resident microbial flora ('microbiota') heavily 
influences human health. Gut bacteria play an integral role in health by exerting protective, 
structural and metabolic effects. A change in the composition of the gut bacteria, or "dysbiosis" 
is hypothesized to play a role in the development of IBD. The majority of gut bacteria belong to 
two phyla, Bacteroidetes and Firmicutes. A reduced concentration of Bacteroidetes and 
Firmicutes, responsible for the anaerobic production of short chain fatty acids (SCFA) (i.e. 
acetate, propionate, and butyrate) integral to human health, is well documented in IBD. 
Specifically, butyrate has many anti-inflammatory and anti-proliferative properties, and is 
decreased in IBD, making it an attractive marker of study. It is unknown how SCFA are 
influenced by IBD disease activity and severity, therapy and disease type. Furthermore, this 
study only included newly diagnosed IBD patients, to limit the confounding that plagues most 
observational studies examining patients with longstanding disease. This study examined the 
relationship between gut microbiota, SCFA and biomarkers in IBD. 
Author role: I completed the SCFA lab analysis, statistical analysis and manuscript 
preparation and writing for this chapter.  
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7.1  Introduction 
The pathogenesis and etiology of IBD, although not completely understood, is 
hypothesized to develop as a result of the interaction between three factors - genetic 
susceptibility, environmental exposures and host immune response (Cashman & Shanahan, 
2003). The intestinal microflora is a key environmental factor influencing IBD in both subtypes, 
CD and UC, since genetically engineered animal models of IBD do not develop colitis under 
germ-free conditions  (i.e. knock-out mice without gut bacteria) (Taurog et al., 1994). 
Human health is highly dependent on the relationship between human mucosal sites and 
the resident microbial flora ('microbiota') (Vinolo, Rodrigues, Nachbar, & Curi, 2011). Healthy 
individuals have a microbial ecology that is characterized by a stable dominant microbiota, 
exhibiting high biodiversity and resilience (Marteau, 2009). In contrast, the microbiota in IBD 
patients is less diverse (Kelly & Mulder, 2012). Reduced diversity may result in innappropriate 
mucosal cellular responses, that could cause the prolonged inflammatory response observed in 
intestinal disease (Murphy et al., 2012). A difference in the composition of the gut bacteria, or 
"dysbiosis", has been observed between IBD patients and healthy controls, although the 
significance to IBD pathogenesis is unknown (Froyland, 2010; Swidsinski et al., 2002). If this 
imbalance could be recognized it could serve as an important diagnostic tool in IBD (Froyland, 
2010).  
The role of the gut microbiota in IBD is discussed in Chapter 2.3.1.2 of this document, 
along with being recently reviewed elsewhere (Hold et al., 2014). Microbiota can be organized 
by taxonomic rank – from phylum to species, through class, order, family and genus (Froyland, 
2010). The major phyla found within human GI tracts, regardless of health or disease, are found 
within four bacterial categories: the Firmicutes, Bacteriodetes, Proteobacteria and 
Actinobacteria (Eckburg et al., 2005; Frank et al., 2007; Ley, Turnbaugh, Klein, & Gordon, 2006). 
Most of the microbiota in healthy humans belong to the Bacteroidetes and Firmicutes phyla 
(Eckburg et al., 2005; Hold, Pryde, Russell, Furrie, & Flint, 2002; Suau et al., 1999). Higher 
levels of Bacteroidetes in CD patients compared with controls have been observed (Keighley et 
al., 1978; Ruseler-van Embden & Both-Patoir, 1983). Furthermore, a reduced abundance of the 
phyla Firmicutes has been well documented in IBD patients (Frank et al., 2007; Peterson, Frank, 
Pace, & Gordon, 2008; Sokol et al., 2006). Within Firmicutes, the species, Clostridium leptum 
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comprises up to 25% of the fecal microbiota population (Lay et al., 2005; Sghir et al., 2000). 
This group is largely responsible for the fermentation of unabsorbed carbohydrate, producing 
short-chain fatty acids, and has been shown to be reduced in both CD and UC (Kabeerdoss, 
Sankaran, Pugazhendhi, & Ramakrishna, 2013). The most abundant member of C. Leptum is 
Faecalibacterium prausnitzii a major producer of butyrate in the gut (Louis & Flint, 2009; Sokol 
et al., 2008). The microbial composition of the gut during the development and diagnosis of IBD 
is not well known, making the study of newly diagnosed populations important  
 SCFA are the major metabolic products of anaerobic fermentation of dietary compounds 
in the colon by bacteria (Treem et al., 1994). The amount of SCFA produced are dependent on 
the number and type of microbiota, availability of substrate and gut transit time (Argenzio & 
Southworth, 1975; Cook & Sellin, 1998; Owens & Isaacson, 1977; Roberfroid et al., 2010; 
Wong, de Souza, Kendall, Emam, & Jenkins, 2006). Butyrate exerts many positive health 
effects, playing a key role in the physiology and health of the colonic mucosa (Wong et al., 
2006). Additionally, butyrate metabolism is impaired in IBD, due to a decrease in β-oxidation 
(Roediger, 1980; Thibault et al., 2010). Thus, butyrate is suggested to be a factor in the 
development and treatment of IBD, mainly CD and UC (Cummings, 1997; Di Sabatino et al., 
2005). In the majority of SCFA studies in human IBD, fecal concentrations of SCFA are 
positively correlated with clinical measures of disease activity (Mortensen & Clausen, 1996; 
Roediger et al., 1982; Treem et al., 1994). However, the concentration of organic acids in 
relation to disease activity, in both active and inactive states in IBD, have been inconsistent 
(Hove & Mortensen, 1995; Hove et al., 1994; Huda-Faujan et al., 2010). Little is known about 
the relationship between the standard biomarkers assessed in IBD, serum marker hsCRP, the 
fecal biomarkers, FC and Lf, and SCFA and microbial populations in the gut, particularly the 
butyrate producing F. prausnitzii.  
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7.2  Objectives 
The aim of this study was to observe the fecal concentrations of SCFA and microbiota in 
newly diagnosed IBD patients, assess how they differ between disease type and severity, and 
relate to objective markers of inflammation.  
7.3  Materials and methods 
 Patient recruitment: Eligible subjects were diagnosed with IBD within the past 12 
months and seen at the MDIBDC. Individuals ages 18 and older with a diagnosis of IBD based 
on standard criteria and able to provide written informed consent were eligible to participate in 
the study conducted from November 2012 to July 2014 (see section 5.3) (Lennard-Jones, 1989).  
Exclusion criteria in this cohort consisted of patients with infectious diseases, end-stage renal, 
cardiovascular or hepatic disease or who were pregnant. This study was approved by the 
University of Saskatchewan’s Biomedical Research Ethics Board (Bio-REB 09-26).  
Experimental design: Patient demographics (age, gender, disease type, location, 
medication therapy, smoking status) were collected from all participants. At baseline and follow-
up (3 – 6 months), detailed endoscopic (Simple Endoscopic Score – CD [SES-CD], Mayo Score 
for UC) and clinical disease activity measures (CD Activity Index [CDAI], partial Mayo score 
for UC) were calculated. At baseline and follow-up (3 – 6 months), blood and fecal samples were 
collected for biomarker (FC, Lf, hsCRP), microbiota and SCFA determination. 
 Blood was drawn by trained Royal University Hospital personnel and used for hsCRP 
determination. Fecal samples (two 50-gram aliquots) were collected in sterile containers, one left 
thawed for immediate biomarker determination, and one frozen immediately and delivered to the 
Mary Irwin Laboratory of Nutrition at the University of Saskatchewan for microbiota and SCFA 
analysis. Samples were stored at -80 °C until analysis.  
Disease Activity: Endoscopic disease activity was scored by colonoscopists using the 
SES-CD and Mayo Score for UC. SES-CD was categorized as active >7, inactive ≤7, and Mayo 
score active >6 points, inactive ≤6. Clinical disease activity was scored using the CDAI for CD 
and partial Mayo score for UC. CDAI was categorized as active ≥ 150, inactive < 150, and 
Partial Mayo scores active > 2, inactive ≤2.  
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Biomarker analysis: hsCRP was tested using the high sensitivity CRP (latex) reagent on 
the c501 analyzer (Roche Diagnostics Canada, Laval, QC, CA) using the manufacturer’s 
reagents and calibrators (Sánchez et al., 2002). Results were calculated in milligrams per 
millilitre (mg/mL).  
FC was determined using a Quantum Blue® FC High Range Rapid Test using the 
Quantum Blue Reader® point-of-care (POC) desk-top reader (ALPCO Immunoassays, Salem, 
NH, USA). Approximately 30 mg of fecal sample was pressed into a base cap and fitted on the 
extraction tube. This device was filled with 4 mL of extraction buffer and homogenized by 
vortex for 1 minute. A 1:16 dilution was performed with chase buffer and 80 µL was positioned 
into the test cartridge for analysis. Each run took 15 minutes to complete and results were 
displayed in micrograms per gram (µg/g) on the POC display.  
Lf was determined using IBD-SCAN® (TechLab, Inc, Blacksburg, VA, USA). 
Approximately 450 mg of fecal sample was weighed in an Eppendorf tube and diluted at 1:100 
to 1:10,000. Test samples, standards and quality controls were plated in a 96-well plate provided 
with the kit. The plate was read at 450/620 nanometres wavelength microplate reader and results 
were calculated in micrograms per millilitre (µg/mL).  
Microbiota analysis: The frozen fecal sample was thawed and brought to Contango 
Strategies (Saskatoon, SK) immediately for analysis. Approximately 1 gram of the fecal sample 
was separated, homogenized and used for analysis. Targeted DNA sequencing was used to 
identify bacteria present in each sample via polymerase chain reaction (PCR) amplification of 
the v3/v4 region of the 16S ribosomal RNA gene (Klindworth et al., 2013)  Library preparation 
and sequencing was performed as per the manufacturer’s instructions for MiSeq v3 paired-end 
300 bp sequencing (Illumina, San Diego, CA, USA). Library preparation included positive and 
negative controls, with the former consisting of mock communities, and the latter where no DNA 
is added to the PCR, and the sample is carried through to sequencing. After sequencing, the 
forward and reverse reads were merged using PANDAseq (Masella, Bartram, Truszkowski, 
Brown, & Neufeld, 2012). All sequences were then filtered and reads were considered to be low 
quality and discarded if they did not meet the following criteria: average quality greater than 
Q30, longer than 350 bp, and exact match to the forward primer. Additionally, if the read had 
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any base called as N (unknown) it was discarded. The forward and reverse primers were then 
removed from each sequence. Bioinformatics pipelines consisting of internally developed scripts 
and selected QIIME scripts (Caporaso et al., 2010; Edgar, 2010) were used to process the reads. 
Similar sequences were clustered into groups called Operational Taxonomic Units (OTUs) using 
a 97% identity threshold and the pick_de_novo_otus.py script. All OTUs with less than 10 
representative sequences across all samples were discarded as a quality filtering step to remove 
OTUs that may have arisen due to sequencing errors. Taxonomic classification of the OTUs 
were performed using the Greengenes database version 13_8 (DeSantis et al., 2006; McDonald 
et al., 2012). Microbial diversity was determined through observed species, Simpson reciprocal, 
and the Shannon Index, measures of microbial diversity (Magurran, 1988).  
 
SCFA analysis: Phosphoric acid, 85%, and hydrochloric acid, acetic acid, propionic acid, 
isobutyric acid, butyric acid, isovaleric acid, valeric acid, isocaproic acid (internal standard) an 
caproic acid, all purchased at 99%, were obtained from Sigma-Aldrich (Sigma-Aldrich Canada 
Co., Oakville, ONT, CA) (Table 7.1). CHROMASOLV HPLC grade water was also purchased 
from Sigma-Aldrich. For GC analysis, the internal standard, isocaproic acid (ICA), was prepared 
by adding 300 μL of ICA to 20 mL of 25% phosphoric acid, 20 mL of water, and bringing up to 
volume in a 100 mL volumetric flask. The mixed standard was prepared by adding the individual 
fatty acids of interest (Table. 7.1), with 20 mL of 25% phosphoric acid, brought up to volume in 
a 100 mL volumetric flask. Weight of the added internal standard and fatty acids of interest were 
recorded for determination of final concentration.  
From the remaining thawed fecal sample (from the microbiota analysis), between 1-5 
grams was homogenized, weighed and placed in a 30mL Nalgene bottle (in duplicate). A similar 
amount of 2N HCL and 1 mL of 25% m-phosphoric acid was added to the tube and vortexed.  
The sample was centrifuged for 20 minutes at 20,000 x g. Supernatant was filtered through a 25 
mm 0.45 µM Millex-HPF syringe filter (Millipore, Etobicoke, ONT, CA). The filtered sample 
was transferred to four Eppendorf tubes and centrifuged at 22,000 x g for 10 minutes. Samples 
were then ready to be analyzed.  One millilitre (1 mL) of filtered supernatant was transferred to 
GC vials, along with 0.2 mL of internal standard for analysis.  
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Table 7.1 Short chain fatty acids of interest in mixed standard 
Fatty acid Volume (μL) Molar mass (g/mol) 
Acetic acid (AA) 300 60.05 
Propionic acid (PA) 200 74.08 
Isobutyric acid (IBA) 50 88.11 
Butyric acid (BA) 100 88.11 
Isovaleric acid (IVA) 50 102.13 
Valeric acid (VA) 50 102.13 
Caproic acid (CA) 50 116.20 
 
The GC-FID system consisted of an Agilent 6890 GC system equipped with a flame 
ionization detector (FID) and an automatic liquid sampler (Agilent Technologies, Palo Alto, CA, 
USA). A GC – FID chromatogram with a mixed SCFA standard is shown in Figure 7.1. The 
column was a ZB-FFAP capillary column (Phenomoenex, Torrance, CA, USA) (30.0 m × 320 
µm × 0.25 µm). Helium was used as a carrier gas at 1.2 mL/min. A 1 µL sample injection was 
completed in split mode, with an initial temperature of 170°C. GC grade methanol (wash) and 
acetonitrile were used as solvents. A wash and standard injection was made after every 10 
sample injections. Data acquisition was completed with Chemstation (Hewlett– Packard, Palo 
Alto, CA, USA). Quantitative analysis was performed using relative response factors for the 
short chain fatty acids determined with an internal standard, isocaproic acid (ICA) (Appendix 
B). Additionally, samples were freeze-dried using a FreeZonePlus 6L Dry System to analyze 
water content for dry weight calculations (Labconco, Kansas City, MO, USA). Full standard 
operating procedure for this analysis can be found in Appendix B.  
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Figure 7.1 Gas chromatography - flame ionization chromatogram of SCFA mixed standard 
displaying short chain fatty acid peaks. SCFA shown in order of elution: Acetic Acid (4.695 
min), Propionic Acid (5.465 min), Isobutyric Acid (5.723 min), Butyric Acid (6.319 min), 
Isovaleric Acid (6.717 min), Valeric Acid (7.399 min), Isocaproic Acid (8.041 min), Caproic 
Acid (8.471 min).   
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Statistics: Descriptive statistics were used to describe patient demographics and 
biomarker concentrations. Data are presented as mean ± standard deviation unless otherwise 
noted. Biomarkers are presented as median values with interquartile ranges (not normally 
distributed). Unpaired t-test was used to compare means in different disease states (CD vs. UC). 
Paired t-test was used to compare means at different time points (Baseline and Follow-up).  The 
pooled IBD patients were split into quartiles based on F. prausnitzii percent relative abundance 
(n=6). A one-way ANOVA was used to compare means between quartiles of the F. prausnitzii 
group. Homogeneity of variances was assessed using the Levene statistic. Tukey post hoc 
analysis was used to reveal statistically significant differences between groups. A one-way 
ANOVA was used to determine the relationship between SCFA, typical IBD biomarkers and 
markers of microbial diversity. Pearson correlation was used to assess relationship between 
biomarkers and microbiota and SCFA. 
 
7.4  Results 
 During recruitment, 25 patients were screened for potential enrolment and 15 participants 
who met the inclusion and exclusion criteria were subsequently enrolled. Nine of these patients 
submitted follow-up fecal samples for a total of 24 fecal samples collected (15 baseline, 9 
follow-up, 24 total).  The cohort was split between 27% male and 73% female, with a mean age 
of 33.8 years (range 20 - 60 years). In this study, 73% of patients reported never smoking, 13% 
current smokers, and 13% did not answer. The ethnicity of the patient population was 93% 
Caucasian and 7% Aboriginal. Eleven participants (73%) were newly diagnosed with CD and the 
other four (27%) had UC. The demographic and clinical characteristics of this cohort are shown 
in Table 7.2. Of the 11 CD patients, 64% had ileocolonic disease. Disease location was evenly 
split in UC, 50% of patients had pancolonic disease and 50% had procosigmoditis. 
 
hsCRP, FC and Lf were elevated and outside of the normal range at enrolment. At 
enrolment, the median hsCRP concentration was 8.0 mg/L (normal 0 – 7.0 mg/L), FC 
concentration was 1236 μg/g (normal <50 μg/g), and fecal Lf concentration was 53 μg /mL 
(normal 0 - 7.24 μg/mL) (Table 7.3).  
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Table 7.2 Demographics and clinical characteristics of the newly diagnosed cohort (n=15) 
Patient  Age Gender Disease location Smoking  Therapy 
CD1 52 M ileocolonic no anti-TNF agent 
CD2 24 F ileocolonic no immunomodulator 
CD3 20 F ileocolonic no anti-TNF agent 
CD4 25 M ileocolonic no immunomodulator 
CD5 22 F ileocolonic no anti-TNF agent 
CD6 34 F ileocolonic no immunomodulator 
CD7 60 F colonic no none 
CD8 28 F colonic yes immunomodulator 
CD9 32 F colonic yes immunomodulator 
CD10 52 F ileal no immunomodulator 
CD11 32 F ileocolonic n/a ASA 
CD  34.6 ± 13.7              2M / 9F    
UC1 20 M pancolonic n/a ASA 
UC2 34 F proctosigmoidal no ASA 
UC3 35 F proctosigmoidal no ASA 
UC4 37 M pancolonic no ASA 
UC 31.5 ± 7.8               2M / 2F    
Total 33.8 ± 12.2             4M / 11F    
Baseline demographics in 15 newly diagnosed IBD patients (11 Crohn’s disease, 4 
Ulcerative colitis). Disease location is confirmed by colonoscopy.  ASA, amino-salicylic acid, 
Anti-TNF agent, anti-tumour necrosis factor agent, CD, Crohn’s disease, UC, ulcerative colitis.  
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Table 7.3 Biomarker concentration in a full cohort of newly diagnosed patients (n=15) 
 Biomarker Median IQR Q1 - Q3  Normal Range 
    hsCRP (mg/L) 8.0 21.5 3.0 - 24.5 0 - 7.0 
    FC (µg/g) 1236 1481 580 - 1772 < 50 
    Lf (µg/mL) 53.0 279 6.0 - 284.5 0 - 7.24 
Results of biomarker concentration of in full cohort of 15 IBD patients. Results are 
expressed as median values. IQR, Interquartile range, Q1, quartile 1, Q3, quartile 3, hsCRP, 
high sensitivity C-reactive protein, FC, calprotectin, Lf, lactoferrin. 
 
 
Quantifiable DNA for microbiota analysis was obtained from all 15 baseline and 9 
follow-up samples. 16s library sequencing yielded an average of 164,770 reads per sample. The 
negative control (i.e., no DNA added) generated minimal reads, with 616 reads and only ~3% 
retained after quality filtering. Positive mock community control samples passed internal QC 
standards. 
Firmicutes were higher in CD (74.4% ± 14.3) than UC (64.2% ± 21.6), while 
Bacteroidetes was lower in CD (15.1% ± 13.4) than UC (21.4% ± 22.9) (Table 7.4). 
Bacteroidetes were lower at follow-up (8.9% ± 8.3) than baseline (16.8% ± 15.8), while 
Firmicutes were increased at follow-up (77.8% ± 10.2) than baseline (71.7% ± 16.4) (Figure 
7.2).  
The major phyla Firmicutes and Bacteroidetes were reduced in active disease compared 
with inactive disease, with Actinobacteria, Proteobacteria, and Fusobacteria increased (Figure 
7.3).  The concentration of all major SCFA in this study was also shown to be higher in active vs. 
inactive IBD patients (Figure 7.4). Relative abundance of microbiota between paired samples is 
shown in Figure 7.5 
The concentration of SCFA increased across the F. prausnitzii quartiles. Acetic, 
propionic, and butyric acid (AA, PA, BA), the three primary SCFA respectively, increased 
across quartiles (Table 7.5). Generally, biomarkers decreased across F. prausnitzii quartiles. 
High-sensitivity C-reactive protein decreased from the 1st quartile to the 2nd, increased in the 3rd, 
but finally decreased in the 4th quartile. A similar trend was observed in the fecal biomarkers, FC 
and Lf, as the markers decreased from the 1st quartile to the 2nd, increased in the 3rd, and 
decreased in the 4th quartile but not below the values found in the 2nd. Microbial diversity 
increased across F. prausnitzii quartiles. The number of observed species and Shannon Index, 
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increased from the 1st quartile to the 2nd, decreased in the 3rd, and increased again in the final 
quartile  
The assumption of homogeneity of variances was violated for FC and hsCRP (p < 0.05). 
There were no statistically significant differences between quartiles of F. prausnitzii for AA, PA, 
Lf, FC and hsCRP. However, statistically significant differences were observed between 
quartiles of F. prausnitzii and observed species (p < 0.001, between 1st and 4th), Shannon Index 
(p < 0.001, 1st and 2nd), and BA (p < 0.05, 1st and 4th). 
Of the major fecal SCFA (measured in µmol/g wet feces), AA was higher in CD than UC 
(31.5 ± 9.2 vs. 26.2 ± 13.0) and reduced at follow-up compared with baseline (30.1 ± 10.1 vs. 
27.6 ± 13.1). PA was lower in CD than UC (7.5 ± 3.9 vs. 9.7 ± 11.4) and reduced at follow-up 
compared with baseline (8.1 ± 6.3 vs. 6.1 ± 4.3). BA was lower in CD than UC (6.2 ± 3.2 vs. 6.8 
± 7.0) and reduced at follow-up compared with baseline (6.4 ± 4.2 vs. 6.3 ± 5.1). When 
compared with healthy control values (Nilsson, Johansson, Nilsson, Björck, & Nyman, 2008) the 
difference in SCFA were statistically significant (p<0.001).  
Proteobacteria was correlated with all biomarkers, Lf and FC (p>0.01) and hsCRP 
(p>0.05). Propionic acid correlated with Lf (p>0.05) (Table 7.7).  
  
129 
 
 
Table 7.4 Abundance of fecal microbiota in newly diagnosed IBD patients 
Phyla CD (n=11) UC (n=4) Baseline 
(n=15) 
Follow-up     
(n=9) 
All (n=24) Healthy 
(n=20)1 (n=5)2 
Actinobacteria 3.6 ± 2.2   
(1.1 – 7.7) 
4.1 ± 3.7   
(0.1 – 7.5) 
3.7 ± 2.5                
(0.1 – 7.7) 
 
8.4 ± 10.2        
(1.5 – 34.4) 
 
5.5 ± 6.7            
(0.1 – 34.7) 
 0.5 ± 0.4            
(nd – 1.2)2 
Bacteroidetes 15.1 ± 13.4 
(nd – 33.5) 
 
21.4 ± 22.9 
(nd – 46.6) 
16.8 ± 15.8     
(nd – 46.6) 
8.9 ± 8.3           
(nd – 18.8) 
13.8 ± 13.8         
(nd – 46.6) 
53.91  
 
31.7 ± 14.9                       
(12.7 – 48.0)2 
Firmicutes 74.4 ± 14.3 
(52.8 – 91.1) 
64.2 ± 21.6 
(38.8 – 87.9) 
71.7 ± 16.4 
(38.8 – 91.1) 
77.8 ± 10.2     
(61.9 – 91.0) 
74.0 ± 14.4        
(38.8 – 91.1) 
38.91  63.4 ± 13.3                       
(50.8 – 82.4)2 
Fusobacteria 2.6 ± 7.5   
(nd – 25.0) 
nd ± 0.1    
(nd – 0.2) 
1.9 ± 6.4         
(nd – 25.0) 
nd ± 0.0            
(nd – 0.1) 
1.2 ± 5.1             
(nd – 25.0) 
0.51   0.2 ± 0.5                       
(nd – 1.2)2 
Proteobacteria 3.6 ± 5.0   
(nd – 14.8) 
8.1 ± 11.2 
(0.1 – 24.2) 
4.8 ± 7.0         
(nd – 24.2) 
3.4 ± 5.6         
(0.1 – 17.5) 
4.2 ± 6.4              
(nd – 24.2) 
 3.9 ± 3.6                       
(0.8 – 9.9)2 
Tenericutes 0.1 ± 0.5    
(nd – 1.5) 
nd ± 0.0     
(nd – 0.1) 
0.1 ± 0.4         
(nd – 1.5) 
nd ± 0.0            
(nd) 
0.1 ± 0.3               
(nd – 1.5) 
  
Verrucomicrobia 0.2 ± 0.7   
(nd – 2.3) 
1.5 ± 3.0    
(nd – 5.9) 
0.6 ± 1.6         
(nd – 5.9) 
1.3 ± 3.5        
(nd – 10.6) 
0.8 ± 2.4              
(nd – 10.6) 
 0.2 ± 0.3                       
(nd – 0.7)2 
Other 0.4 ± 0.2   
(0.2 – 0.6) 
0.3 ± 0.1   
(0.2 –0.5) 
0.4 ± 0.2        
(0.2 – 0.6) 
0.2 ± 0.1           
(nd – 0.4) 
0.3 ± 0.2               
(nd – 0.6) 
  
Shannon Index 
5.1 ± 0.8  
(3.7 – 6.02) 
4.7 ± 1.8  
(2.1 – 6.4) 
5.0 ± 1.1       
(2.1 – 6.4) 
 
5.0 ± 0.7             
(3.9 – 6.1) 
5.0 ± 0.9             
(2.1 – 6.4) 
5.11  
3.6 ± 0.2 
(3.5-3.9)2 
Results showing the relative abundance of fecal microbiota in newly diagnosed IBD patients, expressed as relative percentage 
(%) of bacteria in feces (mean ± SD [range]). Analysis found minimal to negligible cyanobacteria, euryarchaeota or TM7 bacteria 
present. Microbiota diversity was expressed by the Shannon Index. Shown graphically in Appendix D. nd, no detection; CD, Crohn’s 
disease; UC, ulcerative colitis, Baseline, pooled baseline, Follow-up, pooled follow-up. 1(Wu et al., 2013) – fecal samples, 2(Walker 
et al., 2011) - biopsies.  
 
 
1
2
9
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Table 7.5 Quartiles of Faecalibacterium prausnitzii in pooled IBD patients (total, n = 24; quartile, n = 6)  
 
Table showing trends of short chain fatty acids (SCFA), microbial diversity and biomarkers across F. prausnitzii quartiles. 
SCFA results are expressed in µmol/g wet feces (mean [SD]). AA, acetic acid, PA, propionic acid; BA, butyric acid; FC, calprotectin; 
Lf, lactoferrin; CD, Crohn’s disease. Microbiota diversity was expressed by total observed species and the Shannon Index. A one-way 
ANOVA analysis was used to compare means between groups. **significance p < 0.001, *significance p < 0.05 between groups.  
 
  
 1st (low) 2nd 3rd 4th (high) TOTAL p-value 
Obs. Species 242.7 (85.1)** 610.2 (226.4) 543.5 (171.6) 661.0 (62.1)** 514.3 (217.8) <0.001 
Shannon Index 3.8 (0.9)** 5.5 (0.8)** 5.1 (0.5) 5.5 (0.3) 5.0 (0.9) <0.001 
AA 24.9 (11.3) 27.5 (14.9) 27.6 (8.0) 36.6 (7.7) 29.2 (11.1) 0.293 
PA 4.0 (4.3) 7.2 (6.0) 7.5 (3.0) 10.6 (7.5) 7.3 (5.6) 0.260 
BA 3.1 (2.8)* 5.9 (5.9) 6.1 (2.2) 10.2 (3.6)* 6.3 (4.5)  0.040 
FC (µg/g) 3862 (3855) 910 (514) 1107 (1276) 1040 (795) 1730 (2316) 0.066 
Lf (µg/ml) 275.6 (278.7) 64.1 (105.5) 148.7 (136.7) 98.6 (153.6) 146.7 (187.7) 0.227 
hsCRP (µg/L) 26.0 (26.8) 11.5 (11.9) 17.3 (32.7) 6.2 (6.4) 15.3 (22.0) 0.469 
1
3
0
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Table 7.6 Fecal SCFA concentration in newly diagnosed IBD patients 
SCFA CD (n=11) UC (n=4) Baseline 
(n=15) 
Follow-up 
(n=9) 
All (n=24) Healthy 
(n=20)1 
p-value 
AA 31.5 ± 9.2 
(17.6 – 
44.8) 
26.2 ± 13.0 
(12.5 – 40.4) 
30.1 ± 10.1 
(12.5 – 44.8) 
27.6 ± 13.1       
(7.2 – 48.2) 
29.2 ± 11.1   
(7.2 – 48.2) 
54.2  ± 2.5                       
(19.5 -126.2) 
<0.0001 
PA 7.5 ± 3.9     
(1.8 – 15.6) 
9.7 ± 11.4     
(nd – 25.3)  
8.1 ± 6.3         
(nd – 25.3)  
6.1 ± 4.3          
(0.2 – 12.6) 
7.3 ± 5.6        
(nd – 25.3) 
11.6  ± 0.5                       
(4.5 -22.5) 
<0.001 
IBA 0.7 ± 0.4       
(nd – 1.5) 
0.8 ± 0.6       
(nd – 1.3) 
0.7 ± 0.4         
(nd -1.5) 
0.3 ± 0.3           
(nd – 1.0) 
0.6 ± 0.4        
(nd – 1.5)      
2.1  ± 0.1                       
(4.1 -38) 
<0.0001 
BA 6.2 ± 3.2      
(1.7 – 11.7) 
6.8 ± 7.0      
(nd – 15.3) 
6.4 ± 4.2         
(nd – 15.3)  
6.3 ± 5.1          
(0.3 – 16.0) 
6.3 ± 4.5       
(0.0 – 16.0) 
13.9  ± 0.8                       
(0.9 - 4.8) 
<0.0001 
IVA 1.0 ± 0.6      
(nd – 1.9) 
1.0 ± 0.7      
(nd – 1.7) 
1.0 ± 0.6        
(nd – 1.9) 
0.4 ± 0.4            
(nd – 1.2) 
0.8 ± 0.6        
(nd – 1.9) 
1.5  ± 0.1                       
(0.2 – 4.1) 
<0.0001 
VA 0.6 ± 0.5      
(nd – 1.2) 
0.9 ± 0.6       
(nd – 1.4)  
0.7 ± 0.5         
(nd – 1.4) 
0.8 ± 0.8           
(nd – 2.3) 
0.7 ± 0.6        
(nd – 2.3) 
2.2  ± 0.2                       
(0.3 – 14) 
<0.0001 
CA 0.1 ± 0.2      
(nd – 0.8) 
0.2 ± 0.2      
(nd – 0.4) 
0.1 ± 0.2        
(nd – 0.8) 
nd                      
(nd – 0.1) 
0.1 ± 0.2        
(nd – 0.8) 
1.1  ± 0.1                       
(0.1 – 6.3) 
<0.0001 
Molar ratio 
(aa:pa:ba) 
70:16:14 61:23:16 68:18:14 69:15:16  68:17:15 68:15:17  
Results are expressed in µmol/g wet feces (mean ± SD [Range]). nd, no detection; CD, Crohn’s disease; UC, ulcerative colitis, 
AA, acetic acid, PA, propionic acid, IBA, isobutyric acid, BA, butyric acid, IVA, isovaleric acid, VA, valeric acid, CA, caproic acid, 
Baseline, pooled baseline, Follow-up, pooled follow-up. 1(U. Nilsson et al., 2008) Results are expressed in µmol/g wet feces (Mean ± 
SEM [Range]). An unpaired t-test was used to compare IBD (n=24) and healthy1 values.  
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Figure 7.2 Relative abundance of bacterial phyla in 24 human fecal samples from IBD patients. Phyla legend found on right. Data is 
expressed as percent (%) composition.  
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Figure 7.3 Relative abundance of bacterial phyla between inactive and active IBD patients (n=24). Groups were categorized by 
Crohn’s disease Activity Scores (active ≥ 150, inactive < 150) for Crohn’s disease and Partial Mayo scores (active > 2, inactive ≤2) 
Legend found on right. Data is expressed as relative abundance (%) 
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Figure 7.4 Concentration of fecal short chain fatty acids between inactive and active IBD patients (n=24). Groups were categorized by 
Crohn’s disease Activity Scores (active ≥ 150, inactive < 150) for Crohn’s disease and Partial Mayo scores (active > 2, inactive ≤2) 
Legend found on right. Data is expressed as micromole per gram of wet feces (µmol/g)   
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Figure 7.5 Relative abundance of bacterial phyla in paired samples. Phyla legend found on right. Data is expressed as percent (%) 
composition.  
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Table 7.7 Correlation between microbiota and biomarkers (n=24) 
 Firmicutes Bacteroidetes Proteobacteria Actinobacteria AA PA BA 
Lf -0.224 
(p=0.293) 
-0.203 
(p=0.341) 
 
.781**  
(p>0.01) 
-0.041 
(p=0.849) 
-0.174 
(p=0.417) 
-.427* 
(p>0.05) 
 
-0.223 
(p=0.295) 
FC -0.09 
(p=0.677) 
-0.355 
(p=0.088) 
.806**  
(p>0.01) 
-0.177 
(p=0.408) 
-0.16 
(p=0.454) 
-0.32 
(p=0.127) 
-0.258 
(p=0.224) 
hsCRP -0.154 
(p=0.471) 
-0.036 
(p=0.869) 
.483*     
(p>0.05) 
-0.182 
(p=0.394) 
0.04 
(p=0.852) 
0.001 
(p=0.994) 
-0.156 
(p=0.466) 
Results are expressed in correlation coefficient (p-value). Results are expressed in correlation coefficient (p-value). hsCRP, 
high sensitivity C-reactive protein, FC, calprotectin, Lf, lactoferrin AA, acetic acid, PA, propionic acid, IBA, isobutyric acid, BA, 
butyric acid  *Correlation is significant at the 0.05 level (2-tailed) ** Correlation is significant at the 0.01 level (2-tailed) using 
Pearson Correlation.  
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7.5  Discussion 
The primary objective of this study was to observe the fecal concentrations of SCFA and 
microbiota in newly diagnosed IBD patients. Within 12 months of diagnosis with IBD, fecal 
samples were analyzed for SCFA and microbiota to assess the difference between disease type 
and severity and how they related to surrogate markers of inflammation (i.e. biomarkers).  
The biomarkers in this study, FC, Lf, and hsCRP, acting as surrogate markers of 
inflammation, fell outside the ranges of healthy levels (Table 7.2). Biomarker concentrations 
outside of the normal ranges are expected in an inflammatory condition like IBD (Vermeire, 
2006).  
There is limited knowledge on the abundance of fecal microbiota in newly diagnosed 
IBD patients. Dysbiosis, an imbalance in the composition of gut bacteria, has been observed in 
many ailments concerning the gut, such as IBD patients when compared with controls (Froyland, 
2010; Swidsinski et al., 2002), and colorectal cancer patients, that is characterized by a 
significant reduction in butyrate producing bacteria, such as F. prausnitzii (Wu et al., 2013). 
These type of bacteria are of particular interest as they metabolize fibre and starch to SCFA, that 
helps to strengthen and maintain mucosal barrier function, along with provision of energy to the 
mucosal cells (Scheppach & Weiler, 2004).  
Initially, levels of Bacteroidetes had been shown to be increased in CD patients compared 
with controls (Keighley et al., 1978; Ruseler-van Embden & Both-Patoir, 1983). More recently, 
this Bacteroidetes have been observed to be decreased in IBD (Frank et al., 2007). Our study 
showed decreased relative abundance of Bacteroidetes, particularly compared with fecal levels 
from healthy controls in other studies (Wu et al., 2013). Although not statistically significant, 
Bacteroidetes was observed to be lower in CD patients compared with UC, and lower at follow-
up compared with baseline (Table 7.4).  Additionally, relative abundance of Bacteroidetes have 
been significantly correlated with concentration of the fecal SCFA propionate (Salonen et al., 
2014). Also of note, while the sample size was small (n=3), presence of Bacteroidetes in follow-
up UC patients was almost nil (Figure 7.2). 
A reduced abundance of the phyla Firmicutes has been well documented in IBD patients 
(Frank et al., 2007; Peterson, Frank, Pace, & Gordon, 2008; Sokol et al., 2006). Conversely, our 
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study showed higher levels of Firmicutes particularly compared with fecal levels from healthy 
controls in other studies (74.0 vs 38.9%) (Table 7.4) (Wu et al., 2013). The values were closer to 
those observed in tissue biopsy samples (Walker et al., 2011). It is important to note that our 
results present relative abundance of the microbiota, not absolute values, thus the entire 
population of Firmicutes may be decreased in this study. Although not statistically significant, 
relative abundance of Firmicutes and Bacteroidetes was reduced in active vs. inactive disease, 
while Actinobacteria, Proteobacteria, and Fusobacteria was increased (Figure 7.3).  These 
trends warrant further attention in larger studies with greater statistical power.  
F. prausnitzii has consistently been shown to be decreased in IBD and is a marker of 
Crohn’s disease (Sokol et al., 2008, 2009). A secondary aim of this study was to observe the 
relationship between this important strain of gut bacteria with SCFA and fecal biomarkers. The 
results displayed the pivotal role F. prausnitzii has on gut health and inflammation. Statistically 
significant differences were observed between the lowest and highest quartiles of F. prausnitzii 
and observed species and butyric acid (BA) (Table 6.5). This means that when F. prausnitzii is 
lowest, there is less total diversity of microbiota, which was previously noted to be damaging to 
gut health (Sokol et al., 2008). Additionally, the strong relationship between butyric acid and F. 
prausnitzii shows that not only is production of butyrate compromised in newly diagnosed IBD, 
but is related to this strain of bacteria. Interestingly, the biomarkers showed a strong increasing 
trend across the quartiles of F. prausnitzii, with FC nearing statistical significance (p-value = 
0.066).  
Another aim in this study was the measurement of fecal short chain fatty acids (SCFA). 
The products of microbial fermentation of fibre, SCFA maintain health and membrane integrity 
in the gut, as discussed previously. The study of these molecules is complex – in fecal samples, 
SCFA concentration is the balance between production and absorption, that is affected by where 
fermentation took place, intestinal transit rate and moisture content (Salonen et al., 2014). 
Therefore, interpreting the results of SCFA appearance in the fecal matrix as an indication of gut 
environment is useful, but limited. Nonetheless, intestinal contents and epithelial tissue, that may 
give a better indication of SCFA abundance and expression, are not always available. Recently, 
Huda-Faujan et al. (2010) investigated the concentration of fecal SCFA in IBD patients. In the 
IBD patients the level of acetic acid, 162.0 µmol/g wet feces, butyric acid, 86.9 µmol/g wet 
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feces, and propionic acid, 65.6 µmol/g wet feces, were significantly lower than compared with 
healthy individuals, 209.7, 176.0, and 93.3 µmol/g wet feces, respectively (Huda-Faujan et al., 
2010). Major findings of the Huda-Faujan et al. study agree with ours, SCFA are reduced in IBD 
patients (Table 7.6). It should be noted that the study was conducted in Malaysia where the diet 
consists mainly of starch. The study was also limited by a small sample size of IBD patients 
(n=8). None of the patients showed any diarrheal symptoms two-weeks before samples were 
taken, a strength in this study as moisture content could be controlled, or at least assumed to be 
similar.  
Fecal concentrations of SCFA have been observed to be positively correlated with 
clinical measures of disease activity using the Truelove-Witt’s criteria and CDAI (Mortensen & 
Clausen, 1996; Roediger et al., 1982; Treem et al., 1994). Although not statistically significant, 
the concentration of all major SCFA in this study were also shown to be lower in active vs. 
inactive IBD patients (Figure 7.4).   
 
Future studies will focus on increasing the number of samples at the follow-up period to 
assess the resilience of bacterium through the disease course, particularly as new medications are 
introduced. Additionally, future studies should analyze fecal levels of SCFA to assess efficacy of 
nutritional interventions aimed at increasing these products (Garcia et al., 2008). Furthermore, 
since some prebiotics, such as inulin have been shown to promote growth of F. prausnitzii, 
dietary interventions should monitor the abundance of these bacteria (Froyland, 2010).  As noted 
by Frank et al. (2007), a distinct subpopulation of IBD patients contain microbiota that differ 
entirely from study controls and IBD patients. It would be prudent for future investigators to 
attempt to stratify into these categories to increase quality of results. 
7.6  Conclusion 
Our study highlighted variations in fecal SCFA and microbiota in IBD patients, making 
the newly diagnosed period an important time of study. Our study displays the important 
relationship between microbiota and SCFA concentration - decreasing the relative amounts of 
Bacteroidetes and Firmicutes, responsible for producing SCFA, while increasing other bacteria, 
reduces the absolute amounts of SCFA, which may play a role in the pathogenesis of IBD.   
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CHAPTER 8 
COMMENTARY 
8.1  General Discussion 
Biomarkers hold great promise in the management of IBD. Clinicians are presented with 
different challenges when treating IBD, some due the subjective nature of patient symptoms, 
others as a result of treating a disease that is difficult to observe. Endoscopy is invasive and 
expensive, while patient reported outcomes are subjective and non-specific to IBD; thus, a need 
for cost-effective and reliable markers of disease activity exists. The use of non-invasive, 
surrogate markers of disease could lessen some of these challenges, particularly in diagnosis, 
estimation of disease activity and inflammatory burden, and response to therapy. This thesis 
investigated the role of biomarkers in different domains of IBD: calculating the predictive ability 
within long-standing scoring measures of disease activity, evaluating the utility in a newly 
diagnosed cohort, and setting reference values in pregnancy. Little is known about the 
relationship between non-invasive markers of inflammation and nutrition in IBD; thus, studying 
biomarkers and nutrition was unique to our studies and an additional aim. Each chapter in this 
thesis builds the case for the clinical and predictive ability of biomarkers in IBD.   
In Chapter 4, we examined the importance of biomarkers in a previous dataset observing 
the association between the SES-CD and measures of disease activity in CD. The goal was to 
determine the relationship between individual components of the CDAI (using both PRO- and 
biomarkers variables) and other disease activity variables and the SES-CD, in the effort to create 
a sensitive and specific model (including a PRO-exclusive model) to predict endoscopic disease 
activity. Our new model included biomarkers and some PRO’s, which outperformed the CDAI. 
However, the new model has limitations. Including biomarkers requires the collection and testing 
of fecal and serum samples. Thus the avoidance of diagnostic testing is not averted as it would be 
with a PRO. However, the inclusion of biomarkers also provides an accurate surrogate measure 
of disease activity, which is less costly and invasive than colonoscopy. This type of model has 
far reaching implications; an accurate scoring index would limit the need for colonoscopy in 
clinical practice, reducing the burden on the health care system when monitoring IBD. 
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Furthermore, this model provides less expensive and more accessible primary outcomes for 
clinical trials.  
In Chapter 5 we studied the role of biomarkers in a longitudinal, inception cohort of 
newly diagnosed IBD patients. The major strength of this study was the patient population. 
Studying only newly diagnosed patients limits the heterogeneity (duration of disease, surgery, 
hospitalizations etc.) found in most IBD patient cohorts. Dietary intake was assessed through a 
validated FFQ. The study was limited by a small sample size, but we made some interesting 
observations. FC performed well in predicting endoscopic disease in both CD and UC at 
baseline. At diagnosis, IBD patients have a diet that fits within the AMDR for macronutrients, 
and is adequate in protein intake, but lacks in fibre intake. The major food groups (grain, fruit, 
meat, etc.) were shown to be lower in this patient population compared with reference intakes. 
Interestingly, glycemic index had a strong, positive correlation with fecal biomarkers.  This 
correlation should be interpreted as hypothesis generating (i.e. diet and post-prandial glycemic 
response increase inflammatory biomarkers in IBD). Given the interest in diet and the post-
prandial glycemic response in chronic disease future studies, using more accurate assessment of 
GI and GL (i.e. weighed food records, 24-hr recall with dietitian), should be completed. 
Additionally, both FC and hsCRP were useful in predicting disease activity in our longitudinal 
repeated measures analysis. As previously mentioned, the purpose for studying new diagnosis in 
IBD was to limit confounding in the sample population. Although our patients were newly 
diagnosed, the group remained heterogeneous. Differences in disease type (CD vs. UC), activity, 
and visit participation made the results difficult to interpret. Future studies would benefit from 
recruiting newly diagnosed patients with well-defined exclusion criteria (i.e. only “active” 
patients) at larger recruitment centers. Another limitation is concerned with classification of 
“newly diagnosed” patients – since patients were diagnosed within the last 12 months and placed 
on medical therapy, classifying them as “recently” diagnosed might be more appropriate. Future 
studies, particularly within the study biomarkers and microbiota, might benefit from the study of 
patients before the introduction of medical therapy.  
In Chapter 6, we evaluated FC in healthy pregnancy and IBD patients. Since IBD has a 
peak incidence between 18 – 35 years of age, management during pregnancy is very common. 
Endoscopy is the gold standard is assessing disease activity, although it can be unpleasant and 
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painful for patients, plus time-consuming and expensive to perform. Endoscopy can be safely 
performed in pregnancy, but patients and clinicians still prefer to avoid invasive procedures 
during this time if possible, making assessment through non-invasive surrogate markers 
desirable. We found that FC values were normal in the HP group and significantly lower 
compared with the IBD group. This addition to the literature provides a much needed reference 
value for FC in healthy and IBD pregnancy. Clinicians can test for FC with confidence that it 
isn’t affected by pregnancy, unlike other biomarkers of inflammation (CRP, ESR etc.). 
Lastly, in Chapter 7, we studied the concentration of fecal microbiota and SCFA in 
newly diagnosed IBD patients. Although the sample size was small (n=15), we observed some 
meaningful descriptive trends in the inception period, such as the difference in fecal microbiota 
abundance between IBD and healthy patients. There is a clear trend for dysbosis in newly 
diagnosed patients. These observations will allow us to plan further microbiota studies, through 
targeting specific strains with probiotics or incorporating biomarkers as surrogate markers of 
inflammation.    
Biomarkers hold promise in the study of nutrition and diet in IBD. Diet has been widely 
studied and implicated as an environmental factor in IBD, yet how it influences the disease is 
relatively unknown. Nutritional deficiency is prevalent in IBD, but the role nutrition plays in 
management and intervention is less known. This isn’t due to a lack of focus – outside of 
pharmacologic therapeutics, nutrition is the most studied type of therapy in IBD. Historically, the 
bulk of nutritional studies in IBD have relied on case-control studies gathering nutritional 
parameters between patients and controls. As previously discussed at length in this thesis, 
disease activity can be assessed in IBD using clinical disease activity indices, endoscopic 
indices, serum serological markers, fecal markers and miscellaneous tests (Desai et al., 2007). 
The use of clinical scoring is partially subjective and only give an indirect measure of disease 
activity, while endoscopic scoring is accurate; however, it is expensive and invasive (Desai et al., 
2007). Well-designed studies employing objective measures of disease, such as biomarkers, in 
patient populations with similar disease course could increase the level of evidence in this area. 
In doing so, researchers can discover the true relationship between diet and chronic disease, and 
design interventions to influence this modifiable risk factor.  
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Molodecky et al. (2011) provides an exceptional overview of several of the issues faced 
when investigating environmental determinants of disease, particularly in the context of IBD. 
Recall and diagnostic bias are the most applicable and influential to the study of diet in IBD. 
Recall bias is introduced into a study when the measurement of the environmental exposure is 
dependent on the patient’s ability to recall information. Interestingly, Molodecky et al. (2011) 
also suggests the possibility that study patients may be more motivated than controls to examine 
environmental exposures in an effort to find a relationship. A clear relationship between diet and 
IBD is made even more difficult to ascertain due to a diagnostic bias. The time-line between 
environmental exposures, the onset of symptoms, the diagnosis of the disease and the 
introduction to an observational study all complicates the capture of dietary exposure 
(Molodecky, Panaccione, Ghosh, Barkema, & Kaplan, 2011). Furthermore, evidence showing 
that a patient will change their diet upon the appearance of symptoms complicates the study 
further (Maconi et al. 2010). Additionally, changes in dietary intake that may alleviate functional 
symptoms of disease may not be reflective of the ongoing inflammatory process (Issa & Saeian, 
2011).   
The use of fecal biomarkers as a study outcome and end-point would increase frequency 
of measurement, but more importantly, provide an objective quantification of the therapeutic and 
inflammatory response of a dietary intervention. Increasing the frequency of outcome 
measurements, made possible since biomarkers are less expensive, could highlight aspects of 
patient care that decrease inflammation or maintain remission. A dietary intervention aimed at 
modulating the intestinal inflammatory response could, hypothetically, be measured through 
fecal biomarker concentration. 
 
Our research group comes from various academic backgrounds: nutrition, pharmacy, and 
medicine; with diverse interests, such as diet and chronic disease, medicinal therapy in IBD, and 
disease management in special populations like pregnancy. This group was united by a common 
interest – investigating existing problems with a new lens, or more specifically, a new marker. 
Interdisciplinary work with biomarkers brought us together as a team and allowed us to remodel 
an existing scoring system, study the disease in special populations like new diagnosis and 
pregnancy, and study environmental factors long implicated in IBD. 
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8.2  Conclusion 
The advent of biomarkers in IBD holds promise for the management of this chronic 
intestinal disease. The four studies included in this thesis were a testament to the utility of 
biomarkers in IBD. Biomarkers were observed to be predictive of disease activity and related to 
important nutritional factors, like glycemic index (Chapter 4). They were used retrospectively to 
improve long-standing clinical disease activity scores in prediction of disease (Chapter 5). 
Biomarkers were shown to be significantly different in healthy and IBD pregnancy, adding them 
to the short list of markers useful in this special population (Chapter 6). Lastly, biomarkers were 
shown to have a strong relationship with fecal microbiota and short chain fatty acids, creating 
end-points for nutritional interventions aimed at influencing these communities and intestinal by-
products (Chapter 7). Overall, the importance of biomarkers in IBD was observed throughout 
our studies and should be further investigated for their role in the global management of chronic 
disease.  
8.3  Future directions 
Future work should continue to focus on the study of biomarkers in newly diagnosed 
populations, as this timeframe holds the most promise for elucidating the cause of IBD. 
However, studies should only be planned in larger centers or between multiple centers, to ensure 
proper participant recruitment and feasibility.   
In regards to creating new scores for disease activity, future studies should continue to 
incorporate fecal biomarkers. Additionally, model adaptation to account for variability in SES-
CD subcomponents related to inter-subject variability will be explored in the future 
When studying fecal microbiota, future studies will focus on increasing recruitment in pre- 
and post-measurements to assess the resilience of bacteria through disease course. Dietary 
interventions using prebiotics, such as inulin, should observe the impact on F. prausnitzii, a 
strain of bacteria involved in the production of butyrate.  
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In clinical and applied settings, future work will focus on incorporating biomarkers into 
medical triage, to take advantage of the potential fecal biomarkers have in point-of-care medical 
service and decision making.  
When managing IBD in pregnancy, FC can be used confidently as a surrogate measure of 
inflammation. The relationship between this biomarker and pregnancy outcomes, such as pre-
term delivery and birth weight, should be studied.  
Lastly, biomarkers should be used as endpoints in nutritional interventions. They are 
relatively inexpensive to measure and can be detected reliably and frequently. The influence of 
dietary interventions on the intestinal inflammatory response could be measured through fecal 
biomarker concentration.  
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APPENDIX B –Table B.1 Demographics and clinical characteristics of the newly diagnosed cohort CD patients (n=26) 
Patient  Age Gender Location BMI Smoke  Therapy CDAI SES-CD FC hsCRP Lf SF36 IBDQ 
CD1 44 M colonic 21.6 yes 5-asa 132 12 50 4 2 105 185 
CD2 25 M ileal 26.3 no immuno 139 7 228 23 124 107 184 
CD3 22 F ileal 20.1 no immuno 61 9 890 13 44 100 205 
CD4 19 F colonic 19.0 no immuno 249 21 400 32 146 110 128 
CD5 52 F ileocolonic 35.3 no immuno 132 n.d. 1303 63 1134 n.d 0 
CD6 32 M ileal 18.0 no anti-tnf 193 7 50 1 3 n.d 0 
CD7 33 M ileocolonic 24.8 no anti-tnf 140 18 1487 1 115 n.d 0 
CD8 52 M ileal 27.6 no anti-tnf 161 n.d. 612 19 281 110 201 
CD9 48 M ileocolonic 27.2 no immuno 138 7 762 14 388 106 137 
CD10 48 F ileal 33.2 no immuno 54 n.d. 50 1 1 101 190 
CD11 47 F ileocolonic 19.5 no 5-asa 17 n.d. 847 4 349 n.d 0 
CD12 31 M ileal 21.2 no immuno 96 8 1348 31 452 106 183 
CD13 36 M colonic 33.7 no none 219 5 50 3 298 96 166 
CD14 35 M ileocolonic 35.2 no immuno 256 15 6560 10 949 100 82 
CD15 28 M ileal 33.8 no none -8 2 50 3 6 99 158 
CD16 52 M ileocolonic 33.9 no immuno 59 25 1744 60 296 96 158 
CD17 24 M ileocolonic 30.4 no immuno 354 25 7020 35 466 102 114 
CD18 20 F ileocolonic 21.7 no anti-tnf 132 26 1362 1 216 108 209 
CD19 25 F ileocolonic 25.3 no immuno 21 n.d. 470 4 273 106 194 
CD20 22 F ileocolonic 21.6 no anti-tnf 109 n.d. 1236 13 360 96 175 
CD21 34 F ileocolonic 22.1 no immuno 154 19 657 2 117 107 189 
CD22 60 F colonic 26.6 no none 41 n.d. 2340 8 4 99 175 
CD23 28 F colonic 19.5 yes immuno 288 14 1781 18 1 105 88 
CD24 32 F colonic 21.8 yes immuno 351 n.d. 1781 53 1 101 87 
CD25 52 F ileal 30.3 no immuno 85 n.d. 559 1 6 104 158 
CD26 32 F ileocolonic 29.5 n.d. 5-asa 61 8 600 31 6 105 173 
Baseline demographics in 26 newly diagnosed CD patients. Disease location is confirmed by colonoscopy.  5-asa, amino-
salicylic acid, Anti-TNF, anti-tumour necrosis factor agent, immuno, immunosuppressant CD, Crohn’s disease, CDAI, Crohn’s 
disease Activity Index, FC, fecal calprotectin, hsCRP, high sensitivity C-reactive protein, Lf, lactoferrin SF36, short form 36 health 
survey, IBDQ, inflammatory bowel disease questionnaire, n.d., no data.   
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Table B.2 Demographics and clinical characteristics of the newly diagnosed cohort UC patients (n=16) 
Patient  Age Gender Location BMI Smoke  Therapy PT pMAYO MAYO FC hsCRP Lf SF36 IBDQ 
UC1 41 F pancolonic 28.2 yes immuno 9 8 10 1004 16 408 103 101 
UC2 35 M pancolonic 36.9 no anti-tnf 10 8 11 526 62 54 88 77 
UC3 49 M left-sided 22.6 no 5-asa 3 5 6 50 2 1 83 184 
UC4 70 M left-sided 28.1 no 5-asa 7 6 7 1139 90 61 93 114 
UC5 38 F pancolonic 22.1 no 5-asa 5 3 4 323 1 117 97 147 
UC6 36 M left-sided 30.1 yes anti-tnf 4 2 2 7660 2 878 n.d. 0 
UC7 43 F pancolonic 41.9 no 5-asa 8 9 9 1667 4 264 108 0 
UC8 45 M pancolonic 33.8 no 5-asa 0 0 0 50 0 1 108 205 
UC9 54 M pancolonic 27.2 n.d. 5-asa 2 3 3 994 3 91 112 179 
UC10 50 F left-sided 25.4 no 5-asa 13 5 8 211 1 1 n.d. 0 
UC11 35 M pancolonic 37.7 yes anti-tnf 4 0 0 2035 5 0 n.d. 0 
UC12 20 M pancolonic 25.5 no 5-asa 10 8 11 9878 4 720 99 89 
UC13 34 M proctosigmoidal 18.6 n.d. 5-asa 6 5 7 352 6 53 108 144 
UC14 35 F proctosigmoidal 21.0 no 5-asa 8 4 6 460 2 10 104 149 
UC15 55 F pancolonic 29.6 no 5-asa 6 4 4 50 n.d. 2 101 151 
UC16 37 M pancolonic 24.0 no 5-asa 2 1 1 695 14 4 97 161 
Baseline demographics in 16 newly diagnosed Ulcerative colitis patients. Disease location is confirmed by colonoscopy. 5-asa, 
amino-salicylic acid, Anti-TNF, anti-tumour necrosis factor agent, immuno, immunosuppressant, BMI, body mass index, PT, Powell 
Tuck index, pMAYO, partial Mayo score, FC, fecal calprotectin, hsCRP, high sensitivity C-reactive protein, Lf, lactoferrin, CD, 
Crohn’s disease, SF36, short form 36 health survey, IBDQ, inflammatory bowel disease questionnaire, n.d., no data..
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APPENDIX C: SCFA Analysis 
Chromatographic Services 
Department of Agricultural, Foods, and Nutritional Sciences 
University of Alberta 
 
1.0 Title:  Short-Chain Fatty Acid (SCFA) Analysis 
 
2.0 Purpose:  This procedure outlines the analysis of VFAs in aqueous solutions.  For this analysis, 
aqueous samples are combined with 25% phosphoric acid (4:1; v:v) prior to sampling for GC 
analysis.  It is highly recommended that the addition of 25% phosphoric acid occur at the time of 
sample collection to avoid loss of VFAs during freezing, thawing, and sample preparation, 
however, this procedure assumes that this has not been done. 
 
3.0 Solutions: 
 
3.1 25% Phosphoric Acid (v/v) – 100 mL of 25% phosphoric acid is prepared by combing 29.4 
mL of phosphoric acid (85%) with 70.6 ml water. 
 
3.2 Internal Standard (Istd) - In a 100 mL volumetric flask add approximately 20 mL of 25% 
phosphoric acid, approximately 20 mL water and 300 µL of isocaproic acid (4-methyl-
valeric acid MW 116.20 g/mol).  Bring the volume up to 100 mLwith water and mix well.  
Note: It is necessary to record the weight of isocaproic acid to calculate its final 
concentration (µmol/ml). 
 
3.3 Standard Solution - In a 100 mL volumetric flask add approximately 20 mL of 25% 
phosphoric acid, approximately 20 mL water and the following volumes of individual fatty 
acids:  
 
 Acetic acid 300 µL MW  60.05 g/mol 
 Proprionic acid 200 µL MW  74.08 g/mol 
 Isobutyric acid 50 µL MW  88.11 g/mol 
 Butyric acid 100 µL MW  88.11 g/mol 
 Isovaleric acid 50 µL MW 102.13 g/mol 
 Valeric acid 50 µL MW 102.13 g/mol 
 Caproic acid 50 µL MW 116.20 g/mol 
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Bring the volume up to 100 mL with water and mix well.  Note: It is necessary to record 
the weight of each fatty acid in order to calculate their final concentrations (µmol/ml). 
4.0 Sample Preparation: 
 
4.1 Centrifuge samples (rumen fluid, silage, etc.) at maximum speed for the container (4°C for 
10 min) until a clear supernatant is obtained. 
Note: For samples with lower moisture contents (e.g. feces), it may be necessary to add 
diluted 25% phosphoric acid (4:1, v:v: water:25% phosphoric acid) prior to centrifugation 
in order to obtain enough sample for analysis. 
Following centrifugation, filter sample through a 0.45 μm PVDE filter. 
4.2 In a GC vial (1.8 mL) combine 0.8 mL of sample, 0.200 mL of 25% phosphoric acid, and 
0.200 mL of internal standard solution and mix well. 
 
Note: It is strongly recommended that the phosphoric acid be combined with samples (4:1) 
at the time of sample collection. 
4.3 Standards are prepared by combining 1 ml of standard solution and 0.200 ml of internal 
standard solution in a GC vial (1.8 mL). Mix well. 
 
5.0 GC Conditions: 
 
5.1 GC Column: Stabilwax-DA 30 meter, 0.53 mm ID, 0.5 um df (Restek Corp.). 
5.2 Head Pressure: 7.5 psi. 
5.3 Split vent flow: 20 mL/minute or adjusted as required. 
5.4 Injector Temperature: 170ºC. 
5.5 Column Temperature: 90ºC held for 0.1 min, increased to 170ºC at 10ºC/min and held for 2 
min. Run time is 10 min. 
5.6 Detector Temperature: 190ºC. 
 
6.0 Calculations: 
 
6.1 Response Factor: e.g. for Acetic Acid (A) 
  RRF = [A (µmol) * area Istd] ÷ [area A * Istd (µmol)] 
6.2 Amount in Sample: e.g. for Acetic Acid (A) 
  Amt (µmol) = [area A * RRF * Istd (µmol)] ÷ area Istd 
6.3 Results in 6.2 are divided by the volume of sample put into the GC vial to get the amount in 
µmol/ml. 
7.0 Results: 
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7.1 Typical GC Chromatogram of a Standard: 
 
 
 
7.2 Response Factors:  Approximate relative response factors (RRFs) for VFAs in the 
standards are as follows: 
 
 Acetic acid ~4.0 
 Proprionic acid 2.4 
 Isobutyric acid 1.5 
 Butyric acid 1.5 
 Isovaleric acid 1.2 
 Valeric acid 1.2 
 Caproic acid 1.0 
Note:  This procedure can be extended to provide a concurrent analysis of alcohols (ethanol, butanol etc.).  
The standard must include these alcohols, 400 µl of ethanol and 200 µl of butanol per 100 mL.  Pentanol 
(500 µL/100 mL) is a convenient internal standard.  The initial column temperature is 35ºC and held for 3 
minutes. Total run time is 15 min.  
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 APPENDIX D: Fecal microbiota percent relative abundance in newly diagnosed IBD patients 
 
 
